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Mutations of the p53 gene are common in a wide variety of human
malignancies. Detection of such mutations opens up the possibility of
their use as a marker for the presence of malignancy, with potential
applications in screening, diagnosis and follow up. This project
investigated this potential. Single Stranded Conformational
Polymorphism (SSCP), a PCR based gel electrophoresis technique, was
used to screen for p53 mutations in bladder washing samples from
patients with bladder cancer and breast fluid samples obtained by nipple
aspiration from patients with breast cancer. Exons 5-8 of the p53 gene
which contain over 80% of reported mutations were examined
individually.
The SSCP assay was optimised using DNA extracted from 6 cancer cell
lines (2 with normal p53 and the others each with a mutation in 1 of
exons 5,6,7 or 8) using 6 sets of gel conditions. Each mutant-carrying cell
line could be identified by an unambiguously abnormal SSCP pattern
under at least 3 sets of gel conditions. Dilutions of each of the mutant cell
lines were made with wild type cells to determine the sensitivity of SSCP
to detect the mutation in DNA extracted from the mixture of cells. (This
was of fundamental importance as the clinical samples studied would
inevitably contain such a mixture). SSCP was performed for each dilution
series using gel conditions able to demonstrate that particular mutation.
The sensitivity in detecting mutations varied (range 1-30%) and was
dependent on the conditions used. EJsing optimal conditions for each
mutation a distinct extra band corresponding to the mutation was
discernable at the 1 in 100 level for exon 8 and at 1 in 20 for exons 5, 6
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and 7. These results illustrate the importance of gel conditions in
determining the sensitivity of SSCP in detecting mutations in mixed cell
populations. Because optimal detection conditions varied between
mutations, SSCP was performed under 3 sets of gel conditions for each
exon when screening clinical samples.
Bladder washing samples (31) were collected from patients (27) with
bladder cancer. An abnormal additional SSCP band was detected in 5
samples from 5 different patients suggesting the presence of a p53
mutation. The mutation was in exon 8 in a single case and in exon 6 and
7 each on 2 occasions. In all 5 cases the same abnormal SSCP pattern was
demonstrated in samples of the corresponding bladder tumour. In 3 cases
the presence of mutation was confirmed by direct DNA sequencing,
however in the 2 samples with exon 7 abnormalities it was not possible to
obtain a reamplified PCR product for sequencing. In 1 case bladder
washings were available from the same patient on 2 separate occasions
with one washing demonstrating a mutation and the other not. In 2
further cases a mutation was demonstrated in the bladder tumour but not
in the corresponding washing.
Breast ductal fluids were obtained by nipple aspiration from 21 female
patients with histologically confirmed breast carcinoma. Corresponding
breast tumour samples were also obtained. In view of the small amount
of fluid available DNA extracted from excised tumour was screened for
p53 mutations before studying the corresponding fluid samples. Of the 21
tumours examined 4 were found to have an abnormal SSCP pattern. The
putative mutation was characterised in each case by direct sequencing.
However it was not possible to demonstrate the mutation in any of the
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four fluid samples from the breasts of these women. The problems
encountered included the small amount of DNA extracted from the fluid
samples and the demonstration that breast fluid contains a factor that
inhibits PCR amplification.
In conclusion the sensitivity of SSCP to detect mutations in a mixed cell
population is defined. It is shown that p53 mutations can be detected and
characterised in DNA extracted from bladder washing samples from
patients with bladder cancer, but for clinical applicability sensitivity needs
to be improved. It has not been possible to demonstrate p53 mutations in
breast ductal fluid. However further study of molecular abnormalities as





Malignant disease is a major cause of illness and death throughout the
world. Whilst major advances have transformed the prognosis for
patients with a variety of the less common malignancies such as
leukaemia, lymphoma and testicular cancer, there has been little or only
modest improvement in the cure rates for most of the common solid
cancers in the last 30 years (Sikora et al 1995). It is hoped that improved
understanding of the molecular pathology of malignant diseases can be
translated into advances in treatment (Cortner and Vande Woude 1997).
Furthermore diagnosis of primary or recurrent disease at an earlier stage
than is currently possible may have prognostic benefit.
Mutations in specific oncogenes and tumour suppressor genes are
implicated in the genesis and development of many cancers (Perkins and
Stern 1997). The advent of polymerase chain reaction (PCR) technology
enables the amplification of genetic material in quantities sufficient for
sophisticated analysis (Eeles et al 1992). There is therefore potential for
developing molecular biological techniques to aid in the diagnosis or
monitoring of cancer, using the detection of mutations as a biochemical
marker of disease. Cells exfoliated by tumours into body cavities and body
fluids are an obvious and theoretically attractive medium for
investigating the potential of such techniques.
This thesis describes a pilot study using mutations of the p53 gene, one of
the genes most commonly subject to mutation in malignant disease
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(Stratton 1992), as a molecular marker in 2 common diseases. These are
breast cancer and bladder cancer, using nipple aspirate fluid and bladder
washings respectively as the method of sampling exfoliated cells.
The introduction describes the background to the study. The clinical
importance of both breast and bladder cancer are described. The
importance of the p53 gene, it's relevance to the 2 diseases, and why
aspects of its biology make p53 gene mutations potentially useful markers
of cancer are explored. The biology of breast ductal fluid is reviewed in
relationship to breast cancer as is the literature describing methods
exploring the study of bladder cancer using material found in bladder
washing and urine samples. Methods of detecting oncogene mutations
are described and finally the formal aims of the study are set out.
1.2 Bladder Cancer
Bladder Cancer is a common disease giving rise to approximately 5000
deaths a year in the United Kingdom. The disease is more common in
males than females and in Caucasians than blacks (Keane et al 1995).
Histologically the majority of bladder cancers in the Western developed
world are transitional cell carcinomas with squamous cell carcinomas
accounting for approximately 5% and adenocarcinomas less than 5%
(Cotran et al 1989a). However in Egypt and parts of Central Africa, where
Schistosomal infection is endemic, up to 80% of bladder cancers are
squamous cell in origin relating to the irritative affects of chronic
schistosomal infection on the bladder mucosa (Keane et al 1995). In the
West, whilst bladder cancer can be related to chronic infection, certain
occupational exposures (for example to organic amines and aluminium)
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and drugs such as cyclophosphamide and phenacetin (Scher et al 1997), it
can be regarded primarily as a smoking related illness (Murphy 1989).
Bladder cancer can be divided into superficial and invasive disease. In
superficial disease the tumour is confined to the mucosa, submucosa or
lamina propria of the bladder and the predominant clinical problem is of
establishing local control of the disease because of the tendency for
tumour recurrence and multifocality; these tumours rarely metastasise
(Keane et al 1995, Scher et al 1997). The mainstay of treatment is
transurethral resection with intravesical chemotherapy and intravesical
immunotherapy having an adjunctive role in some clinical situations
(Keane et al 1995, Newling et al 1995). The optimal treatment depends on
the stage and histological grade of the tumour. Recurrence rates are as
high as 50-80% but disease progression to muscle invasive disease occurs
more rarely, in approximately 10-25% of patients (Keane et al 1995, Scher
et al 1997). Muscle invasive disease is defined by the presence of tumour
invading into the bladder's muscular wall or more deeply. In muscle
invasive disease attempts at local tumour control are still important
though in up to 50% of patients the natural history is predominated by
the development of metastatic disease and ultimately death (Keane et al
1995). Treatment of the primary tumour involves either radical surgery
by cystectomy and urinary diversion or external beam megavoltage
radiotherapy with salvage cystectomy for locally recurrent or persistent
disease. Both options have very similar results (Keane et al 1995).The
treatment modality is thus determined by factors such as the age and
general condition of the patient, patient choice, the expertise available
and the philosophy of the doctors involved. The use of neoadjuvant and
adjuvant chemotherapy has been extensively studied and the role of both
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remains controversial (Keane et al 1995, Newling et al 1995, Scher et al
1997). In the United Kingdom chemotherapy in these settings is not
widely used because of the lack of data supporting it's use from good
quality clinical trials. However the treatment of clinically apparent
metastatic disease with platinum based combination chemotherapy offers
the prospect of useful objective response rates (upwards of 40-60%) and
worthwhile palliation of symptoms, but little prospect of cure (Scher et al
1997).
The risk of developing metastatic disease relates directly to the stage and
grade of the tumour and therefore detection of the disease at an earlier
time point in its natural history offers enhanced prospect of cure
(Newling et al 1995). In the absence of curative treatment for metastatic
disease methods of early disease detection are an appealing avenue of
study. Furthermore as bladder cancer is a disease predominantly of elderly
smokers with associated comorbidities, the development of methods
useful in diagnosis or follow-up that could lessen the requirement for
invasive procedures such as cystoscopy would be most useful.
1.3 Breast Cancer
Breast Cancer is the most common female malignancy and the leading
cause of cancer related mortality in women in the United Kingdom
(Keane et al 1990), though in Scotland lung cancer now causes more
deaths, reflecting more an increase in the incidence of the latter disease in
women rather than a major decline in breast cancer mortality (Scottish
Health Statistics 1997) . Breast cancers arise in the ductal and glandular
structures of the breast and following the World Health Organisation
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classification can be divided into noninvasive and invasive tumours
(Azzopardi et al 1992). Noninvasive tumours are largely made up of
Ductal Carcinoma in Situ (DCIS) and Lobular Carcinoma in Situ (LCIS).
The natural history of such lesions is not precisely known, and therefore
there is considerable uncertainty regarding optimal treatment (Harris et al
1997). Undoubtedly the results of mastectomy for DCIS are excellent in
terms of survival, however for localised screen detected disease breast
conserving techniques are under investigation with indications that
treatment by wide local excision followed by radiotherapy, or in certain
groups wide local excision alone is appropriate (Harris et al 1997).
Following a diagnosis of lobular carcinoma in situ, it appears the risk of
subsequently developing invasive cancer is about 9 times greater than
that of the general population, both breasts being equally at risk from
either ductal or lobular invasive disease (Harris et al 1997). Given this,
LCIS is regarded as an indicator of increased breast cancer risk rather than
a premalignant condition with the 2 main treatment options of either
biopsy and careful observation or bilateral mastectomies reflecting this
(Yarnold et al 1995, Harris et al 1997).
Invasive or infiltrating carcinomas of many types are described with by
far the most common being invasive ductal carcinomas, which either in
pure form or admixed with other types account for 75% of invasive breast
cancers. Invasive lobular carcinomas and medullary carcinomas account
for most of the remainder (Cotran et al 1989b,Yarnold 1995).
The etiology of breast cancer is complex, however as the breast is a
structure that is subject to endocrine influences it comes as no surprise
that hormones have a bearing on the development of breast cancer. The
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risk of developing breast cancer increases with increasing length of
reproductive life, with an early menarche and late menopause being
adverse factors. Breast cancer is more common in the nulliparous than
the multiparous whilst early age at first pregnancy and breast feeding
have a protective effect (Cotran et al 1989b). The role of exogenous
hormones is controversial but there would appear to be an increased risk
with hormone replacement therapy (Harris et al 1997). Genetic factors are
also important with inheritance of mutations in genes such as BRCA 1,
BRCA 2 and p53 accounting for a small but distinct subset of breast cancers
often with an early age of onset (Ford and Easton 1995).
The treatment of breast cancer is complex and rapidly evolving. The two
major objectives of treatment are to obtain local disease control with due
consideration to optimal cosmesis, and to maximise survival with
appropriate systemic therapy. The treatment of local disease traditionally
involves surgical removal of the tumour with either a wide local excision
(for small tumours) followed by postoperative radiotherapy, or
mastectomy with or without radiotherapy depending the clinical and
pathological risk factors found for the individual patient (Yarnold 1995).
The use of neoadjuvant or preoperative systemic therapy either with
cytotoxic chemotherapy or endocrine treatments especially in patients
with large primary tumours is the subject of ongoing evaluation
(Cameron and Leonard 1995). The axillary lymph nodes are also treated by
surgery or radiotherapy, though an appropriate surgical axillary node
sample if pathologically clear of disease may obviate the need for further
axillary treatment (Yarnold 1995).
From a meta-analysis of adjuvant systemic therapy it is clear that for most
17
patients the risk of metastatic disease and therefore risk of death from
breast cancer is substantially reduced by treatment with either adjuvant
hormonal therapy or polychemotherapy (Early Breast Cancer Trialists'
1992). What is less clear is whether combinations of hormonal and
cytotoxic therapy have additional advantages for certain patient groups,
and whether or not more intensive marrow ablative treatments have a
role in those with adverse prognostic factors (Yarnold 1995, Harris et al
1997). Both these issues are currently being addressed in multicentre
randomised clinical trials. There is also renewed interest in the influence
of optimal local disease control on survival. Two recent publications
suggest that reduction in loco-regional recurrence obtained by giving
post-operative radiotherapy following mastectomy positively influences
survival (Overgaard et al 1997, Ragaz et al 1997).
It is clear that despite advances in treatment the morbidity and mortality
of breast cancer remain huge health care problems. It is also clear that
patients presenting with early stage disease have a better prospect of long
term survival (Yarnold 1995). It would therefore be hoped that by
detecting disease at an earlier stage in its natural history the prospect of
longterm survival may be improved. It was on this basis that breast
cancer screening programmes were evaluated and subsequently widely
introduced in many parts of the world. Randomised trials have shown an
overall benefit for mammographic screening this being largely restricted
to women in the 50-69 year old age group (Miller 1993,Yarnold 1995).
Several issues remain unresolved, such as the optimum frequency of
screening and the benefit to subjects outside the above age group. Several
possible reasons for poor results in women aged 40 - 49 have been cited.
Poor sensitivity of mammography in younger women with radiologically
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dense breasts, possible differences in the biology of pre and
postmenopausal breast cancers, and the relative failure of therapy in the
younger age group may all be contributing factors (Miller 1993). Whatever
the reasons it is relevant to consider other possible approaches to the
earlier detection of breast cancer. In this regard the study of breast ductal
fluid obtaind by nipple aspiration is potentially interesting and the
investigation of such fluid samples was one of the objectives of this study.
The reasons for choosing nipple aspirate fluids as a vehicle for
investigation and the relationship of such fluids to the biology of breast
cancer are discussed in a subsequent section of the introduction (1.8).
1.4 p53: General Introduction
The p53 tumour suppressor gene and its protein product have been the
subject of a vast amount of research work over the past 18 years, firstly
because of their common involvement in the malignant process and
secondly because of their biological complexity. Approximately 50% of
human cancers carry structural changes in the gene, most commonly in
the form of point mutations and in many others the effects of wild type
p53 are perturbed by other mechanisms, making p53 aberrations an
almost universal step in the development of human cancers (Hollstein et
al 1991). The following is a brief overview of the structure and function of
the gene and its product emphasising those features of most relevance to
the present study, rather than an exhaustive review of the subject.
p53 was originally described in 1979 as a normal cellular protein that was
able to bind to the large transforming antigen of the SV40 DNA virus
(Lane and Crawford 1979, Linzer and Levine 1979). The gene is 20 kb long,
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has 11 exons (Lamb and Crawford 1986) and is located on the short arm of
chromosome 17, at 17pl3.1 (Benchimol et al 1985, McBride et al 1986). The
gene product is a 393 amino acid nuclear phosphoprotein 53 kd in
molecular weight, hence the protein's name (Harris and Hollstein 1993).
It is noteworthy that exon 1 is a noncoding sequence separated from
exon 2 by a very long intron. The significance of this is unclear but may be
a reflection of how the gene is regulated (Soussi et al 1990). 5 clusters or
domains of amino acids are highly conserved between species implicating
them as central to the protein's function and include the binding site of
the large T antigen. Domains I, III, IV, and V are specified by parts of
exons 2,5,7,and 8 respectively and domain II specified by parts of exons 4
and 5 (Soussi et al 1990). Domains II-V are found in the hydrophobic
central part of the protein molecule and alterations in the composition of
these domains through mutation can alter the structure and binding
properties of the protein (Soussi et al 1990).
In human malignancies approximately 80% of mutations in p53 are
missense point mutations which are frequently but not invariably
associated with loss of heterozygosity at the gene locus (Harris and
Hollstein 1993). The vast majority of p53 mutations in human cancers are
somatic rather than germline. Inherited p53 mutations such as in the Li
Fraumeni syndrome are exceedingly rare and characterised by a distinct
clinical pattern of tumour types arising at a young age (Malkin et al 1990).
It is now apparent that the majority of somatic point mutations detected
are clustered in 4 hotspots coinciding with the 4 most highly conserved
regions of the gene. These areas represented by codons 132-143 (exon 5),
174-179 (exon 5), 236-248 (exon 7), and 272-281 (exon 8) accounted for 86%
of mutations detected in an initial series from a variety of human cancers
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(Nigro et al 1989). In a review of the mutational spectrum of p53 in
human cancers 98% of described abnormalities were found between
codons 110 and 307. Whilst the majority of studies looked only at exons 5-
8, those that looked further suggest mutations outside this area are
unusual (Hollstein et al 1991). Study of mutational spectra has revealed
differences in patterns of mutation between different diseases and may
well reflect the etiological influence of the exogenous and endogenous
genotoxins implicated in the pathogenesis of those diseases (Hollstein et
al 1991). This is most clearly illustrated by the effect of aflatoxin on the
nature of p53 muations in hepatocellular carcinoma (Harris 1996a).
The precise function or rather the full range of functions and
relationships of p53 in normal tissues and in the malignant process is not
as yet fully understood though an evolving model is emerging. p53 was
originally thought to be an oncoprotein with transforming activity,
however it has transpired that all the p53 constructs used in these early
experiments contained p53 mutations and it was subsequently
demonstrated that wild type p53 acts as a potent suppressor of
transformation (Lane and Benchimol 1990), and it is now clear that p53
has antiproliferative and antitransforming activity, acting as an inhibitor
of oncogenesis. p53 is therefore now regarded as a tumour suppressor
gene and an eloquent model proposing p53 as the guardian of the genome
has been described (Lane 1992). It is envisaged that p53 is a molecular
policeman, accumulating when DNA is damaged, shutting off replication
and allowing repair, or if this is not possible directing the cell to apoptosis.
Cells without wild type p53 cannot carry out this arrest of the cell cycle;
they are thus genetically less stable because division can occur without
repair of the accumulating damage potentially leading to the production
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of malignancy (Lane 1992). This model is depicted in Figure 1.1a (page 24).
The importance of p53 in the process of apoptosis (cell suicide or
programmed cell death) was emphasised by the subsequent
demonstration that p53 is required for radiation induced apoptosis. Thus
the loss of p53 can lead to inappropriate survival of cells following DNA
damage and the potential for survival of cells that have undergone
neoplastic transformation (Lowe et al 1993, Clarke et al 1993). This
however is not the whole story and it is evident that whilst wild type p53
may be a tumour suppressor, at least some of the mutant forms as
illustrated by the original work on p53's function have transforming
effects more typical of an oncogene product. This is further confirmed by
the demonstration that certain mutants exhibit gain of function, such as
enhanced tumourigenicity and transactivation of the MDR1 (multiple
drug resistance) gene promoter (Dittmer et al 1993). This taken together
with the requirement for the integrity of the transactivation domain of
the protein suggest that gain of function is dependent on the action of
mutant p53 as an aberrant transcription factor (Lin et al 1995). It would
appear therefore that wild type p53 is a tumour suppressor but at least
some mutant forms of the protein are cancer promoting.
Before considering the mechanisms by which p53 exerts its effects in more
detail it is appropriate to summarise what is known about the structure of
the protein itself. It consists of 3 main regions. Firstly an N or amino
terminal region of 75 amino acids is primarily involved in transcriptional
activation. A central domain is largely involved in the sequence specific
binding of the molecule to DNA (critical to wild type p53 function) and a
carboxy or C terminal region contains nuclear localisation signals, sites
recognising DNA damage and sites involved in oligomerisation of the
22
protein (Levine et al 1994, Harris 1996b). From the above it could be
proposed that p53 transactivates the genes adjacent to sites of sequence
specific DNA binding (Vogelstein and Kinzler 1992). It would appear that
such binding is most efficient when p53 forms tetramers and that the
formation of mixed tetramers between wild type and mutant forms of p53
is responsible for the dominant negative effects demonstrated by some
mutant forms of p53 (Wang et al 1994, Milner 1995). The structure of p53
and the relationship of this to its function is illustrated in
Figure 1.2 (page 25).
The demonstration that the central core of the p53 protein contains the
sequence specific DNA binding domain (Pavletich et al 1993), the
elucidation of the central core's crystal structure and how this relates to
DNA binding (Cho et al 1994) has allowed insight into how mutations of
the gene exert their effect. The majority of p53 mutations are missense
mutations in the highly conserved areas of the gene, the very areas
coding for the central core that is critical for site specifc DNA binding and
hence gene transactivation, and subsequently the downstream effects of
the protein. Mutations in this region can be divided into 2 broad groups,
firstly DNA contact mutants in which critical DNA contact residues are
aberrant preventing binding and secondly structural mutants in which
DNA binding is lost through the mutation leading to an abnormal
protein conformation (Rolley et al 1995).
p53 mediates it effects in 3 main ways, firstly it may be directly involved
as an inhibitor in the process of DNA replication, secondly it acts as a
transcription factor for some genes and lastly may repress transcription of
others ( by binding to TATA binding protein and thus inhibiting its
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Figure 1.1
Role of p53 in Response to DNA Damage
(Adapted from Carson and Lois 1995)
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function as transcription factor) (Barton 1995, Selivanova and Wiman
1995, Harris 1996b). Examples of genes transactivated include GADD 45
(growth arrest on DNA damage), p21 or WAF1, BAX and those
repressed include Bcl2, IGF-IR and IGF-II, that is the transactivation of
genes promoting growth arrest and apoptosis is enhanced and that of
genes inhibting apoptosis is repressed (Harris 1996b). A simple model of
p53's response to DNA damage has been described in which GADD45 and
p21 production are enhanced. These proteins associate with PCNA
(proliferating cell nuclear antigen) and most CDKs (cyclin dependent
kinases) factors important in DNA replication and cell cycling,
promoting growth arrest and directing the cell towards DNA repair or
apoptosis if repair is not possible (Carson and Fois 1995, Harris 1996b).
Obviously this model is incomplete but it emphasises the main tumour
supressing activities orchestrated by wild type p53 namely cell cycle
control, DNA repair and apoptosis. This model is illustrated in
Figure 1.1b (page 24).
Whilst, because of the nature of the current study the frequency and
nature of p53 mutations has been emphasised it is important to stress that
p53 can be inactivated by at least 2 other mechanisms. Firstly the
transforming proteins of several DNA viruses including the large T
antigen of SV 40 and the HPV 16/18 E6 protein can bind and sequester p53
preventing its normal function, possibly with the purpose of allowing
progression to S phase thus allowing viral DNA replication (Selivanova
and Wiman 1995). Secondly binding and sequestration can occur with
certain nuclear proteins, predominant amongst these being MDM2 , a
protein regulated by p53 itself and thus probably normally involved in a
negative feedback control loop (Selivanova and Wiman 1995, Harris
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1996b). Gene amplification of MDM2 and consequent abnormal
sequestration of p53 has been shown to be important in the escape of
some sarcomas from p53 mediated growth control (Oliner et al 1992).
It is thus apparent that p53 can be inactivated through mechanisms that
demonstrate loss of function and/or gain of function, with the potential
for some aberrant forms of the protein to exert dominant negative effects
on wild type protein.
Most interest has focussed on the role of abnormal p53 in tumour
development. However of potentially equal importance is the realisation
that many anticancer therapies exert their effects through DNA damage
and the induction of apoptosis as a result of the damage inflicted. Of
relevance therefore are clinical and laboratory studies implicating p53
mutations in the resistance to a variety anticancer agents by the
attenuation of apoptosis, and the consequent notion that p53 may be an
interesting molecule to target therapeutically (Lowe 1995).
Much of the literature on p53 in human malignancy has focused on the
correlation between p53 status and clinical, pathological and biological
factors. It is relevant therefore to discuss briefly the methods employed in
assessing p53 status. Two major approaches have been adopted. The first
involves DNA analysis either by direct sequencing or more commonly by
selective sequencing of only those samples identified as mutant by a
mutation screening technique such as Single Stranded Conformational
Polymorphism (SSCP) (Casey et al 1996). The more widely used approach
has been to assess p53 status by immunohistochemistry (IHC) (Casey et al
1996). Normal p53 has a very short half life of only a few minutes
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(Reihsaus et al 1990) and is therefore not detectable by IHC. Most mutant
forms of the protein have a prolonged half life allowing
immunohistochemical detection (Hinds et al 1990, Iggo et al 1990), the
implication being that if there staining is present there is mutant protein
and thus a mutation in the gene (Varley et al 1991). There remains
controversy as to the reliability of each of these approaches in detecting
p53 mutations (Casey et al 1996, Sjogren et al 1996). DNA based studies
have largely concentrated on the more conserved areas of the gene (exons
5-8) and may thus underestimate the frequency of mutations (Elledge
1996) . Furthermore methods such as SSCP will fail to detect 10% -30% of
mutations (Prosser 1993). A number of methodological factors have a
profound influence on immunohistochemical staining. These include
the antibody used (Elledge et al 1994a ), whether the tissue is frozen or
fixed (Bartek et al 1990b ), and the method of tissue fixation (Fisher et al
1994). Such factors as well as the subjective nature of IHC scoring and the
absence of a uniform definition of abnormality all contribute to the
diversity of results reported (Elledge 1996). Furthermore it is apparent that
certain mutations such as splice site mutations and premature stop
codons may not give rise to the expression of any protein and therefore
no staining (Casey et al 1996, Sjogren et al 1996). Additionally in some
circumstances p53 can accumulate in the absence of detectable gene
mutation with the biological significance of this remaining unclear (Casey
et al 1996). Nevertheless IHC is widely available and easy to perform and
consequently despite the above reservations has allowed elucidation of
many facets of the role of p53 in malignant disease.
In summary p53 appears to have a pivotal role in the cell's response to
genotoxic stress. It is commonly mutated in human cancers and if not is
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frequently inactivated by other means. Most mutations are missense
mutations concentrated in exons 5-8 of the gene, the nature of the
mutations reflecting the selection advantage in terms of aberrant growth
conferred by the mutation rather than total loss of protein. The frequency
of mutations lend the detection of such mutations to investigation as
potential molecular markers of malignancy. The localisation of the
mutations found within the gene and their nature determine appropriate
strategies for their detection, as is discussed later.
1.5 p53 in Bladder Cancer
It is likely that accumulation of several genetic abnormalities is involved
in the development of bladder cancer (Linehan et al 1997). Whilst the
series of events is not yet as clearly defined as in the pathway described
for colon cancer (Fearon and Volgelstein 1990), it has been proposed that
there are at least 2 distinct molecular pathways in bladder cancer.
Chromosome 9 abnormalities appear to be important in the development
of superficial tumours with low risk of progression to invasive disease
and p53 mutations being implicated as an early event in the development
of carcinoma in situ lesions with their higher propensity to progress
(Spruck et al 1994).
An increasing body of work is accumulating regarding p53 mutations in
bladder cancer. On the basis that loss of heterozygosity is common in the
17p region in bladder tumours (Olumi et al 1990) Sidransky and
colleagues (1991) studied 18 bladder cancers and found 11 (61%) to contain
p53 mutations. Subsequently in another small series it was reported that
p53 mutations were common especially in invasive and high grade
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tumours (Fujimoto et al 1992). In a larger series Esrig et al (1993) found
32/73 tumours to contain mutations most commonly in exon 8 where a
hotspot was detected at codon 280. Mutations were found in the other
exons (5-7) studied and a relationship was found between the site of the
mutations and the intensity of immunohistochemical staining. Other
sizeable series have confirmed p53 mutations to be frequent (Spruck et al
1993, Spruck et al 1994, Goto et al 1997). Whilst it is difficult to make an
accurate estimate of the percentage of patients with bladder cancer whose
tumours contain p53 mutations, an estimate of around 40-60% of patients
with invasive disease seems reasonable, although lower incidences have
been reported (Suzuki and Tamura 1993, Oyasu et al 1995).
Several studies have focussed on the molecular epidemiology of bladder
cancer with special reference to the role of p53. As discussed earlier
bladder cancer is predominantly a smoking related disease in this country,
however other aetiological factors are important, for example
Schistosomiasis is implicated in the endemic form of Squamous cell
carcinoma of the bladder found in Egypt (Keane et al 1995). Endogenous
(spontaneous ) and exogenous or environmental mutagens are
responsible for specific types of mutation , with transitions for example
resulting from spontaneous deamination of 5-methylcytosine to
thymidine and G:C to T:A transversions commonly induced by
environmental carcinogens (Williamson et al 1994). The high frequency
of such transversions found amongst p53 mutations in bladder cancers
would suggest a major role for exogenous mutagens in bladder cancer
(Williamson et al 1994). G:C to T:A transversions are common in lung
cancer and whilst a high incidence has been described in smokers with
bladder cancer as compared to nonsmokers ( Uchida et al 1995) others
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have not found this ( Spruck et al 1993). Transitions are more common in
Schistosomal bladder cancer and it has been proposed that nitric oxide
released as part of the inflammatory response to infection in the bladder
may be responsible for the resultant deamination of 5-methylcytosine
(Warren et al 1995). The pattern of p53 mutations in urothelial tumours
associated with phenacetin abuse is in keeping with the drug having a
chronic irritative effect rather than causing promutagenic DNA lesions
(Petersen et al 1993). It is also noteworthy that multiple p53 mutations
(generally an uncommon event) have been reported in the bladder
cancers of smokers (Spruck et al 1993) and arylamine dye workers (Taylor
et al 1996) as well as in those associated with Schistosomiasis
(Ramchurren et al 1995) and in arsenic related bladder cancers in the black
foot disease area of Taiwan (Shibata et al 1994).
It is clear that p53 mutations (whether assessed by IHC or direct mutation
detection) are more common in tumours of high grade rather than low
grade and in invasive disease rather than superfical disease (Wright et al
1991, Fujimoto et al 1992, Esrig et al 1993, Furihata et al 1993, Miyamoto et
al 1993). Furthermore mutations are more common in carcinoma in situ
than in papillary superficial tumours. The presence of p53
immunohistochemical staining in greater than 20% of cells from
carcinoma in situ samples has been shown in a small series to be strongly
associated with disease progression and on multivariate analysis this
appeared to be independent of other variables (Sarkis et al 1994). Likewise
an association has been found between p53 staining and disease
progression following transurethral resection for T1 bladder cancers
(Sarkis et al 1993) and whilst this may be because p53 positive (or mutant)
tumours tend to be of high grade (Thomas et al 1994) these data reflect
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the biological aggressiveness associated with p53 aberrations.
Given the association between biological aggressiveness and p53
mutations it is reasonable to consider whether or not p53 has a role as a
prognostic factor of outcome in bladder cancer. In an early series whilst
p53 overexpression as detected by IHC was associated with poor survival
this was not independent of known prognostic factors (Lipponen 1993a).
A similar finding has been reported for mutations detected by PCR-SSCP
(Vet et al 1994). However an influential report on a large series of 243
cases of bladder cancer treated by cystectomy showed that p53
accumulation detected by IHC correlated more strongly with disease
recurrence and survival than either stage or grade (Esrig et al 1994).
Additionally p53 overexpression assessed in 90 patients all treated with
the same regimen of neoadjuvant chemotherapy was an independent
adverse prognostic factor (Sarkis et al 1995). Further, more recent studies
describe no independent prognostic value attributable to p53 status, or to
value only in a subset of patients (Kuczyk et al 1995, Nakopoulou et al
1995, Glick et al 1996, Okuno et al 1996). Given the diversity of methods
used to assess p53 and the heterogeneity of the patients both within and
between cohorts, this is not surprising. Thus, whilst it appears p53
continues to show promise as a prognostic marker, further large studies
of uniformly treated patients assessed by standard methods are required.
Given the pivotal role of p53 in the cells response to DNA damage and
the mechanisms of action that most non-surgical anticancer therapies
display, further work to elucidate the predictive value of p53 status in
relation to response to specific treatments is required, however
preliminary data have not demonstrated a relationship between
radiosensitivity and p53 status in bladder cancer (Ogura et al 1995). It is
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also important that at some stage the prognostic and predictive effects of
p53 status as assessed by immunohistochemistry and by sequence analysis
are compared so that the significance of the widely recognised discordance
between these methods can be addressed.
Where precisely the development of p53 mutations fits into the natural
history of bladder tumours remains unclear. There appear to be at least 2
molecular pathways for bladder cancer development, with p53 mutations
occuring early in the pathway associated with aggressive invasive disease
(Spruck et al 1994). The fact that loss of heterozygosity at the p53 locus
(Tamada et al 1994) and p53 mutations can occur before muscle invasion
(Oyasu et al 1995, Schlechte et al 1997) as well as the recent demonstration
that the acquisition of p53 mutations may precede the diagnosis of
invasive disease by some months (Vet et al 1996) emphasises the
potential for screening for p53 mutations as a useful way of identifying
patients with a high risk of disease progression. The detection of identical
mutations in multiple and recurrent tumours suggests a high but not
100% incidence of clonality in such tumours (Habuchi et al 1993a,
Petersen et al 1993, Vet et al 1996, Goto et al 1997). This lends credence to a
potential use of a known mutation for an individual patient as a marker
for monitoring disease in follow up after treatment. Further the frequent
presence of p53 mutations especially in high grade and invasive tumours
makes the detection of such mutations a potential marker for the
presence of disease. The question remains as to which exons should be
studied in the present investigation. Several groups have studied exons 5-
8 alone on the basis of the early work suggesting these areas harbour most
mutations (Miyao et al 1993, Petersen et al 1993, Spruck et al 1993, Shibata
et al 1994, Vet et al 1994, Schlechte et al 1997). Others have looked at
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additional exons but found mutations only in 5-8, Sidransky et al (1991):
exons 5-9, Lianes et al (1994): exons 2-9 and Cordon-Cardo et al (1994):
exons 5-9. Others studying various combinations of exons 2-11 have
found only 9 of 54 mutations to lie outside exons 5-8 namely 4 in exon 4, 3
in exon 10 and 1 each in exons 9 and 11 (Habuchi et al 1993b, Miyamoto et
al 1993, Williamson et al 1994). Given the above it was decided to screen
only exons 5-8 alone in the current study accepting that some mutations
would be missed; this was felt acceptable as the prime objective of the
study was to establish the principle that mutations could be indentified
and characterised in bladder washings rather than carrying out a
comprehensive investigation characterising every mutation present.
1.6 p53 in Breast Cancer
Initial pointers to the fact that p53 mutations may be involved in breast
carcinoma came from the observation that 17p was a frequent site of loss
of heterozygosity in the disease (Mackay et al 1988). Prosser et al (1990)
were the first to demonstrate p53 mutations in breast cancer when they
found 13% of 60 tumours to contain mutations in exons 5 or 6. Further
work from the same group found 41 mutations in 136 breast cancers
when studying exons 5-9 and estimated that up to 40% of breast tumours
were likely to contain mutations if the whole gene was considered (Coles
et al 1992).
There is debate as to whether immunohistochemistry (IHC) is a reliable
marker of p53 mutation in breast cancer. Deng et al (1994) found IHC to be
quite specific but not very sensitive in detecting mutations and whilst
others (Lohman et al 1993, Schneider et al 1994) have found reasonable
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correlation between the two, others report a significant disparity
(MacGeogh et al 1993). Some of this inconsistency may be accounted for by
methodological differences between series. Interestingly it has been
shown that cytoplasmic staining of p53 detected by IHC can occur with
normal p53, presumably the p53 being inactivated and accumulating by
nuclear exclusion rather than by mutation (Moll et al 1992). A
comprehensive study which compared the prognostic significance of p53
sequence abnormalities and IHC found sequence data to be of greater
prognostic value, and documented the discrepancy rates between the 2
methods of assessing p53 status, and explored their significance (Sjogren
et al 1996).
Reported incidence of p53 mutations vary between series from 16% to
40% (Andersen et al 1993, Dunn et al 1993, Merlo et al 1993, Sasa et al 1993,
Tsuda et al 1993, Saitoh et al 1994). A rate of 40% of locally advanced breast
cancers bearing mutations has been reported (Faille et al 1994) and as will
be discussed below the frequency of mutations has been noted to vary
between histological types of breast cancer (Marchetti et al 1993 a,b).
Mutation rates of 13-22% have been reported from CIS (Harris 1992,
Elledge et al 1993). Direct comparison is again difficult between series
because of methodological differences and differences in the part of the
gene studied. The majority of studies have been confined to exons 5-8 or
5-9 and whilst mutations do occur outside these areas they are
comparitively rare (Casey et al 1996, Sjogren et al 1996). It is perhaps
reasonable to estimate that over 80% of p53 mutations in breast cancer are
found in exons 5-8.
It is clear that breast tumours commonly accumulate abnormalities in
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several genes during carcinogenesis but unravelling the genetic events in
breast cancer is hampered by difficulty in studying early and preneoplastic
lesions (Walker and Varley 1993). The nature, number and sequence of
events is not clear in breast cancer nor is the precise place of p53 in
scheme. It was believed that acquired or somatic p53 mutations were
found solely in malignant lesions (Bartek et al 1990 b, Allred et al 1993 b,
Eriksson et al 1994). However a number of immunohistochemical studies
imply the presence of accumulated p53 in occasional benign tumours and
epithelial hyperplasias of the breast (Heyderman and Dagg 1991,
Koutselini et al 1991, Schmitt et al 1995). The significance of this p53
staining is uncertain, as is whether p53 positivity in this setting equates
with the presence of mutation, though a recent report has confirmed the
presence of mutations in a small number of benign breast lesions of
varied histological type (Millikan et al 1995). This having been said it
appears that p53 overexpression and p53 mutations are rare events in
normal breast and in benign lesions. There is mounting evidence that p53
mutations occur quite frequently in DCIS, and that mutations are more
common in high grade or comedo type DCIS (i.e. those lesions that
histologically have the highest risk of progressing to invasive cancers)
(Bartek 1990b, Poller et al 1993, Eriksson et al 1994, O'Malley et al 1994). It
has been demonstrated in tumours having both invasive and in-situ
components that the immunohistochemical staining pattern and
intensity was the same in all cytologically malignant cells, and
furthermore that the presence of the same mutation can be confirmed in
both components ( Davidoff et al 1991). These observations are consistent
with p53 being involved in the early stages of breast cancer development
(Harris 1992).
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Both immunohistochemical studies and gene sequencing data have
suggested that the frequency of p53 aberrations differ between histological
types of breast cancer. Mutations are more common in invasive ductal
carcinomas than in lobular cancers (Poller et al 1992, Marchetti et al
1993a,b) and mutations are rare in the well-differentiated special types of
breast carcinoma with favourable prognosis (Marchetti et al 1993a,b,
Rosen et al 1995). The exception to this would appear to be medullary
carcinomas which although demonstrating some features of poor
differentiation have a favourable prognosis but frequently display p53
mutations (Marcheti et al 1993a,b, Rosen et al 1995). It would appear
important therefore to consider the proportions of tumours of various
histological types when comparing series (Domagala et al 1993) especially
if p53 status is being related to prognosis.
The nature and locations of p53 mutations found in a particular
malignant disease may reflect the nature of causative mutatagenic insults.
In reviewing the spectrum of mutations in breast cancer Biggs et al (1993)
found a higher incidence of G to T transversions at CpG dinucleotides
when compared to colon cancer with a hotspot at codon 157. A similar
pattern is seen in lung cancer and is more in keeping with the effect of an
as yet unidentified exogeneous mutagenic agent rather than random
endogeneous mutational events (Biggs et al 1993). The observation of
different patterns of mutation in specific populations of patients and the
apparent high incidence of p53 mutations in Japan, a country with a low
incidence of breast cancer, emphasise that molecular approaches to
epidemiology may advance the understanding of the biology of the
disease (Blasyk et al 1994, Hartmann et al 1996).
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With regard to bilateral breast cancers, whilst an initial
immunohistochemical study suggested that somatic p53 mutations did
not play a major role in the pathogenesis of bilateral disease (Ackerman et
al 1995), a subsequent study demonstrated a significantly higher incidence
of p53 mutations in bilateral compared to unilateral cancers, implying the
possibility of biological or aetiological differences (Kinoshita et al 1995).
Given the rarity of breast cancer in males the series investigating p53 in
relation to this disease are understandably small. The findings are
however consistent with those reported for the disease in women.
Immunohistochemical studies have shown p53 positivity in 29% and
54% of cases studied (Bruce et al 1996, Joshi et al 1996) and point
mutations have been detected in 12 of 29 (41%) tumours (Anelli et al
1995) with a suggestion that p53 status may be of prognostic importance
(Anelli et al 1995).
Somatic mutations in breast cancer are clearly common events. It is thus
relevant to consider whether inherited or germline mutations have an
important role in the disease. Germline p53 mutations are the underlying
defect giving rise to the Li-Fraumeni familial cancer syndome, one
feature of which is a high incidence of breast cancer (Malkin et al 1990). It
appears however that germline mutations are rare in non-Li- Fraumeni
familial breast cancer (Prosser et al 1991, Warren et al 1992, Preudhomme
et al 1993) with the majority of multiple case families attributable to
BRCA1 and BRCA2 mutations (Ford and Easton 1995). Likewise studies
on patients who have developed breast cancer at a young age (Borresen et
al 1992, Sidransky et al 1992) or who have bilateral disease (Liderau et al
1992) show that inherited p53 mutations are rare events in these settings.
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Abnormal p53 (whether assessed by immunohistochemistry or mutation
analysis) is associated with a number of clinical, pathological and
biological adverse prognostic factors in breast cancer. Abnormal p53 is a
common feature of locally advanced (Faille et al 1994) and inflammatory
breast cancers (Riou et al 1993), although when pooling the results of
several studies there does not appear to be a clear relationship between
either tumour size and p53 status (Elledge et al 1993 ) or axillary lymph
node involvement and p53 status (Harris 1992). p53 abnormalities are
associated with high grade tumours, aneuploid tumours and tumours
with a high S phase fraction and high mitotic rate (Isola et al 1992, Allred
et al 1993a, Lipponen et al 1993b). Furthermore p53 aberrations are
associated with the low levels of oestrogen and progesterone receptors
(Cattoretti et al 1988, Mazars et al 1992, Allred et al 1993a, Tsuda et al 1993).
As with bladder cancer therefore p53 mutations in breast cancer appear to
be associated with factors regarded as demonstrating aggressive disease
(Elledge and Allred 1994).
Given this association it is reasonable as with bladder cancer to ask
whether p53 has a role as a prognostic or even predictive factor. Until
recently the issue has been complicated by a plethora of inconsistent
studies using a variety of techniques in varying cohorts of patients
(Elledge 1996). Whilst the overall impression especially from larger
studies was that p53 mutations did appear to be an indepent adverse
prognostic factor especially in patients with node negative disease, this
was not a universal finding (Elledge at al 1993, Elledge 1996). However a
seminal series of papers reporting the prognostic significance of p53
mutations as detected by sequencing of the whole coding region of the
gene have enforced the view that p53 mutations do have an adverse
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prognostic effect (Bergh et al 1995, Jansson et al 1995, Sjogren et al 1996).
Furthermore the work demonstrated that patients with p53 mutations
and positive lymph nodes appeared to benefit less from adjuvant therapy
especially with tamoxifen (Bergh et al 1995). The demonstration that
mutations of p53 at the critical sites for sequence specific DNA binding
are associated with primary resistance to adriamycin therapy emphasises
that p53 status may have a predictive role in the outcome to specific
therapies and that therefore knowledge of p53 status may potentially be
used to tailor the choice of therapy for an individual patient (Aas et al
1996).
In summary therefore mutations of p53 are a common event in breast
cancer and are appropriate events to study as a potential biochemical
marker for the presence of malignancy. As in the studies undertaken on
bladder cancer it was decided to confine the screening of mutations to
exons 5-8 of the p53 gene as these contain the large majority of mutations
described.
1.7 Urine Samples and Bladder Washings In Relation To Bladder Cancer
The epithelium of the bladder, the site of origin of most bladder tumours,
is in contact with the urine and epithelial cells are shed into it (Cotran et
al 1989a). Whilst cystoscopy with biopsy is the mainstay for the diagnosis
and monitoring of patients with bladder cancer cytological evaluation of
voided urine samples has an important adjunctive role in some clinical
settings (Scher et al 1997). The majority of patients with carcinoma in situ
(CIS) of the bladder will exhibit malignant cells in their urine and
cytology can be abnormal prior to the appearance of visible endoscopic
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abnormalities (Cowan et al 1987, Murphy 1990). Urine cytology is less
reliable for those patients with papillary-superficial and invasive bladder
cancers due to the small number of malignant cells shed and the
heterogeneity of cells present, with cytology being more sensitive for high
grade bladder cancers than for low grade cancers (Esposti et al 1978, Cowan
et al 1987, Maier et al 1995). Urine cytology samples are particularly
difficult to interpret following the use of radiotherapy or chemotherapy
(either systemic or intravesical) due to the resultant presence of treatment
related cellular dysplasia (Borgmann et al 1993, Wiener et al 1993).
The procedure of bladder washing (in which a small volume of saline is
repeatedly injected into and withdrawn from the bladder via a catheter or
cystoscope) increases the cellularity of specimens presumably due to the
disruption of cells from the urothelial surface by the trauma of the fluid's
injection (Walther 1992). The cytological evaluation of bladder washing
samples is more sensitive than that of voided urine though there is
controversy as to whether or not patients should be catheterised purely to
collect such a sample (Murphy 1990, Matzkin et al 1992).
A number of strategies have been adopted to enhance the diagnostic
potential of urine samples and bladder washing samples. An early
avenue was the use of flow cytometry to assess the DNA content of such
samples, the presence of an aneuploid cell population infering
malignancy (Rosai 1993). Whilst it has been suggested that the combined
use of cytology and flow cytometry may allow a decrease in the intensity
of cystoscopic follow up after treatment (Murphy et al 1986) this has not
become standard practice. It has been demonstrated that voided urine
samples are probably not suitable for routine clinical use, with bladder
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washings providing superior samples (Mellon et al 1991). In a review of
the role of flow cytometry in bladder cancer Walther (1992) concludes that
the technique may have a role in monitoring response to therapy in
patients with CIS, but that it remains suboptimal awaiting further
technological and methodological improvements to maximise its utility.
Attempts have been made to enhance cytological evaluation of both
urine and bladder washing samples by the use of immunocytochemical
staining against a variety of tumour antigens with indications that this
may aid in the detection of low grade tumours (Lin et al 1988, Sagerman
et al 1994, Tanaka et al 1994). Other approaches have included the
measurement of tumour related proteins such as nuclear matrix
protein 22 (Miyanaga et al 1997) E- cadherin (Ross et al 1996), cytokeratin
fragments (Senga et al 1996) and tumour associated hyaluronic acid
(Lokeshwar et al 1997), and the measurement of tumour related enzymes
such as beta-glucuronidase (Ho and Kuo 1995) and hyluronidase (Pham et
al 1997), but problems with either sensitivity, specificity or both
predominate.
The Bard bladder tumour antigen (BTA) test is a latex agglutination test
detecting basement membrane complexes in urine samples that has been
the subject of several studies in the diagnosis and assessment of bladder
cancer. From these studies it can be concluded that whilst the test is more
sensitive than either urine or bladder wash cytology it is less specific in
the detection of malignant cells and as such its role, if any, in clinical
practice is yet to be established (Ianari et al 1997, Kirollos et al 1997,
Sarosdy 1997)).
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A promising preliminary report involves the measurement of the
activity of telomerase, an enzyme expressed by most cancer cells which is
involved in maintaining telomere length and thus enhancing the
malignant cells capacity for continuing proliferation. Kinoshita et al
(1997) demonstrated telomerase activity in 41 of 42 (98%) bladder cancer
specimens and in 55% and 84% of corresponding urine and bladder
washing samples respectively, the measurement of telomerase showing
better sensitivity than conventional cytology.
Malignancy associated chromosomal aberrations in the urine and bladder
washing samples of patients with bladder cancer can be detected by
fluorescence in situ hybridisation (FISH) (Meloni et al 1993, Wheeless et
al 1994). Though the technique may find a role in diagnosis and follow up
of patients with bladder cancer , if s relative lack of sensitivity suggests it
major use may lie in the study of the biology of the disease (Wheeless et
al 1994).
It is becoming increasingly apparent that the most promising way of
maximising the diagnostic use of urine and bladder washings is in the
study of molecular markers, and as such it is relevant to review the
findings of other workers. A number of approaches have been adopted,
all with the common aim of trying to develop and evaluate potential
methods using samples gathered by non-invasive or minimally invasive
means for the diagnosis and follow up of bladder cancer.
Some bladder cancers contain multiple copies of certain genes such as
c-erb B2 and EGF-R and such gene amplification has been demonstrated
in a proportion of bladder washing samples from patients with high grade
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but not low grade bladder tumours (Lonn et al 1993). Though these results
are of interest in establishing the principle that cancer associated genetic
changes are demonstrable in such samples, it is noteworthy that all
positive samples in this study were abnormal cytologically, and as such
the method may have little advantage over conventional pathological
studies. Furthermore to be able, by PCR methods, to establish with
confidence increased gene copy number requires a high proportion of
cancer cells in the sample, a situation that may only occasionally be
found.
Using a similar approach Matsumara et al (1994) have described the
detection of variant exons of the CD44 gene (an abnormality associated
with many tumour types) in a high proportion of urine samples from
patients with bladder cancer. The biology of this gene in malignant
disease requires further study and whilst the use of this marker should be
further explored, concern remains about specificity of the marker in view
of the presence of false positive results in 17% of non tumour bearing
controls (Matsumara et al 1994). The relience of the assay on analysing
RNA adds to the complexity as this requires meticulous storage and
handling of samples to prevent degadration.
Of greater interest is the potential of microsatellite marker analysis in
urine samples. Microsatellites are highly polymorphic tandem repeats of
short DNA sequences occurring very commonly throughout the genome
easily amenable to study by PCR. Using a panel of tri- and tetranucleotide
repeats an alteration in at least one of the loci studied in 26% of tumour
samples from patients with either head and neck, lung or bladder cancer,
has been demonstrated (Mao et al 1994). Furthermore the authors were
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able to detect the same alterations in corresponding sputum and urine
samples, with dilution assays suggesting that the assay may be able to
detect 1 tumour cell in 200-1000 normal cells. Using an expanded panel of
markers the same group (Mao et al 1996) demonstrated microsatellite
abnormalities in 19 out of 20 patients with bladder tumours, as well as in
2 patients with only atypia on biopsy. The changes found were generally
present in both the urine and the tumour. But as many of the markers
studied are involved early in the evolution of bladder tumours, and
peripheral blood rather than normal bladder mucosa was used as the
source for control DNA, it remains possible that the changes found are
associated with preneoplastic urothelium rather than being specific to
bladder cancer per se. However in a study including some of this cohort it
is apparent that the absence of microsatellite abnormalities previously
present following treatment is a good predictor of disease free status;
furthermore the presence of alterations correlates well with or predates
recurrence (Steiner et al 1997). These results merit prospective evaluation
with appropriate controls, and whilst employing a large panel of markers
the authors feel that the ongoing development of a reliable
non-radioactive method would allow rapid introduction of such assays
into clinical practice if its utility is confirmed (Steiner et al 1997).
Of relevance to the present study is work performed looking at the
possibility of detecting specific tumour associated gene point mutations in
urine or bladder washing samples. H-ras is a member of the ras family of
oncogenes, and point mutations in this gene are implicated in the biology
of bladder cancer, indeed the first documented H-ras mutation was in a
bladder cancer cell line (Reddy et al 1982). The frequency of such
mutations in bladder cancer is however a contentious issue: initial
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reports suggested an incidence of 10-16%, and whilst other series have
reported frequencies ranging between 30-75% (Levesque et al 1993,
Linehan et al 1997) a large study of 152 cases found an incidence of only
6% (Knowles and Williamson 1993). Additional concerns about the use of
H-ras as a disease marker include the observation that mutation may be
restricted to only some areas of a proportion of tumours and uncertainty
about the significance of H-ras mutations in the biology of bladder cancer
(Levesque et al 1993). Despite the above uncertainties a number of
interesting studies on H-ras mutations in shed urothelial cells have been
reported. Firstly Levesque et al (1993) demonstrated H-ras mutations by
SSCP in 4 out of 9 urine or bladder washing samples from patients with
bladder cancer. In 1 case tumour, urine and bladder wash DNA were
available and all 3 demonstrated the same abnormality, but unfortunately
no other corresponding tumour material was analysed. Secondly
Fitzgerald et al (1995) identified H-ras mutations in 44% of 100 urine
sediments from bladder cancer patients, again using SSCP, but reported
data on the mutational status of the corresponding tumour in only 9
cases, 7 of which demonstrated the same mutation. Given the authors
observation that, in follow up urine samples, a proportion of patients
exhibited a mutation in the absence of visible tumour it is possible that at
least on occasions the mutation detected represents a preneoplastic event.
A third study using a PCR restriction enzyme based assay reported an
incidence of H-ras mutations of 15.2 % of 33 bladder cancers and
confirmed the presence of the same mutations in bladder washout
specimens (Hong et al 1996). Even if H-ras mutations have limitations as
a marker, these studies demonstrate that oncogene mutations can be
demonstrated in urine and bladder wash samples.
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The potential for using p53 abnormalities as a molecular marker has
received some attention. Sidransky and colleagues (1991) demonstrated
the same p53 mutations which had previously been characterised in the
primary tumour to be present in urine samples from 3 patients with
bladder cancer. They used cloning techniques with mutant specific
oligonucleotides that by definition required prior knowledge of the
specific mutation being sought in the urine. The theoretical usefulness of
such mutation detection was illustrated by the retrospective
demonstration of the same p53 mutation found in the cystectomy
specimen of a former United States Vice President, Hubert Humpheries
in a cytologically negative urine sample taken 9 years earlier (Hruban et al
1994). However with the widespread nature of the potential sites for p53
mutations within the gene, p53 mutant specific oligonucleotide probes
are not a viable screening tool for the early diagnosis of bladder cancer but
may have a role in follow up of patients whose primary tumour contains
a characterised mutation. Two recent papers, both published after the
current study was underway, illustrate the potential for studying p53 in
bladder washings or urine samples. In the first p53 abnormalities were
demonstrated in the bladder washings of 6/13 patients with superficial
bladder cancer who progressed to invasive disease but only in 1 /13 who
did not progress. SSCP was used as the mutation screening method and
the authors were able to demonstrate the presence of p53 mutations in
washings several months prior to the development of invasive disease,
and therefore concluded that p53 mutations may be important in the
transition from superficial to invasive disease. The p53 status of the
primary tumour was assessed in only 2 cases. In both of these a p53
mutation had been demonstrated in bladder washings prior to the
development of invasive disease. The same mutations were found in the
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subsequent invasive tumours, but interestingly not the bladder washing
samples taken when invasive disease was found. Whilst these data are
preliminary they confirm, as does the current study, the feasibilty of
detecting and characterising p53 mutations in bladder washing samples
(Vet et al 1996).
The second study identified p53 mutations in tumour samples from
13/28 patients with multifocal bladder cancer. Thirty urine samples from
8 patients with mutations were collected at diagnosis and during 2 years
of follow-up. Twenty four of these demonstrated the same mutation as in
the primary tumour; the 6 negative samples coincided with negative
cystoscopies, as interestingly did 6 of the positive urine samples. Of these
latter patients 2 were lost to follow up and the other 4 developed
recurrence within a few months suggesting the maintenance of an
abnormal exfoliating tumour cell population in the absence of obvious
tumour. In this study the mutation detection was all performed by direct
sequencing, a method possibly less sensitive than SSCP (Smith et al 1992),
and it was estimated that the mutation carrying cells represented between
20 % and 70% of the sample (Xu et al 1996 ) in contrast to the 1-7%
estimated by Sidransky et al (1991).
A further important study on bladder washings assessed p53 expression
immunocytochemically using flow cytometry. Abnormal p53 expression
was found in 24% of 90 bladder washing samples from patients with
superficial bladder tumours and 33% of 12 samples from patients with
invasive disease (Griffiths et al 1995). The concordance between p53
expression in washings and corresponding tumours was only 74%, and
the authors suggest that dual parameter analysis with a second marker
48
such as cytokeratin may improve sensitivity by enabling only epithelial
cells to be analysed. It must be emphasised that the primary objective of
this study was to assess p53 expression in bladder washings as a
prognostic marker rather than as a marker of the presence or absence of
disease; however it was found that abnormal DNA content was of greater
predictive value (Griffiths et al 1995). The final reported study on p53 and
urine samples has adopted a different approach. Short term culture of
urinary exfoliated cells was performed on samples from 52 patients with
urothelial tumours. Successful passage was obtained in 77% of cases, there
was over 90% concordance between immunohistochemical analysis of
the tumour and the urinary cultures and it is suggested as a non-invasive
method for early detection and follow up of bladder tumours (Okuno et al
1996). However such a method, even if high specificity and sensitivity
could be demonstrated, is unlikely to find a clinical role in view of the
technical demands of such a strategy.
Given the above, further studies on the potential use of the detection of
specific gene mutations as a marker for the presence of malignancy are
justified in patients with bladder cancer. Bladder washings were used in
this study because of the improved cellularity discussed above,
maximising the chances of detecting mutations in shed epithelial cells.
This was felt particularly important for a pilot study given the low
proportion of mutant carrying cells described in urine samples by
Sidransky et al ( 1991). The reasons for choosing p53 mutations as a
marker are discussed earlier.
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1.8 Breast Ductal Secretions and Nipple Aspirate Fluid
The developed female breast secretes and absorbs fluid constantly even in
the resting state (Petrakis 1986). This fluid is secreted by the alveolar
ductal system of the breast and is absorbed by the same system, the fluid
therefore being in intimate contact with the epithelium that gives rise to
the majority of breast cancers (Wynder and Hill 1977). Perhaps
surprisingly this fluid and the epithelial cells shed into it have
historically received little attention from clinicians and scientists
interested in breast cancer, the fluid being regarded as an uninteresting
proteinaceous material containing sloughed off degenerative cells of little
importance (Petrakis 1986). However over the last 20 years interest has
increased, largely due to the development of a simple and reliable
method for sampling this fluid (Sartorius et al 1977). The method is
described in detail in Chapter 2 (section 2.3.2), but briefly involves the
application of negative pressure to the cleaned nipple by means of a
plastic cup attached to a syringe. The resulting fluid is collected from the
surface of the nipple in a suitable tube for storage (Sartorius et al 1977).
The method has been widely used in an outpatient setting and is safe,
reliable and well tolerated by patients (Sartorius et al 1977, King et al 1983,
Dairkee and Hackett 1986), and yields a fluid sample in a much greater
proportion of patients than a previous method using a maternity breast
pump (Papanicolaou et al 1958).
Since the introduction of the Sartorius method a substantial body of data
has been reported regarding breast fluid obtained by nipple aspiration.
The fluid is referred to as Nipple Aspirate Fluid ( NAF ) to distinguish it
from the fluid obtained from aspiration of breast cysts. Before reviewing
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some of this data and its relationship to breast cancer, it is important to
review the reliability of the technique in obtaining a sample of fluid and
the characteristics of the subject that influence this.
Whether a sample is useful for clinical or research purposes depends on
the proposed use of the fluid. In broad terms studies on NAF can be
divided into those investigating the cellular characteristics of the fluid
using cytological techniques and those investigating its biochemical
properties. The former requires a sample containing well preserved cells
whilst meaningful biochemical studies can be performed on small
acellular samples (Gruenke et al 1987a). In an early study involving 1503
women fluid containing sufficient cells for cytological evaluation was
obtained from 55% of subjects with a further 11% yielding fluid
unsuitable for cytological study due the scarcity of ductal epithelial cells or
the degenerate nature of those cells present. 65% of women aged aged 31-
50 years yielded cellular fluid samples (Sartorius et al 1977). Furthermore
in a separate study fluid was obtained from 76% of Caucasian women
under 51 years of age and 55% of Caucasian women 51 years and older
(Petrakis et al 1975). A review pooling results from 6 studies describes four
features that are consistently associated with the successful obtainment of
NAF: 1) age 35-50 years, 2) early age of menarche, 3) non- asian ethnic
origin and 4) previous lactation. The studies revealed that the effect of
parity could be accounted for by breastfeeding and the effect of age was
independent of menopausal status (Wrensch et al 1990). It is therefore
reasonable to conclude that a cohort of suitably aged subjects will yield a
sample of fluid in the majority of cases. It may also be of relevance that
the fluid obtained from women with breast disease tends to be more
cellular than that from normal breasts (King et al 1975).
As stated above studies of NAF can be divided into those concentrating
on either the cellular or biochemical aspects of the fluid; both will be
considered in turn, along with relevant data from studies on spontaneous
discharging breast fluid. Breast fluid from patients with symptomatic
breast discharge can be of diagnostic value and there are numerous
historical reports the primary diagnosis of breast cancer being made on
the basis of cytological smears of such fluid (Papanicolaou et al 1958) . In a
recently published series auditing the use of nipple discharge cytology 7 /
15 breast cancers from 338 patients with nipple discharge were correctly
identified by cytology and it was concluded that whilst examination of
such fluid was a useful adjunct to other diagnostic modalities it was not
safe to rely on it as the sole modality of investigation of nipple discharge
(Groves et al 1996). It is noteworthy also that the majority of patients with
spontaneous nipple discharge do not have breast cancer. The main
cellular components of breast ductal fluid (obtained either by nipple
aspiration or spontaneous discharge) are ductal epithelial cells, foam cells,
macrophages, blood cells (most commonly white cells) and squamous
epithelial cells (Papanicolaou et al 1958). Foam cells are the most
frequently occuring cell type and whilst their histiogenic origin remains
unclear the available evidence points towards a phagocytic rather than
epithelial derivation. (Petrakis 1986). Foam cells are regarded as having
little diagnostic value, however it is of interest that in one study a model
based on cytometric image analysis of foam cells correctly placed 83% of
patients with a variety of malignant and benign breast pathologies in the
correct diagnostic group whilst convention cytological criteria failed to
demonstrate any distinguishing features (King et al 1984).
In terms of cytology most interest has centred on the ductal epithelial cells
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present in NAF. In an early series reporting on the cytology of NAF 27
fluids were classed as suspicious of carcinoma, and the diagnosis of cancer
was confirmed in 18 (66%) of these patients. Of these 18, 7 were diagnosed
by aspirate cytology alone the patients all having normal mammography
and clinical examination (Sartorius et al 1977). Subsequently in a further
study of 1744 asymptomatic subjects 280 satisfactory samples revealed 8
with atypical cells with only 1 subject being confirmed as having a
carcinoma (Buehring 1979). Using strict cytological criteria for the
diagnosis of malignancy 21% of 34 patients with a known malignancy
could have their diagnosis confirmed by aspirate cytology (King et al
1983). Perhaps these authors more important finding was the strong
association of cells showing features of atypical hyperplasia in NAF
samples with atypical ductal hyperplasia in the patients' corresponding
operative breast tissue specimen, both in the absence and presence of
coexisting malignancy. In view of the significant association between
atypical ductal hyperplasia and the subsequent development of breast
cancer (Page et al 1985) these abnormal hyperplastic cells in aspirate fluid
could reasonably be hypothesised to be a marker of breast cancer risk.
Furthermore it was noted that the fluid from 70% of the patients with a
malignancy demonstrated such cells (King et al 1983).
It has been demonstrated that there is an association between the
presence of dysplastic epithelial cells in NAF and the subject having a first
degree relative with breast cancer. This association is strongest when
other breast cancer risk factors, such as gross fibrocystic disease are also
present, implying either an additive or synergistic adverse effect of these
factors and family history on the breast epithelium (Petrakis et al 1982).
Subsequently the same group demonstrated a significantly increased
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incidence of breast cancers developing during follow up of a cohort of 420
women with cells displaying atypical hyperplasia in nipple aspirate fluid
as compared to an age and race matched group of controls with "normal"
fluid (Petrakis et al 1987a). A further prospective cohort study, with an
average of 12.7 years of follow-up, on 2700 white women without
symptoms of breast disease demonstrated an increased risk of breast
cancer development in certain patient groups (Wrensch et al 1992). The
authors assessed any fluid obtained cytologically and correlated the
findings with subsequent development of breast cancer. The subjects were
divided into 5 groups as follows: no fluid obtained, fluid cytologically
unsatisfactory, fluid with normal cytology, fluid showing hyperplasia and
fluid showing atypical hyperplasia. The risk of breast cancer developing
during the study was lowest in those from whom no fluid was obtained.
The relative risk was significantly higher in those with epithelial
hyperplasia ( 2.5 , 95% confidence interval 1.1 - 5.5) and those with atypical
hyperplasia (4.9, 95% confidence interval 1.7 - 13.9). Additionally those
with a first degree relative with breast cancer and atypical hyperplasia
appeared to be those most at risk (Wrensch et al 1992). Nodular densities
on mammograms have been described as a marker of increased breast
cancer risk (Wolfe et al 1983) and a relationship between high density
mammograms and cytological atypia in NAF specimens has been
reported (Lee et al 1994).
Collectively these data strongly support the hypothesis that the presence
of dysplastic cells in nipple aspirate fluids is associated with an increased
risk of breast cancer. Whilst it can be concluded that the cytological study
of nipple aspirate fluids is not a suitable modality to be used as primary
diagnostic tool, malignant cells can be detected in a proportion of women
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with breast cancer and cells associated with subsequent breast cancer risk
are readily identifiable. Unfortunately to date the specificity and
sensitivity are not of the required level to guide intervention at an
individual patient level if the cytological examination of NAF were to be
considered as either a screening tool or primary diagnostic tool. However
the cellular material present in NAF may well serve as a suitable source
of DNA and/or RNA for use in molecular biological studies.
Nipple aspirate fluid is biochemically complex containing a variety of
chemical species including proteins, lipids, carbohydrates, both steroid
and peptide hormone and a plethora of exogenous substances (Rose 1986,
Petrakis 1993). Studies on the biochemistry of NAF have given some
useful insights into the function of the breast and how function may
relate to disease. Sanchez et al (1992) characterised NAF by gel
electrophoresis and protein sequencing into 2 classes, types I and II.
Whilst all fluids may contain albumin, type I fluids are closely related in
protein composition to cyst fluid (containing Zn a2 glycoprotein,
apolipoprotein D and gross cystic fluid protein 15) and type Ft fluids are
similar to milk (containing lactoferrin, lysozyme and lactalbumin).
Furthermore type I fluids were present in 93% and 88% of patients with
no breast disease or benign breast disease respectively with only 43% of
patients with malignant breast disease having a type I fluid. These
different patterns possibly reflect differences in in the hormonal
environment of the breast in benign or malignant settings (Sanchez et al
1992). Breast fluid contains immunoglobulins including Ig G, Ig M and Ig
A,the latter being in the secretory form and often at higher levels than in
plasma (Petrakis 1977, Yap et al 1981).
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Given the hormonal influences on the breast in health and disease, the
hormonal composition of nipple aspirate fluid is of considerable interest.
Oestrogen, prolactin (Wynder and Hill 1977), progesterone (Rose et al
1986), testosterone (Hill et al 1983) and dihydroepiandrosterone sulfate
(Miller et al 1981) are detectable often at higher levels than in plasma, and
it would appear that ductal epithelial cells can actively transport steroid
and peptide hormones against a concentration gradient (Wynder et al
1981). Breast fluid oestrogen concentrations are many fold higher than
those in serum and whilst serum levels fall with the menopause NAF
levels remain high (Ernster et al 1987, Petrakis et al 1987b). Additionally
NAF oestrogen levels are lower in premenopausal parous women with
levels increasing gradually over several years after the cessation of
breastfeeding (Petrakis et al 1987b). Therefore the reduced risk of breast
cancer in those who have breast fed may in part be related to lower
cummulative exposure to high oestrogen levels (Ernster et al 1987,
Petrakis et al 1987b). Increased concentration of testosterone in breast
fluid has been reported in breast cancer patients compared to healthy
controls (Hill et al 1983).
It is clear therefore that breast fluid has it's own hormonal
microenvironment. This may well be relevant to disease processes within
the breast because of the potential effect of the hormones on the ductal
epithelium. The above data illustrate that serum levels of hormones give
only at best a crude picture of the hormonal environment of the breast
and that a different and potentially more relevant picture can be obtained
by the study of NAF.
A major lipid component of breast fluid is cholesterol and significant
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quantities of cholesterol and cholesterol's oxidative breakdown products
can be detected (Petrakis et al 1981). There is evidence from model systems
that cholesterol epoxides (the main group of breakdown products) are
both mutagenic and carcinogenic (Morin et al 1991, Petrakis 1993). It's
therefore of interest that there appears to be an association between
increased levels cholestrol epoxides and proliferative benign breast
disease (Wrensch et al 1989). Furthermore concentrations of both
cholesterol and cholesterol beta epoxide are reduced in breast milk with
this reduction being detectable in NAF for up to 2 years following the
cessation of breast feeding (Gruenke et al 1987b). It has therefore been
postulated that the alveolar ductal system of parous women who have
breast fed are exposed to lower cumulative levels of such potential toxins
and that this may be relevant to the lower incidence of breast cancer in
women who have breast fed (Gruenke et al 1987b). In this context it is of
interest that the Tanka women of Hong Kong who suckle their infants
only from the right breast have an increased incidence of left sided breast
cancers suggesting that stagnation of toxins may be important etiologically
(Ing et al 1977). Certainly there is additional evidence that toxins are
accumulated by the breast, for example nicotine and cotinine (a nicotine
metabolite) are detectable in breast fluid within half an hour of smoking
(Petrakis et al 1978, Hill and Wynder 1979). Additionally a proportion
breast fluid samples from both non pregnant and pregnant women are
Ames test positive indicating the presence of mutagenic agents in the
fluid (Petrakis et al 1980, Petrakis 1986, Scott and Miller 1990). As is the
case with hormones these data imply that the local environment of the
ductal epithelium is directly affected by the contents of breast fluid.
The possibility that cancer associated antigens may be found in nipple
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aspirate fluid and correlate with disease status has been explored. Prostatic
specific antigen (PSA) was previously thought to be exclusively found in
the prostate but is now known to be present in some breast tumours
(Diamandis et al 1994) and to be associated with a good prognosis (Yu et al
1995). Recently PSA has been detected in NAF samples (Sauter et al 1996).
A cohort of women with invasive breast cancer or at variable risk of
developing breast cancer were studied. The levels measured varied
widely but an inverse relationship was found between PSA levels and
breast cancer risk (Sauter et al 1996). The levels of carcino embryonic
antigen (CEA) have been measured in the breast fluid of 26 women with
spontaneous breast discharge. All 4 patients subsequently diagnosed as
having an underlying breast cancer were members of a group of 7 cases
exhibiting the highest CEA levels (Kahana et al 1981). The authors
concluded that breast fluid CEA measurement may have an adjunctive
role in the diagnosis of patients with symptomatic nipple discharge,
though in this context CEA was showing features of a tumour-associated
rather than tumour-specific protein.
Epidermal growth factor (EGF) is a mitogen for mammary cells and
transforming growth factor alpha is a related polypeptide involved in the
autocrine regulation of breast cancer (Dickson and Eippman 1997). Both
have been detected in human milk and in nipple aspirate fluid from
nonlactating women. The preliminary data suggest that EGF levels are
higher in subjects with benign breast disease compared to normal controls
(Rose et al 1992) and whilst there is currently no data indicating whether
or not levels of these factors are related to the risk or presence of breast
cancer further study is warranted (Vogel et al 1992)
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Attention is turned finally to the molecular biology of breast fluid. Given
the nature of the fluid and its association with breast epithelium it is
reasonable to hypothesise that useful information may be gained by the
use of molecular biological techniques to study nipple aspirate fluid. This
potential has however not been widely explored. A Japanese group have
reported increased levels of the c-erb B2 oncoprotein (a member of the
epidermal growth factor receptor family ) in the breast fluid of patients
with symptomatic spontaneous breast discharge and breast cancer as
compared to benign disease, and also found a good correlation between
the protein levels in the tumour and fluid (Inaji et al 1993). Furthermore
the same group were able to demonstrate by PCR the amplification of the
c-erb B2 gene in discharge fluid of a patient with a non palpable breast
carcinoma, a similar level of amplification being found in the tumour but
not in white blood cells (Motomura et al 1994).
To date only 1 study has been reported investigating p53 in breast fluid.
Using an immunohistochemical method no staining for p53 was found
in any 19 smears of breast fluid obtained from women with breast
discharge, but staining indicative of abnormal or mutant p53 was found
in 19/40 fine needle biopsy specimens from patients with breast cancer
(Koutselini et al 1991). The report does not clearly state the diagnoses of
the patients with nipple discharge but by implication they would all
appear to have had benign disease. There have been no published reports
on p53 and breast fluid obtained by nipple aspiration.
It can therefore be seen that although there are a few small studies
investigating oncoproteins and growth factors there have been no data
describing the detection of mutations in specific oncogenes or tumour
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suppressor genes in nipple aspirate fluids ( or spontaneous breast
discharge) published.
Preliminary work using specific primers have allowed the amplificaton
by the polymerase chain reation (PCR) of DNA from the genes for
aromatase, a interferon c-erb B2 and p53 (P Sourdaine, personal
communication of unpublished data) and one of the major aims of this
project was to investigate whether mutations of the p53 gene were
detectable in nipple aspirate fluid from patients with breast cancer.
1.9 Mutation Detection and Single Stranded Conformational
Polymorphism (SSCP)
The studies on clinical samples described in subsequent chapters centred
on the detection of mutations in the p53 gene. As has been discussed, the
majority of p53 mutations described to date have been single base point
mutations, rather than large deletions or other gross aberrations (Harris
and Hollstein 1993). Furthermore the mutations found, whilst
concentrated in the more highly conserved regions of the gene are still
present over a large proportion of the coding sequence (Soussi et al 1990,
Hollstein et al 1991). These factors are thus of great importance in the
choice of an appropriate mutation detection methodology. Direct
sequencing of PCR amplified fragments of DNA is regarded as the "gold
standard" method of mutation detection being sensitive and definitive
with the presence of a mutation being identified and characterised in the
same process (Sklar and Costa 1997). The major disadvantage is the
technical complexity of producing large runs of readable sequence
combined with the time consuming and resource intensive nature of the
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technique when used on a large number of samples (Sklar and Costa
1997). A number of methods have been developed to screen for the
presence of unknown mutations, allowing the identification of mutation
carrying samples, with the mutation subsequently being characterised by
direct sequencing, and include (Grompe 1993, Prosser 1993, Sklar and
Costa 1997):
1) Single Stranded Conformational Polymorphism analysis (SSCP)
2) Denaturing Gradient Gel Electrophoresis (DGGE)
3) Chemical Mismatch Cleavage ( CMC) and a variant of this using
Carbodiimide (CDI)
4) Heteroduplex analysis
5) RNase A cleavage
None of these screening methods is ideal and the choice of method
employed in any particular study will depend on the nature of the
samples being studied , the size of the products of interest, the degree of
sensitivity required as well as the resources and technical expertise
available (Grompe 1993). With the likely increasing availiability of
automated direct sequencing , the role of such screening techniques may
in many situations become redundant at some stage in the future,
(Grompe 1993, Prosser 1993). Currently however screening tests continue
to be an efficient way of maximising rapid mutation detection in terms of
both resources and labour-intensity.
It is not appropriate to review in detail the underlying principles of all the
above techniques, but the major advantages and disadvantages will be
briefly summarised as they are relevant to the choice of method that was
made.
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The most obvious limitations of RNase A cleavage are the requirement
for radiolabeled RNA and the techniques limited sensitivity being able to
detect only 50-60% of mutations (Grompe 1993, Prosser 1993). CDI and
CMC are sensitive techniques but labour intensive and utilise hazardous
chemicals and as such have not found widespread use (Grompe 1993,
Prosser 1993). Heteroduplex analysis whilst easy to perform probably is
less sensitive than optimised SSCP in mutation detection (Prosser 1993).
DGGE relies on the detection of the differences in migration as PCR
products gradually denature as they pass through a gel containing an
increasing concentration of denaturing agents such as urea and
formamide (Fischer and Lerman 1983). The sensitivity of the technique
has been greatly enhanced by the attachment a 40 base pair GC rich
sequence (GC clamp) to the upstream end of one of the PCR primer pair
preventing the clamped end denaturing and thus accentuating migration
differences (Sheffield et al 1989). The technique requires the computer
assisted generation of primer sequences that ensure an appropriate
melting profile for the amplified product so that the likelihood of
mutation detection is maximised. Primers have been designed to cover
the entire coding regions of exons 5-8 of the p53 gene and it has been
suggested that the sensitivity of this technique approaches 100% (Moyret
et al 1994). However use of the widely used primers designed by Borresen
and colleagues (Borresen et al 1991) which cover the conserved regions
but not the entirity of exons 5-8 would have failed to detect several of the
mutations found in the current study. The major disadvantage of the
technique is the effort required to establish the method for the particular
PCR products of interest (Prosser 1993). One potential advantage of the
technique in general terms was seen as a potential disadvantage for the
present study, namely the products are visualised by non isotopic
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methods which may have a limiting effect on the ability to detect rare
mutation carrying products when DNA from a mixture of wild type and
mutation carrying cells is studied.
SSCP was first described in 1989 (Orita et al 1989 a, b) and has subsequently
become the most widely used mutation screening technique (Grompe
1993). It relies on the separation of a double stranded DNA product into 2
radiolabeled single strands prior to electrophoresis on a non denaturing
polyacrylamide gel. Under such conditions the single strands form their
own sequence dependant secondary structure which determines the
mobility of the fragments on electrophoresis, with point mutations
potentially leading to mobility shifts relative to wild type strands. In
addition some of the DNA reanneals to reform double stranded DNA
whose migration on the gel is determined by size rather than sequence.
The principle of SSCP is shown schematically in Figure 1.3 (page 64).
Under appropriate conditions SSCP may detect from 75-98% of mutations
(Ravnik-Glavac et al 1994). Sensitivity of SSCP is improved when gels
with a high concentration of acrylamide and low concentration of
crosslinker (bisacrylamide) are employed (Glavac and Dean 1993) and
mutation detection is enhanced by the use of more than one set of gel
conditions, including the addition of glycerol to the gel and the running
of gels at different temperatures (Orita et al 1989 a,b, Glavac and Dean
1993, Vidal-Puig et al 1994). The size of PCR product studied has a
profound effect on sensitivity (Sheffield et al 1993) and it has been
estimated that for products of around 200 base pairs or less sensitivity is
approximately 90% falling to 80% for 300-350 base pair products (Hayashi
and Yandell 1993). It is accepted that the optimisation of SSCP is largely
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empirical and has to be established for each primer pair (Glavac and Dean
1993, Prosser 1993), with the best results obtained when 2 or 3 sets of gel
conditions are used (Hayashi and Yandell 1993,Vidal-Puig et al 1994). The
wide body of literature supporting it's use, its applicablity to PCR products
of the length of interest in p53 mutation detection, the comparative
simplicity of the technique and the use of product radiolabelling
(allowing the potential to detect low intensity electrophoretic bands by
prolonged autoradiography in samples containing a low proportion of
tumour derived DNA) all contributed to the decision to use SSCP as the
mutation detection method in the present study. A further attraction was
the potential to excise mutation carrying bands from dried gels for the
purposes of sequencing, a major benefit when only a proportion of the
sample carries the mutation (J Prosser, personal communication).
One further method that has received attention is Dideoxy Fingerprinting
(ddF) a hybrid between dideoxy sequencing and SSCP (Sarkar et al 1992).
In this technique the product of 1 Sanger dideoxy chain terminating
sequencing reaction is subjected to electrophoresis through a non
denaturing polyacrylamide gel. This enables the presence of a mutation
to be inferred by the loss or gain of a termination segment and / or by the
presence of a mobility shift of one or more termination segments due to
conformational changes caused by the mutation. This method has a high
degree of redundancy, has a sensitivity approaching 100% and has been
demonstrated to be efficient in the detection of p53 mutations (Blaszyk et
al 1995). The predominant reasons for not using it in the place of SSCP in
this study were concern over the potential difficulty in interpreting the
gels with the multiplicity of bands that could be envisaged in samples
containing a mixture of wild type and mutant product, as well as the
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inferior ability demonstrated for direct sequencing to demonstrate the
presence of mutations in such a mixture compared to SSCP (Smith et al
1992, Wu et al 1993).
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1.10 AIMS OF STUDY
The study set out to investigate a number of issues. Since p53 mutations
are amongst the most common genetic aberrations described to date in a
wide variety of cancer types including bladder cancer and breast cancer
there is potential for studying such genetic changes in exfoliated tumour
cells sampled in a non-invasive or minimally-invasive manner to serve
as a potential marker of malignancy.
The objectives of the study were thus as follows:
1) To develop a PCR-SSCP assay to screen exons 5-8 of the p53 gene for the
presence of mutations.
2) To optimise conditions for mutation detection and define the
sensitivity of the assay to detect the presence of mutation in mixtures of
mutation- and non mutation-carrying cells (as the clinical samples to be
later studied would almost certainly contain such a mixture).
3) To determine whether p53 mutations could be detected in bladder
washings obtained from patients with bladder cancer, correlating the
findings with those from corresponding tumour DNA.
4) To investigate whether p53 mutations could be detected in the nipple
aspirate fluid of patients with breast cancer, correlating the findings with
those from corresponding tumour DNA.





The reagents used and their suppliers are listed below alphabetically and
are followed by a list of the suppliers' addresses. Where appropriate





































DNA Ladder (100 Base Pair)
Dulbecco's Modified Eagle's Medium








Kodak X-OMAT XAR-5 film
Light Mineral Oil






PCR Reaction Buffer, lOx
(no Magnesium Chloride)
PIC/Taq DNA Polymerase
Phosphate Buffered Saline Tablets
Proteinase K
QIAamp tissue kit
QIAquick gel extraction kit

















































Amersham Pharmacia Biotech UK Ltd, Amersham Place, Little Chalfont,
Bucks, U.K.
BDH Merck, Hunter Boulevard, Magna Park, Lutterworth, Leics, U.K.
Biorad Laboratoris Ltd, Biorad House, Maylands Avenue, Hemel
Hempstead, Herts, U.K.
Boehringer Mannheim, Diagnostics and Biochemicals Ltd, Bell Lane,
Lewis, East Sussex, U.K.
Fisons Scientific Equipment, Bishop Meadow Road, Loughborough, Leics,
U.K.
FMC BioProducts, 191 Thomaston Street, Rockland, Maine, USA.
Gibco BRL Life Technologies, Fountain Drive, Inchinnan Business Park,
Paisley, U.K.
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Imperial Cancer Research Fund, Central Services, Oligonucleotide
Synthesis Laboratory, Clare Hall Laboratories, Blanche Lane , South
Mimms, U.K.
Promega U.K. Ltd., Delta House, Chilworth Research Centre,
Southampton, U.K.
Qiagen UK Ltd, Boundary Court, Gatwick Road, Crawley, West Sussex,
U.K.
Scotlab Biosciences Ltd, Kirkshaws Road, Coatbridge, Strathclyde, U.K.
Sigma Chemical, Fancy Road, Poole, Dorset, U.K.
Techne (Cambridge) Ltd, Duxford, Cambridge, U.K.
Unipath Ltd, Basingstoke, Hampshire, U.K.
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2.2 Buffers and Dyes
The following Buffers and Dye solutions were used:
DNA Loading Dye:
0.25% bromophenol blue
0.25% xylene cyanol ff
30% glycerol in distilled water
Phosphate Buffered Saline:





0.1% xylene cyanol ff
5mM NaOH
Tris Acetate Buffer (TAE): 50x stock solution pH 8.0:
242 gm Trizma Base
100 ml, 0.5M EDTA pH 8.0
57.1 ml, Glacial Acetic acid
made up to 1 litre with distilled water
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Tris Borate Buffer (TBE): lOx stock solution pH 8.0:
108 gm, Trizma Base
55 gm, Boric Acid
40 ml, 0.5M EDTA pH8.0
made up to 1 litre with distilled water
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2.3 Subjects and Sample Collection
2.3.1 Nipple Aspirate Subjects
As described in the introduction (section 1.8) several factors have been
reported to be associated with the ability to collect nipple aspirate fluid
samples from female subjects, including younger age , non-Asian
ethnicity increasing parity and previous breastfeeding. With these in
mind the following recruitment criteria were used: all subjects were
female patients aged 55 years or younger with a histologically confirmed
diagnosis of breast cancer who had not had any previous treatment for
their cancer or previous surgery to that breast. These criteria were chosen
to maximise the numbers recruited whilst maintaining a reasonable
likelihood of any individual subject yielding a fluid sample. All subjects
had given written informed consent, having had the nature of the
procedure and the purpose of the research explained to them and having
read the subject information sheet (see Appendix 1 for consent form and
subject information sheet).
2.3.2 Nipple Aspirate Collection
Nipple aspirate samples were collected as follows employing a
modification of the technique originally described (Sartorius et al 1977). .
The aspiration technique has been widely used without anaesthesia,
however as all subjects in the study were scheduled to have an
anaesthetic for their planned operation, the samples were collected
immediately after the induction of anaesthesia to minimise subject
inconvenience. The nipple was cleaned with an alcohol impregnated
swab and the perspex suction cup placed over the nipple. The perspex
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suction cup is shown in Figure 2.1. It consists of an inner chamber 1.7 cm
in diameter and an outer concentric chamber 2.9 cm in diameter, each
chamber having an adaptor/port allowing a syringe to be attached. The
outer port of the suction cup was attached by flexible plastic tubing to a
10ml. syringe and the central port to a 50ml. syringe. Negative pressure
was applied via the outer port creating a seal between the skin of the
areola and the suction cup. Negative pressure was then created over the
nipple by gently and gradually withdrawing the the plunger of the 50ml
syringe to approximately the 20 ml mark. This negative pressure was
maintained for approximately 20 seconds and then released. Any fluid
expressed was then collected in a glass capillary tube and the tube sealed at
both ends with plasticene, or alternatively the fluid was aspirated into a
0.65ml microfuge tube using a 200ul micropipette and a sterile disposable
tip. The tube was labelled and stored at -2C)0C prior to analysis. If no fluid
was visible the process was repeated on a further 2 or 3 occasions at which
stage if no fluid was obtained the subject was deemed a non-secretor . To
avoid contamination of the samples, gloves were worn at all times when
collecting and handling the sample. The suction cups were cleaned
thoroughly with detergent, rinsed in water and air dried after use and
then wiped with an alcohol wipe prior to use.
2.3.3 Breast Tumour Samples
Breast tumour specimens were obtained for DNA extraction from all
patients from whom a nipple aspirate fluid sample was obtained. At the
completion of the subject's operation the resected specimen was
examined fresh by the duty pathologist. The tumour was identified and
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Figure 2.1
Photographs of the apparatus used for collection of nipple aspirate fluid
samples. The perspex suction cup has inner and outer chambers each
with if s own adaptor allowing the attachment of a syringe by flexible
plastic tubing.
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separate samples dissected for histological evaluation and for oestrogen
receptor assessment. If sufficient tumour was available an additional
sample was snap frozen in a cryotube in liquid nitrogen for the purposes
of the current study and the tissue stored in liquid nitrogen until the time
of DNA extraction. In those cases in which there was insufficient tumour
DNA was obtained by extraction from paraffin embedded rather than
fresh tumour.
2.3.4 Breast Tissue-Normal
In a small number of patients a separate sample of macroscopically
normal (i.e non-malignant) breast tissue was also taken and stored in
liquid nitrogen until the time of DNA extraction.
2.3.5 Bladder Washouts: Subjects and Sample Collection
Patients were identified from cystoscopy operating lists as having a
possible or definite diagnosis of invasive bladder cancer. Such operations
were attended by the investigator and bladder washout samples gathered
as follows: the subject was cystoscoped under general anaesthetic and if
the presence of a bladder tumour was confirmed a bladder washout was
performed prior to tumour resection. The bladder was drained via the
cystoscope and a 60ml bladder syringe filled with normal saline was
attached to the end of the cystoscope. The saline was introduced into the
empty bladder and aspirated and reintroduced on 3-5 occassions
(Hermansen et al 1988). Approximately 30-50mls of fluid were retrieved at
the end of the procedure and emptied into 2 sterile containers. The
samples were then spun down by centrifugation at 2000 rpm for 10 mins
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and the supernatant discarded. The cellular pellets were resuspended in
1 ml of phosphate buffered saline and transferred to 2ml cryotubes. These
were centrifuged for 5 mins at 1000 rpm and the supernatant again
discarded. The resulting pellets from each washout were then stored in
liquid nitrogen until assayed.
The procedure of collecting bladder washouts is very similar to washouts
performed routinely by the surgeons either prior to tumour resection in
the presence of bleeding from the tumour to improve operative visibility,
or at the completion of resection to evacuate resected tumour. For this
reason specific patient consent was not obtained as materially no extra
procedures other than those routinely performed were being undertaken.
2.3.6 Bladder Tumour Specimens
A sample of fresh tumour was stored, if available, in patients with
bladder tumours from whom a bladder washout specimen had been
obtained. When appropriate the bladder tumour was resected
transurethrally via a cystoscope by the surgeon. At the end of the
procedure the bladder was drained and then evacuated in the
conventional manner and the resected tissue separated by sieving.
Macroscopically representative pieces of tumour were stored immediately
in cryotubes in liquid nitrogen. The histology of the tissue stored was
assumed to be similar to that reported by the pathologists in the subject's
case records. If no tumour was available for the purposes of this study




DNA was extracted from cultured cells, breast and bladder tissue, bladder
washing samples and nipple aspirate fluid samples using the QIAamp
tissue kit (Qiagen). The reagents proteinase k (17.8mg/ml), buffer ATL,
buffer AL and buffer AW were all included in the kit and were prepared
following the manufacturers instructions. The composition of buffers
ATL, AL and AW was not indicated by the manufacturers. The principle
of the method is that following cell lysis nucleic acids are selectively
absorbed on to a silica-gel based membrane prior to elution with an
appropriate buffer. The procedure was performed following the
manufacturers instructions and is briefly described below.
2.4.1a PNA Extraction from Cultured cells
DNA was extracted from approximately 10^ cultured cells. The frozen
pellet of cells was brought to room temperature and 200jnl of phosphate
buffered saline, 25gl of proteinase k (17.8mg/ml) and 200jj1 of buffer AL
were added. The sample was mixed immediately by vortexing and
incubated at 70°C for 10 mins. Ethanol (210^1) was added and the sample
again mixed by vortexing, prior to loading onto a QIAamp spin column
in a 2ml collecting tube which was centrifuged at 800 rpm for 1 min. The
collection tube was discarded and the spin column placed in a clean
collection tube. Wash buffer AW (500pl)was added to the spin column
which was centrifuged at 800rpm for 1 min. The collection tube was again
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discarded, the spin column placed in a 3rd collection tube and a further
500pl of buffer AW added. The column was centrifuged at 800rpm for 1
min and then for a further 2 mins at 1400 rpm, to remove traces of buffer.
Finally the spin column was placed in a clean 1.5ml microfuge tube and
the DNA eluted by the addition of 200ul of lOmmol Tris HC1 pH 9.0
preheated to 70°C to the spin column and centrifugation at 800rpm for 1
min. The purity and concentration of the DNA were assessed by
absorbance spectrophotometry at 260 and 280nm. The concentration of the
DNA was adjusted to approximately lOOng/pi.
2.4.1b DNA Extraction from Frozen Tissue (Breast and Bladder)
DNA was extracted from approximately 25mg aliquots of tissue (breast or
bladder) cut from the frozen samples that had been stored in liquid
nitrogen. The tissue was cut into small pieces with a clean scalpel blade,
thawed and placed in a 1.5ml microfuge tube to which 180pl of buffer ATL
was added. 20ul of proteinase k (17.8mg/ml) was added and the sample
mixed by vortexing, followed by incubation at 55°C until the tissue had
completely lysed (typically 1-3 hours). Following the incubation buffer AL
(200pl) was added, mixed by vortexing and the sample incubated at 70°C
for 10 mins. Ethanol (21 Opl) were then added to the sample, which was
mixed and the sample loaded on to a spin column. Subsequent steps were
performed as described above.
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2.4.1c PNA Extraction from Paraffin embedded tissue (Breast and
Bladder)
Paraffin embedded tissue blocks were obtained from the Pathology
Department at the Western General Hospital. DNA was extracted as
follows using the protocol suggested by the manufacturers for paraffin
embedded tissue. Paraffin embedded tissue (25mg) was placed in a 2ml
microfuge tube and xylene (1200pl) added. The sample was vortexed
thoroughly, and the sample centrifuged at 1400 rpm. for 5 minutes. The
supernatant was removed by pipetting without disturbing the tissue
pellet and 1200pl of ethanol was added to remove residual xylene. The
sample was centrifuged for 5 minutes at 1400 rpm. and the ethanol
supernatant removed by pipetting. Further ethanol (1200pl) was added,
the sample recentrifuged and the supernatant removed once more. The
tube was left open and incubated at 37°C for 10 minutes to enable residual
ethanol to evaporate. Subsequently buffer ATL (180 pi) was added and the
remaining steps in the procedure were performed as for the frozen tissue
method, except that the DNA sample was eluted in 50pl of lOmmol
Tris HC1 pH 9.0 rather than 200pl because of the lower yield of DNA.
2.4.Id DNA Extraction from Bladder Washing Specimens
DNA was extracted from bladder washing specimens using the same
protocol as for extraction from cultured cells except that the final DNA
elution was made with 50pl of lOmmol Tris HC1 pH 9.0.
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2.4.1e DNA Extraction from Nipple Aspirate Samples
DNA was extracted from nipple aspirate samples by the method
recommended by the manufacturers for extraction of DNA from small
samples of blood, cerebrospinal fluid, or bone marrow dried on
microscope slides. This is essentially the method described for cultured
cells except that the nipple fluid sample was initially thawed then
dissolved in 180[h of phosphate buffered saline and the final DNA
elution was in 30- 50pl of lOmmol Tris HC1 pH 9.0 depending on initial
sample size.
2.4.1f Further Methods of DNA Preparartion from Nipple Aspirate
Fluid Samples.
In addition (as described in Chapter 5 section 5.5) 2 other methods of
preparation of nipple aspirate fluids for PCR amplification were
evaluated. In the first method approximately 5pl of nipple aspirate fluid
was placed in a Eppendorf tube, with no additional preparation and the
PCR reaction mix added; the rationale being that for a simple cellular
sample dispersed in a body fluid the temperature cycling of a PCR reaction
was all that was required to release DNA into solution to act as the
template for the reaction to proceed. This method had previously been
described as having being used successfully on nipple aspirate fluid
(Motomura et al 1994). Secondly a modification of a method originally
described for the PCR amplification of single cell samples such as sperm
was used (Li et al 1988, Kovach et al 1991). In this method cell lysis was
performed by the additon of a lysis buffer to the nipple aspirate sample
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(releasing DNA into solution) in an Eppendorf tube prior to the addition
of the other PCR reagents. Briefly: 5 pi of nipple aspirate fluid was added
to a microfuge tube along with 2pl of lOx PCR reaction buffer (Promega),
4pl 0.1M DTT, 0.6pl of proteinase K (17.8mg/ml) and 2pl of 17pM SDS
made up to 20pl with sterile distilled water. This was incubated at 37^C for
1 hour and then 85^C for 5 minutes. The 20ul of solution was then used
as the template for a lOOpl PCR reaction.
2.4.2 Polymerase Chain Reaction
2.4.2a Polymerase Chain Reaction Oligonucleotide Primers
Four pairs of primers were designed, each to amplify individually the
whole of either exon 5,6,7 or 8 of the p53 gene. The primers were derived
from the intronic areas flanking the areas of interest (enabling the whole
of the exon to be amplified) using sequence x54156 for the human p53
gene obtained from the European Molecular Biology Laboratory Genbank
database (sequence submitted by Chumakov PM.). The sequence of exons
5-8 and flanking introns is shown in Appendix 2. All primers were
20mers and had the following sequences:
Exon 5 sense 5' TGTGCCCTGACTTTCAACTC
antisense 5' AACCAGCCCTGTCGTCTCTC
Exon 6 sense 5' TGATTCCTCACTGATTGCTC
antisense 5' ACCCCAGTTGCAAACCAGAC
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Exon 7 sense 5' AAGGCGCACTGGCCTCATCT
antisense 5' CAGTGTGCAGGGTGGCAAGT
Exon 8 sense 5' GGACCTGATTTCCTTACTGC
antisense 5' GAGGCATAACTGCACCCTTG
The above primer pairs gave products of the following lengths:
Exon 5 263 base pairs, the 5' end of the sense primer being 42 bases
upstream from the 5' end of exon 5 and the 5' end of the antisense primer
being 37 bases downstream of 3' end of the exon.
Exon 6 157 base pairs, the 5' end of the sense primer being 24 bases
upstream from the 5' end of exon 6 and the 5' end of the antisense primer
being 20 bases downstream of 3' end of the exon.
Exon 7 181 base pairs, the 5' end of the sense primer being 40 bases
upstream from the 5' end of exon 7 and the 5' end of the antisense primer
being 30 bases downstream of 3' end of the exon.
Exon 8 241 base pairs, the 5' end of the sense primer being 50 bases
upstream from the 5' end of exon 8 and the 5' end of the antisense primer
being 54 bases downstream of 3' end of the exon.
All primers were synthesised by the Imperial Cancer Research Fund
Central Services Oligonucleotide Synthesis Facility. They were supplied
dry and were prepared for use by removing sideproducts of the synthesis
process as follows. The dried pellet was dissolved in 200pl 0.3M sodium
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acetate, lOmM MgC^and 600j.il cold ethanol added. The mixture was left
overnight at -20°C, centrifuged and washed with 80% cold ethanol prior
to reconstitution in sterile distilled water. The concentration was assessed
by spectrometry at 260nm, and adjusted as appropriate to 200ng/ml.
2.4.2b Polymerase Chain Reaction
The polymerase chain reaction was used to amplify specific exons of the
p53 gene. The methods used were based on those described by Saiki (1990).
Reactions were performed either in 20j.il or 100j.il total volume depending
on the purpose of the reaction. When the PCR was performed to optimise
reaction conditions for each primer pair, or to generate PCR product to be
used for direct sequencing a lOOjil reaction was performed. When the
purpose of the reaction was to generate a radiolabeled product for SSCP
analysis a 20jil volume was used (primarily to minimise the amount of
radioactivity used). In experiments investigating the the amplification of
DNA from nipple aspirate samples both reaction volumes were
employed depending on the precise nature of the individual experiment
as described in Chapter 5.
For a IOOjliI standard PCR reaction ljil of DNA (at approximately lOOng/pl)
was added to each reaction tube. A reaction master mix was prepared on
ice containing appropriate multiples of the following reagents:
lOpl of lOx PCR reaction buffer
2ja1 dNTPs at lOmM
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ImM MgC12 (4pl of 25mM stock solution)
lpl of each of the appropriate pair of primers (200ng/ml)
80.5pl of distilled water
0.5pl ( 2.5units) of PIC/Taq DNA polymerase
The master mix was mixed by vortexing and centrifuged to eliminate
bubbles. 99pl were added to each reaction tube. Following mixing and
centrifugation lOOpl of light mineral oil was added to each tube to
prevent evaporation during thermal cycling. In each PGR experiment a
tube containing distilled water instead of DNA template was used as a
negative control to ensure the absense of contaminants in the reaction.
This tube was prepared last. PCR reactions were performed on a Techne
PIIC 3 Thermal Cycler (Techne). Cycling conditions are described below.
For a 20pl reaction the procedure was as described above save that no
mineral oil was used as these reactions were all performed on a Techne
PHC 3 Thermal Cycler with a heated lid .The master mix was again
prepared on ice and contained appropriate multiples of the following
reagents depending on the number of samples being studied:
2pl of lOx PCR reaction buffer
2pl dNTPs at 2mM
ImM MgCl2 (0.8pl of 25mM stock solution)
0.2ul of each of the appropriate pair of primers (200ng/ pi)
13.5pl of distilled water
0.3pl (1.5 units) of PIC/Taq DNA polymerase
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19j.il of the master mix were added to each reaction tube containing ljil of
DNA (at approximately lOOng/jd).
The same cycling conditions were used as for 1 OOjil reactions (see below).
When the reaction was radiolabeled for subsequent SSCP analysis 0.2j»l
(0.074 MBq) of Redivue a-32p dCTP was added per sample to the master
mix with a corresponding reduction in the volume of distilled water.
2.4.2c Polymerase Chain Reaction Cycling Conditions
The following cycling conditions were used for both 20jil and lOOjd PCR
reactions:
An initial denaturing step at 94°C for 7 mins, followed by 35 cycles of 1
min at 94°C to denature the DNA, 1 min at 53°C (exon 6), 57°C (exons 5
and 8) or 59°C (exon 7) to allow primer annealing, and 1 min at 72°C for
product elongation and then a final 10 min period at 72°C.
2.4.3 Single Stranded Conformational Polymorphism (SSCP)
2.4.3a Single Stranded Conformational Polymorphism Analysis Using
Non-Denaturing Polvacrylamide Gel Electrophoresis
The following methods are based on those previously published (Orita et
al 1989b, Glavac and Dean 1993). Initially a 20ql PCR reaction was
performed, labelled with 32p a-dCTP using approximately lOOng of
sample DNA as the template. Following this the PCR product (2j.il) were
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mixed with SSCP loading dye (10gl) and the resultant sample mixed,
microfuged and heated to 95°C for 5 minutes then immediately chilled on
ice prior to loading on the gel for electrophoresis. This procedure of
heating and chilling in the presence of the formamide in the dye was
undertaken to denature the double stranded PCR product into 2 single
strands. The chilled sample (4-8pl) was loaded into a square toothed well
of a non-denaturing polyacrylamide gel. All gels were 0.4mm thick, and
the glass plates prepared for gel casting by washing in detergent, drying ,
wiping with ethanol, and then wiping with dimethyldichlorosilane
solution (aiding plate separation following electrophoresis).
Gels of the following composition were used:
8% acrylamide with 2% bisacrylamide in lx TBE with no glycerol
8% acrylamide with 2% bisacrylamide in lx TBE with 10% glycerol
10% acrylamide with 1.3% bisacrylamide in lx TBE with no glycerol
10% acrylamide with 1.3% bisacrylamide in lx TBE with 10% glycerol
Temed (65gl) and freshly prepared 10% ammonium persulphate (325gl)
were added to the gel solution immediately prior to casting the gel to
promote polymerisation.
Gels containing glycerol were either run at 10W constant power at room
temperature, or at 40W constant power at 4°C. Gels without glycerol were
run at 40W constant power at 4°C . All gels were pre-run at the
appropriate power for at least 15 minutes before sample loading to ensure
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the gel was at uniform temperature. The sample loading wells were
irrigated with electrophoresis buffer to remove unpolymerised
acrylamide, the samples loaded, and the gel run until the first dye front of
the SSCP loading dye (bromophenol blue) was at the bottom of the gel;
this required electrophoresis for approximately 4 hours for gels without
glycerol at 4°C, 8 hours for gels with glycerol at 4°C and 16 hours for gels
with glycerol at room temperature. All electrophoresis was performed
using a Life Technologies' model S2 sequencing gel apparatus (Gibco BRL)
with lx TBE in both the upper and lower buffer reservoirs. Following
electrophoresis the gel was transferred to Whatman paper and covered
with cellophane prior to drying with a gel drier and subsequent
autoradiography, using Kodak X-OMAT XAR-5 film.
2.4.3b Single Stranded Conformational Polymorphism Analysis Using
MDE Gel Matrix
SSCP was also performed on MDE (mutation detection enhancement)
gels. MDE is a polyacrylamide derived matrix that has been reported to
offer more reliable mutation detection by SSCP compared to acrylamide
gels (Liu and Sommer 1994). The procedure was identical to that described
above for polyacrylamide gels except that 0.6x TBE was used in both the
upper and lower buffer reservoirs of the electrophoresis apparatus and
the followind gel compositions and running conditions were used:
0.5 MDE in 0.6x TBE with no glycerol
0.5 MDE in 0.6x TBE with 5% glycerol
Gels were run either at room temperature at 6W constant power or at 4°C
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at 25W constant power. Gels were again run until the first dye front
(bromophenol blue) was at the bottom of the gel; this required
electrophoresis for approximately 4 hours for gels without glycerol at 4°C
8 hours for gels with glycerol at 4°C, 8 hours for gels at room temperature
without glycerol and 12-14 hours for gels with glycerol at room
temperature.
2.4.4 DNA Sequencing
Direct sequencing was performed with the Sequenase Version 2.0 DNA
sequencing kit (Amersham) using a modification of Winship's method
(Winship 1989, Prossser et al 1990). All reagents were included in the kit
unless otherwise stated. The primers used were those described
previously for use in PCR reactions.
Firstly a lOOul PCR reaction was performed to amplify the fragment to be
sequenced. The product was subjected to electrophoresis on a 1.5% agarose
gel containing ethidium bromide and visualised under ultraviolet light
to ensure the integrity of the PCR reaction. The product was purified to
remove excess or unincorporated reagents and primers using the
QIAquick PCR purification Kit (Qiagen), following the manufacturers
instructions (Section 2.4.5). The purified product (l-5pl, representing
approximately 50ng of DNA) was used as the template for the sequencing
reaction.
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2.4.4 a Sequencing: Annealing reaction
The annealing reaction was set up comprising lpl dimethyl sulphoxide
(DMSO), lpl of either the relevant sense or antisense primer, 1 -5pi of
purified DNA template, 2pl sequenase reaction buffer made up to a final
volume of lOpl with distilled water. The resulting mix was placed at
100°C for 2 mins and immediately transferred to a dry ice/methanol bath
for primer annealing to take place.
2.4.4b Sequencing: Labelling reaction
The sequenase enzyme was diluted 1+7 with sequenase dilution buffer
and the labelling mix diluted 1+15 with distilled water. Termination
tubes were set up for each product containing 0.2pl DMSO and 1.8pl of
either ddG, ddA, ddT or ddC termination mix.
To the frozen annealing reaction lpl 0.1M dithiotheitol (DTT),
0.5pl/0.185Mbq^S-dATP (aS, > lOOOCi/mmol), 2pi diluted labelling mix
and 1.5pl diluted sequenase enzyme were added, mixed and incubated at
room temperature for 5 mins.
2.4.4c Sequencing: Termination Reaction
Labelling reaction mixture (3.5pl) was added to each of the four tubes
containing the 2pl termination mixes, placed at 37°C for 10 minutes and
transferred back to room temperature before adding sequencing stop
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solution (4pl).
All products were sequenced in both the sense and antisense directions,
that is using both members of the primer pair in turn. On occasions the
resultant sequence contained unreadable compressions, particularly in
areas rich in the bases G and C. Under these circumstances the sequencing
reaction was repeated substituting dlTP for dGTP in the reactions by the
use of the appropriate labelling and termination mixes, as supplied by the
manufacturer.
2.4.4d Denaturing Gel Electrophoresis of Sequencing Products
Denaturing gel electrophoresis was performed on the sequencing
products. Gels (0.4mm thick) were cast (the glass plates having been
prepared for gel casting as for SSCP gels) using 65ml of a ready to use
sequencing gel mix (6% w/v acrylamide/0.315% bisacrylamide, 7M urea,
lx TBE), to which 65pl of Temed and 325pl of freshly prepared 10%
ammonium persulphate were added immediately prior to casting.
Electrophoresis was performed at 35W constant power at room
temperature using a model S2 sequencing gel apparatus (Gibco BRL) with
0.4mm thick shark toothed combs and lx TBE in both the upper and
lower buffer reservoirs. The gel was prerun at 35W for at least 15 mins
and the wells washed out with the electrophoresis buffer (to remove any
unpolymerized acrylamide) prior to loading the samples. The samples
were heat denatured at 95°C for 5 mins and immediately chilled on ice
prior to loading. 4-8 pi of product were loaded per well. Only intact
non-leaking wells were used and lanes containing air bubbles were
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avoided. Electrophoresis was performed for 2- 3 hours depending on the
product length, the aim being to maximise the length of readable
sequence, whilst avoiding loss of bands off the end of the gel and the loss
of definition that occurs due to bands being too close to one another.
Following electrophoresis the gel was transferred to Whatman paper and
covered with cellophane prior to drying with a Gel drier and subsequent
autoradiography, using Kodak X-OMAT XAR-5 film.
2.4.5 Purification of PCR Products for Sequencing
PCR products to be used for direct sequencing were purified to remove
excess or unincorporated reagents and primers, using the QIAquick PCR
purification kit (Qiagen). Buffer PB and buffer PE were included in the kit.
The manufacturers instructions were followed and are described briefly:
5 volumes of buffer PB were added to 1 volume of PCR reaction, mixed
and applied to a QIAquick spin column placed in a 2ml collection tube.
The sample was spun at 1400rpm in a microcentrifuge for 1 minute, the
elute discarded and 0.75 ml of buffer PE added to the column which was
again centrifuged for 1 minute. The flow through fluid was discarded
prior to a further 1 minute spin to remove traces of buffer PE. Finally the
spin column was placed in a clean 1.5 ml microfuge tube and the purified
product eluted by the addition of 30ql of 10 mM Tris-HCl (pH8.5) to the
column, which was then centrifuged at 1400 rpm for 1 minute; the
elution fluid containing the purified product.
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2.4.6 Agarose Gel Electrophoresis
Non-radiolabelled PCR products were visualised by agarose gel
electrophoresis. 1.5% agarose gels were used made up in lx TAE buffer,
with lOpl of ethidium bromide (10mg/ml) added per 100ml of gel. PCR
products were mixed with DNA loading dye (5:1), prior to loading on to
the gel (5pl or 20[d of PCR product being used depending on the well size
of the gel poured).The gels were run in lx TAE buffer at 100-160 V
depending on gel size for approximately 40 minutes (allowing the first
dye front to migrate approximately 5-7 cm). A 100 base pair ladder was run
in 1 lane to permit the product size to be assessed. Following
electrophoresis the gel was visualised using an ultra-violet light box and
if a permanent record was required of the gel a polaroid photograph was
taken. Electrophoresis was performed using DNA Sub-Cell or Wide Mini
Sub-Cell apparatus (Biorad) depending on the gel size required.
2.4.7 Extraction of PCR Products from Gels
2.4.7a Extraction of PCR Products from 1.5% Agarose Gels
On occasions it was necessary to extract a PCR product from a 1.5% agarose
gel for subsequent use. A QIAquick gel extraction kit (Qiagen) was used
following the manufacturers instructions. Buffer QX1 and buffer PE were
supplied with the kit. The method is described briefly. The band of
interest was visualised under ultra-violet light and excised from the gel
using a clean scalpel blader. The gel slice was weighed in a 1.5 ml tube and
3 volumes of buffer QX1 were added per volume of gel. The sample was
incubated at 50°C for 20 minutes and 1 gel volume of isopropanol added.
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The sample was added to a spin column placed in a 2ml collection tube
and centrifuged at 1400 rpm for 1 minute. The flow through was
discarded and 0.5 ml of buffer QX1 added to the column which was again
spun in the same manner.The flow through was discarded and 0.75 ml of
buffer PE added. The column was centrifuged twice for 1 minute, the flow
through being discarded between occasions. The spin column was then
placed in a clean 1.5 ml microfuge tube and the purified product eluted by
the addition of 50[il of 10 mM Tris-HCl (pH 8.5) to the column, which was
centrifuged at 1400 rpm for 1 minute; the elution fluid containing the
purified product.
2.4.7b Elution of Single Stranded DNA from Pried SSCP Gels
Samples demonstrating a an SSCP pattern suggestive of a p53 gene
mutation were sequenced. If the sample appeared to contain
predominantly the mutant form sequencing was performed on PCR
product purified from a lOOpl PCR reaction. However if the mutant form
was present in low proportion compared to wild type a suitable
abnormally migrating SSCP band was excised from the SSCP gel for
elution and subsequent reamplification prior to sequencing. The gel was
marked with several dots of radiolabeled ink prior to autoradiography.
The autorad was developed and the gel and film aligned using the ink
markers before being stapled together. The single stranded DNA band of
interest was identified and excised from the gel. The fragment of gel was
placed in a 1.5ml microfuge tube and sterile distilled water (100i.il) was
added. The fragment was disrupted by maceration using a sterile
disposable pipette tip and the sample left overnight on a rotator at 4°C to
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elute. The elute (10-20 pi) was used as a single stranded template for a
lOOpl PCR reaction. The resultant product was subsequently purified and
sequenced as described in section 2.4.4.
2.4.8 Cell Lines and Tissue Culture
2.4.8a Cell lines
Human cancer cell lines with known normal and abnormal p53
mutations were identified for use in developmental and dilutional
experiments.
Cell lines with normal p53 : 2 cell lines were identified from the
literature with a normal p53 sequence, firstly MCF-7 a breast cancer cell
line has been shown to have a normal sequence for p53 cDNA from
exons 4-9 (Casey et al 1991) and A2780 an ovarian cancer cell line has a
normal p53 sequence covering the entire coding region of the gene
(Brown et al 1993).
Cell lines with p53 point mutations : human cancer cell lines carrying p53
point mutations were identified from a database housed at the European
Molecular Biology Laboratory (Hollstein et al 1994).
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Cell line Origin
exon 5 (Hensel et al 1991)
H69 Small cell lung cancer
Mutation
codon 171 GAG-TAG
exon 6 (Nigro et al 1989)
T47D Breast cancer codon 194 CTT-TTT
exon7 (Yaginuma et al 1992)
OVCAR3 Ovarian cancer codon 248 CGG-CAG
exon 8 (Bartek et al 1990a)
MDA MB231 Breast cancer codon 280 AGA-AAA
None of the above 4 cell lines carrying point mutations have been shown
to carry a wild type copy of the affected exon, that is their DNA can be
considered to be a template for amplification of a pure source of mutant
sequence for the relevant exon.
2.4.8b Tissue Culture
The breast cancer cell lines MCF-7, MDA MB 231, and T47 D were grown
in Dulbecco's modified Eagle' medium supplemented with 10% heat
inactivated foetal calf serum. The ovarian cancer cell lines A2780 and
OVCAR 3, and the small cell lung carcinoma cell line H69 were grown in
RPMI 1640 medium supplemented with 10% heat inactivated foetal calf
serum. All cells were maintained at 37^C in a humidified incubator with
5% CO2/ 95% air. Pellets containing lO'7 cells were prepared and stored in
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cryotubes in a -SO^C freezer. Pellets for each cell line were prepared as
were mixtures of each of the mutant carrying cell lines (H69, OVCAR 3,
MDA MB 231, and T47 D) with both of the cell lines containing wild type
p53 ( A2780 and MCF-7) such that in each case the mutation carrying line
was present in ever decreasing concentrations : 50%, 30%, 20%, 15%, 10%,
5% and 1%. Cell counting was performed on a Coulter Counter and for
the cell line mixtures counting was performed in quadruplicate. All the




ESTABLISMENT AND OPTIMIZATION OF SINGLE STRANDED
CONFORMATIONAL POLYMORPHISM ANALYSIS FOR THE
DETECTION OF P53 MUTATIONS IN SHED TUMOUR MATERIAL
Objectives: These were to :
1) design and optimise PCR primers to amplify reliably the entire coding
sequence of each of exons 5,6,7 and 8 of the p53 gene.
2) identify one or more cell lines with a wild type p53 gene sequence and
for each exon of interest to identify a cell line carrying a mutation in that
exon (Chapter 2.4.8a).
3) confirm the p53 status of those cell lines identified by direct sequencing.
4) use DNA from the cell lines to optimise SSCP conditions for mutation
detection and subsequently to define the sensitivity of SSCP to identify
the presence of a mutation in a mixed cell population (i.e. in mixtures of
wild type and mutant carrying cells). This latter objective was of
fundamental importance to the studies on clinical material as both nipple
aspirate fluid and bladder washing samples were likely to contain
substantial proportions of normal cells of non-tumour origin.
3.1 Optimisation of PCR reaction conditions
As described in Materials and Methods (section 2.4.2a), 4 pairs of PCR
primers were designed to amplify the whole of exons 5, 6,7, and 8 of the
p53 gene. Using standard reaction methods, the 2 major variables that
need optimisation for each pair of primers are the annealing temperature
and the magnesium concentration. The annealing temperature is
determined by the length of the oligonucleotide primer and the ratio
within the primer sequence of guanosine plus cytidine (which pair in
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double stranded DNA with 3 hydrogen bonds) to adenosine plus
thymidine (2 hydrogen bonds). Whilst formulae exist that can predict
primer annealing temperatures, in practice they require to be determined
empirically. Magnesium concentration can affect many aspects of the PCR
reaction, including primer annealing, polymerase enzyme activity and
DNA strand dissociation temperature (Innis and Gelfand 1990).
Commonly useful concentrations vary between 1 and 2 mmol final
concentration in the PCR reaction (Innis and Gelfand 1990). Using a
standard lOOpl PCR reaction 4 Mg2+ concentrations (1,1.25,1.5 and 2
mmol) were assessed for each primer pair , at each of the following
annealing temperatures: 51°C, 53°C, 55°C,57°C and 59°C, in addition exon
7 was assessed at 61°C, all other reagent concentrations and reaction
parameters being fixed. Optimal conditions were defined as those in
which a single intense band of PCR product of the appropriate size could
reproducibly be visualised following agarose gel electrophoresis.
Illustrative examples of the effect of annealing temperature and Mg2+
concentration on reactions are shown in Figure 3.1. It can be seen that for
both exon 5 and 6 PCR products single bands of product of the appropriate
size (263 and 157 base pairs respectively) are visualised at a Mg2+
concentration of lmmol. However for higher concentrations of 1.5 and 2
mmol non-specific extra bands are seen. Additionally for exon 6 reactions
it can be seen that the yield of PCR product (indicated by the intensity of
the band of product visualised on agarose gel electrophoresis) is greater
when an annealing temperature of 53°C rather than 57°C is used.
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For all 4 pairs of primers a Mg2+ concentration of lmmol was optimal
(with higher Mg2+ concentrations frequently giving rise to nonspecific
extra bands of product). The following annealing temperatures were
adopted for subsequent use:
Exon 5 primer pair 57°C
Exon 6 primer pair 53°C
Exon 7 primer pair 59°C
Exon 8 primer pair 57°C
The same annealing temperatures and Mg2+ concentrations were equally
suitable for 20pl PCR reactions.
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Figure 3.1
Agarose gel electrophoresis demonstrating the effect of Mg 2+
concentration and annealing temperature on PCR reactions,
a) Annealing Temperature 57°C.
DL abcdef ghijkl
Lanes a-f represent pairs of samples of exon 5 PCR products with PCR
Mg2+ concentrations of 1,1-5 and 2 mmol respectively, and lanes g-1
represent pairs of exon 6 PCR products with PCR Mg2+ concentrations of
1,1.5 and 2 mmol respectively. DL represents a 100 base pair DNA ladder.
b) Annealing Temperature 53°C.
DL m n
Lanes m and n represent a pair of exon 6 PCR products with a PCR Mg2+
concentrations of 1 mmol, all reaction conditions being the same as used
in Figure 3.1a except for the annealing temperature. DL represents a 100
base pair DNA ladder.
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3.2 p53 Status of Cancer Cell Lines Used
The cell lines used are described in the materials and methods chapter
(2.4.8a). The p53 status of each of the cell lines used was established by
direct sequencing of the exons of interest.
The sequence of exons 5,6,7 and 8 of cell lines MCF-7 and A2780 was
confirmed to be wild type (gels not shown; sequence listed in Appendix 2).
DNA from these cell lines was therefore used as a source of control wild
type DNA in subsequent studies.
Figure 3.2 demonstrates mutations found in cell lines H69, T47D ,
OVCAR 3 and MDA MB 231, alongside examples of corresponding wild
type sequence. The mutations are listed below and confirm those reported
previously (Hensel et al 1991, Nigro et al 1989, Yaginuma et al 1992, Bartek
et al 1990a):
H69 exon 5 codon 171 GAG -TAG
T47D exon 6 codon 194 CTT -TTT
OVCAR 3 exon 7 codon 248 CGG-CAG
MDA MB231 exon 8 codon 280 AGA- AAA
It was confirmed that no additional mutations were present in the exons
studied, and that both from sequencing gels and subsequent SSCP patterns
none of the cell lines carried a wild type copy of the relevant exon in
addition to the mutated one. These cell lines were therefore used as
sources of control mutant DNA in subsequent studies.
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Figure 3.2
Autoradiographs of sequencing gels demonstrating the presence of p53
mutations in cancer cell lines H69, T47D, OVCAR 3, and MDA MB 231.
a) i) Cell line A2780 carries a wild type GAG sequence at codon 171 in exon
5 of the p53 gene, whilst ii) cell line H69 is seen to have a GAG - TAG
mutation at this site.
b) i) Cell line A2780 carries a wild type CTT sequence at codon 194 in exon
6 of the p53 gene., whilst ii) cell line T47D is seen to have a CTT - TTT
mutation at the same site.
GATC GATC
iOLf
c) i) Cell line A2780 carries a wild type CGG sequence at codon 248 in exon
7 of the p53 gene, whilst ii) cell line OVCAR 3 is seen to have a CGG-CAG
mutation at this site.
d) i) Cell line A2780 carries a wild type AGA sequence at codon 280 in
exon 8 of the p53 gene, whilst ii) cell line MDA MB 231 is seen to have an
AGA-AAA mutation at this site.
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3.3 Assessment of the Effect of SSCP Gel Conditions on Distinguishing
Wild Type and Mutant PCR Products Using Polyacrylamide Gels
The gel composition and running conditions are known to be of critical
importance in the ability of SSCP to demonstrate the presence of a
mutation. The technique was originally described using a 5% acrylamide
gel at room temperature. However as discussed in Chapter 1.9 reports
suggest that modifications such as the addition of 5-10% glycerol to the
gel, running the gel at 4°C or the use of a higher concentration of
acrylamide (8-10%) with a low concentration of bisacrylamide (1.3-2%)
may enhance mutation detection. The addition of glycerol is felt to be
particularly important at room temperature. It has been stressed that for
optimal mutation detection the product to be screened should be run
under 2 or more sets of gel conditions. Taking these data into account the
ability of SSCP to infer the presence of a mutation in the 4 known
mutation carrying cell lines was assessed under a variety of gel
conditions. The gel conditions assessed were as follows:
A) 8% acrylamide, 2% bisacrylamide with 10% glycerol run at
room temperature (8G,RT)
B) 10% acrylamide, 1.3% bisacrylamide with 10% glycerol run at
room temperature (10G,RT)
C) 8% acrvlamide, 2% bisacrvlamide with no glycerol run at 4^C' U - - U KS S
(8NG,C)
D) 10% acrylamide, 1.3% bisacrylamide with no glycerol run at
4°C (10NG,C).
E) 8% acrylamide, 2% bisacrylamide with 10% glycerol run at
40C (8G,C)
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F) 10% acrylamide, 1.3% bisacrylamide with 10% glycerol run at
40C (10G,C)
For each exon 32P radiolabelled PCR was performed using duplicate
samples of DNA from each of the 2 wild type cell lines and the mutation
carrying line. The demonstration of a difference between samples was
only considered to have been successful when there was an unequivocal
SSCP pattern difference between the wild type and mutant samples. In
instances when the migration pattern was similar/equivocally different
the samples were considered to be indistinguishable by SSCP under those
particular running conditions. Samples were run on at least 2 separate
occasions using products from separate PCR reactions. Examples of
autoradiographs are shown in Figure 3.3 and the results summarised in
Table 3.1.
It can be seen that for all mutation carrying cell lines an abnormal SSCP
pattern was seen under at least 3 sets of gel conditions, but that only 1
mutation (OVCAR 3, exon 7) was clearly identifiable under all conditions
studied. In all cases the SSCP patterns of both the wild type cell line DNA
samples (MCF-7 and A2780) were indistinguishable (data not shown). It is
seen that on occasions there are several single strand bands visualised
rather than the 2 expected. This is a common occurence with SSCP and is
explained by the ability of any given single strand to adopt more than 1
conformation under SSCP conditions, with each conformation having it's
own migration pattern. It is also noteworthy that, whilst the results
appeared reproducible in that if an abnormal SSCP pattern appeared for a
particular set of gel conditions repeat testing would again demonstrate a
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difference compared to wild type, gels run at room temperature did show
a degree of variabiltiy in the exact pattern probably reflecting the effect of
differences in ambient room temperature on the conformation adopted
by the individual single strands.
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Figure 3.3
Autoradiographs of SSCP gels demonstrating the effect of gel running
conditions on the ability of SSCP to distinguish wild type from mutation
carrying PCR products. Gel types: A = 8% acrylamide, 2% bisacrylamide
with 10% glycerol run at room temperature, B = 10% acrylamide, 1.3%
bisacrylamide with 10% glycerol run at room temperature, C = 8%
acrylamide, 2% bisacrylamide with no glycerol rim at 4°C,D = 10%
acrylamide, 1.3% bisacrylamide with no glycerol run at 4°C, E = 8%
acrylamide, 2% bisacrylamide with 10% glycerol run at 4°C, F = 10%
acrylamide, 1.3% bisacrylamide with 10% glycerol run at 4°C. Lanes
labelled W carry wild type product and M carry mutant product, d
indicates that wild type and mutant product were considered
distinguishable on SSCP and i that they were indistinguishable or
equivocally different.
a) Exon 5: comparing SSCP patterns for wild type PCR product and
mutation carrying product from H69 cell line.
Gel A B CD E F
d d i i d i
WM WM WM WM WM WM
b) Exon 6: comparing SSCP patterns for wild type PCR product and
mutation carrying product fromT47D cell line.
Gel A B C D E F
I - T" -- ••
d d i d i i
WMWMWMWM WMWM
c) Exon 7: comparing SSCP patterns for wild type PCR product and
mutation carrying product from OVCAR 3 cell line.
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d) Exon 8: comparing SSCP patterns for wild type PCR product and
mutation carrying product from MDA MB 231 cell line.






The effect of polyacrylamide gel running conditions on the ability of SSCP
to detect a difference between wild type PCR product (WT) and products
carrying mutations in exons 5, 6, 7 or 8 of the p53 gene (H69, T47D,
OVCAR 3, MDA MB 231 respectively). DIST indicates that mutant and
wild type were clearly distinguishable and IND that they were
indistinguishable. Gel type is as defined in section 3.3.
Exon 5 Exon 6 Exon 7 Exon 8
Gel H69/WT T47D/WT OVCAR3/WT MDA /WT
A: 8G,RT DIST DIST DIST IND
B: 10G,RT DIST DIST DIST DIST
C: 8NG,C IND IND DIST DIST
D: 10NQC IND DIST DIST DIST
E: 8G,C DIST IND DIST DIST
F: 10G,C IND IND DIST DIST
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3.4 Sensitivity of SSCP in Mutation Detection in a Mixed Cell
Population Using Polvacrvlamide Gels
It was regarded as being of central importance to the subsequent clinical
studies to assess the sensitivity of SSCP to detect mutations in a mixture
of mutation-carrying and wild type cells. This would model the nature of
the clinical samples to be collected (which from their nature, would be
likely to contain such a mixture). Previous work had suggested that
mutations could be detected using SSCP in mixtures containing a lower
limit of between 5% and 25% of mutation carrying cells (Smith TA et al
1992, Wu J et al 1993 ). Accordingly duplicate series of cell dilutions were
prepared for each mutation carrying cell line containing a range from 1%-
50% of mutant cells made up with MCF-7 or A2780 cells respectively.
PCR-SSCP was performed on DNA from each of the dilution series on
those gel types that had earlier been shown to demonstrate that particular
mutation. The MCF-7 and A2780 series were run in parallel, so that in
effect the experiments were performed in duplicate. Representative
examples are illustrated in Figure 3.4 and the results summarised in Table
3.2. It is seen that the range of limits of sensitivity obtained was wide
(range 1-30% of mutation carrying cells in the sample), but that for each of
the 4 mutations studied 1 or more sets of gel conditions yielded a most
sensitive detection limit of 5% or fewer mutant cells. It is noteworthy that
on the occasions when the results between the A2780 and MCF series
differed, in each case, greater sensitivity was seen with the A2780 series.
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Figure 3.4
Autoradiographs of SSCP performed on polyacrylamide gels
demonstrating examples from the range of sensitivities of mutation
detection in DNA extracted from mixtures of wild type and mutation
carrying cells. M denotes mutant product, W wild type and X% indicates
the percentage of mutation carrying cells in samples. Arrows indicate
abnormally migrating mutant bands.
a) SSCP of p53 exon 8 PCR products rim on an 8% acrylamide gel without
glycerol at 4°C. The presence of an abnormal SSCP pattern remains
discernable in mixtures of cells containing 1% of mutation carrying cells.
W 50% 30% 20% 15% 10% 5% 1% M
b) SSCP of p53 exon 5 PCR products rim on an 8% acrylamide gel with
glycerol at 4°C. The presence of an abnormal SSCP pattern is discernable
in mixtures of cells containing 5% or more mutation carrying cells.
W 50% 30% 20% 15% 10% 5% 1% M
c) SSCP of p53 exon 7 PCR products run on a 10% acrylamide gel without
glycerol at 4°C. The presence of an abnormal SSCP pattern is discernable
in mixtures of cells containing 5% or more mutation carrying cells.
d) SSCP of p53 exon 8 PCR products run on an 8% acrylamide gel with
glycerol at 4°C. The presence of an abnormal SSCP pattern is discernable
in mixtures of cells containing 30% or more mutation carrying cells.
W 50%_30^ 20% 15% 10% 5% 1% M
US
Table 3.2
The effect of SSCP gel running conditions on the ability of SSCP to
demonstrate the presence of mutation carrying DNA in the presence of
wild type DNA. For each gel condition used the sample containing the
lowest percentage of mutation carrying cells in which an abnormal SSCP
pattern could be discerned is indicated. Gel type is as defined in section 3.3
Exon 5: dilutions of EI69 cells with p53 wild type A2780 and MCF 7 cells
Gel A2780 series MCF-7 series
A: 8G,RT 5% 10%
B: 10G,RT 5% 10%
E: 8G,C 5% 5%
Exon 6: dilutions of T47 D cells with p53 wild type A2780 and MCF 7 cells
A2780 series MCF-7 series
A: 8G,RT 30% 30%
B: 10G,RT 30% 30%
D:10NG,C 5% 10%
Exon 7: dilutions of OVCAR 3 cells with p53 wild type A2780 and MCF 7
cells
A2780 series MCF-7 series
A: 8G.RT 5% 10%
B: 10G,RT 5% 10%
C: 8NG,C 5% 10%
D: 10NG,C 5% 10%
E: 8G,C 20% 30%
F: 10G,C 20% 20%
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3.5 SSCP Using MDE Gel Matrix
The use of a novel polyacrylamide-derived matrix, MDE (Mutation
Detection Enhancement) has been reported to significantly improve the
ability of SSCP to resolve subtle conformational differences between
samples, with resultant increased sensitivity in terms of mutation
detection (Liu and Sommer 1994). It was therefore felt appropriate to
investigate whether these properties may also offer an advantage in terms
of the sensitivity of mutation detection in a mixed cell population. A
variety of gel conditions have been described for MDE, and for the
purposes of this study the following were assessed, taking into account
the manufacturers recommendations:
A: 0.5x MDE in 0.6x TBE with no glycerol run at room temperature
(MNG,RT)
B: 0.5 AIDE in 0.6x TBE with 5% glycerol run at room temperature
(MG,RT)
C: 0.5 MDE in 0.6x TBE with no glycerol run run at 4°C (MNG,C)
D: 0.5 MDE in 0.6x TBE with 5% glycerol run at 4°C (MG,C)
Two series of experiments were performed, the first to establish which gel
conditions were able to demonstrate a difference in SSCP pattern between
wild type PCR product and that of each of the 4 mutation carrying cell
lines and the second to establish the limits of detection for SSCP when
mutant and wild type cell mixes were analysed.
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3.5.1 Assessment of the Effect of SSCP Gel Conditions on Distinguishing
Wild Type and Mutant PCR Products Using MDE Gels
For each exon 32P radiolabeled PCR-SSCP was performed using samples
of DNA from a wild type cell line and the mutation carrying line. The
demonstration of a difference between samples was only considered to
have been successful when there was an unequivocal SSCP pattern
difference between the wild type and mutant samples. In instances when
the migration pattern was similar/equivocally different the samples were
considered to be indistinguishable by SSCP under those particular
running conditions. Samples were run on at least 2 separate occasions
using products from separate PCR reactions, results in all cases being
concordant. The effect of gel type on the SSCP pattern for exon 8 samples
is illustrated in Figure 3.5, and the results are summarised in Table 3.3.
For each mutation an abnormal SSCP pattern was seen under at least 2
sets of conditions, with the exon 7 mutation seen under all 4 and
therefore in this small series MDE gels would appear to offer no particular
advantage to the polyacrylamide gels tested earlier. The addition of
glycerol to MDE gels would appear to improve the likelihood of mutation
detection, with a difference between wild type and mutant being seen in 7
out of 8 occasions for glycerol containing gels and 3 out of 8 for gels




Autoradiographs of SSCP gels demonstrating the effect of MDE gel
running conditions on the ability of SSCP to distinguish wild type from
mutation carrying exon 8 PCR products. Gel types: A = 0.5x MDE gel with
no glycerol run at room temperature, B = 0.5x MDE gel with 5% glycerol
run at room temperature, C = 0.5x MDE gel with no glycerol run at 4°C,
D = 0.5x MDE gel with 5% glycerol rim at 4°C. Lanes labelled W carry
wild type product and M carry mutant product, d indicates that wild type
and mutant product were considered distinguishable on SSCP and i that
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Table 3.3
The effect of MDE gel running conditions on the ability of SSCP to detect a
difference between wild type PCR product (WT) and products carrying
mutations in exons 5, 6, 7 or 8 of the p53 gene (H69, T47D, OVCAR 3,
MDA MB 231 respectively). DIST indicates that mutant and wild type
were clearly distinguishable and IND that they were indistinguishable.
Exon 5 Exon 6 Exon 7 Exon 8
Gel H69/WT T47P/WT OVCAR3/WT MDA /WT
A: MNG,RT IND IND DIST IND
B: MG,RT DIST DIST DIST IND
C: MNG,C IND IND DIST DIST
D: MG,C DIST DIST DIST DIST
3.5.2 Sensitivity of SSCP in Mutation Detection in a Mixed Cell
Population Using MDE Gels
The primary objective of this series of experiments was to establish
whether or not SSCP performed using a variety of MDE gel conditions
was superior in sensitivity to polyacrylamide gel analysis. Consequently
DNA from the cell mixes described earlier were used, but this time using
only the A2780 series of mixes in the l%-20% range. Each series was run
on each of the gel conditions able to demonstrate the mutation in that
particular exon on 2 occasions using products from the same PCR
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reaction. Autoradiographs illustrating gels from throughout the range of
sensitivities detected are shown in Figure 3.6. The results are summarised
in Table 3.4 below, showing in each case the lower limit of detection for
each dilution series, in terms of percentage of mutation carrying cells in
the sample. NA indicates that for that particular mutation and gel type
the sensitivity was not assessed because mutant and wild type forms were
indistinguishable. Where results differed between the 2 runs the second
result is shown in brackets.
Table 3.4
Exon 5 Exon 6 Exon 7 Exon 8
Cell Mix H69/WT T47D/WT OVCAR 3/WT MDA/WT
Gel Type
A: MNG, RT NA NA 5% NA
B: MG, RT 5% >20% 15% NA
C: MNG,C NA NA 5% 10%
D: MG,C 5% >20% 15% (10%) >20%
It can be seen that as for acrylamide gels there is substantial variability in
the sensitivities observed. The lower limit of detection was 5% mutation
carrying cells for 2 of the mutations studied. However for the T47D /
Wild Type mix the mutation was not detectable at the 20% level for either
of the gel conditions studied, and for the MDA/ Wild Type mix the
detection limit was 10%. The use of MDE gels for SSCP under the
conditions studied appeared therefore to offer no advantage in terms of
sensitivity over acrylamide gels.
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Figure 3.6
Autoradiographs of SSCP performed on MDE gels demonstrating
examples from the range of sensitivities of mutation detection in DNA
extracted from mixtures of wild type and mutation carrying cells. M
denotes mutant product, W wild type and X% indicates the percentage of
mutation carrying cells in samples. Arrows indicate abnormally
migrating mutant bands.
a) SSCP of p53 exon 7 PCR products run on a 0.5x MDE gel without
glycerol at room temperature. The presence of an abnormal SSCP pattern
is discernable in mixtures of cells containing 5% or more mutation
carrying cells.
W 20% 15% 10% 5% 1% M
b) SSCP of p53 exon 8 PCR products run on a 0.5x MDE gel without
glycerol at 4°C. The presence of an abnormal SSCP pattern is discernable
in mixtures of cells containing 10% or more mutation carrying cells.
W 20% 15% 10% 5% 1% M
Figure 3.6
c) SSCP of p53 exon 8 PCR products run on a 0.5x MDE gel with
5% glycerol at 4°C. The presence of an abnormal SSCP pattern is not
discernable even in mixtures containing 20% mutation carrying cells.
99*999"
lillili
W 20% 15% 10% 5% 1% M W
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Discussion
The above data illustrate a number of important points:
1) The ability of SSCP to detect the presence of a mutation depends
critically on the gel conditions used.
2) The sensitivity of SSCP in detecting the presence of mutations in a
mixed cell population also depends critically on the gel conditions used.
3) Since in only one instance an abnormal SSCP pattern was seen for a
sample containing only 1% of mutation carrying cells, this is likely to be
the best limit of sensitivity achievable with this technique. This was not
tested by performing further dilutions as in the context of the other
results even if a lower level had been found it would not have been
typical of that commonly achievable.
4) When using polyacrylamide, a lower detection limit of 5% or better
was achieved for each of the 4 A2780/mutant dilution series, the optimal
gel conditions being variable and unpredictable. This level could be
regarded as a realistic practical limit of detection.
5) MDE gels appeared to offer no particular advantage over
polyacrylamide gels, either in terms of disinguishing mutant from wild
type PCR products, or in terms of the ability to detect SSCP abnormalities
in samples containing only a small proportion of mutation carrying cells.
Thus as the MDE gel matrix is considerably more expensive than
acrylamide it was not further used.
6) When there was a sensitivity difference between the A2780 and MCF-7
dilution series this was always in the same direction (the detection limit
being lower in the A2780 series). The reasons for this are not clear though
it could either reflect a systematic error in counting of one of the cell
lines or possibly a difference in p53 gene copy number between the 2 cell
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lines. The differences were never more than to the next dilution level
and as such did not materially affect the conclusions or implications of
the results.
It can be concluded that to maximise mutation detection in a mixed cell
population SSCP has to be performed on at least 2 or 3 different sets of gel
conditions because the sensitivity of any particular gel type for a particular
mutation can not be predicted. There have been only 2 previous reports
of studies addressing this issue. Wu et al (1993) performed SSCP on
mixtures of wild type DNA and tumour DNA from 2 tumours with p53
point mutations. In one case the detection limit was 5% and in the other
15%. Smith et al (1992) describe a study mixing cells with and without a
heterozygous mutation of the CTP synthetase gene. The mutation was
identifiable by SSCP in mixes containing 25% of mutation carrying cells.
This latter study's results are not directly comparable to those
investigating p53 mutations, as the CTP synthetase mutation carrying
cells also carried one normal copy of the gene, further diluting the
effective proportion of the mutation, whereas in the case of a p53
mutation the second allelle is most commonly deleted. However even if
this is accounted for, the limits of detection are not as good as in the
present study. It is perhaps noteworthy that both the above studies would
appear to have used only 1 set of SSCP conditions, emphasising the
importance of using multiple conditions if sensitivity is to be maximised.
There are little published data on the sensitivity of other mutation
detection screening methods in this context, such as dideoxy
fingerprinting, heteroduplex analysis, denaturing gradient gel
electrophoresis and chemical cleavage of mismatch. However as the
limiting factor in all techniques would be the resolution of identifying an
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abnormally migrating DNA product on an electrophoresis gel, none are
likely to improve significantly on that demonstrated for SSCP. As
discussed elsewhere if the objective changes to the detection of previously
characterised mutations improvement of several orders of magnitude can
be achieved.
It has been reported that the use of MDE gel matrix increases the
sensitivity of SSCP in distinguishing wild type and mutant PCR products
(Liu and Sommer 1994). This was not demonstrated in the current study,
however these findings are consistent with further reports (Ravnik-
Glavac et al 1994, Vidal-Puig and Moller 1994) that indicated that fully
optimised SSCP using acrylamide gels was as sensitive as with MDE gels.
There are no published data on the sensitivity of SSCP in detecting
abnormailities in mixed cell populations using MDE, but the current
study does not support the use of MDE in this setting.
From a practical point of view a decision had to taken as to the SSCP gel
conditions to be used to analyse the samples from the 2 clinical studies
undertaken. Bearing in mind the variability of the results seen it was
decided to choose for each exon 1 room temperature gel with glycerol, 1
gel at 4°C with glycerol and 1 at 4°C without glycerol. The gels were
chosen largely on the basis of the sensitivity of the gels to demonstrate
mutations in cell mixing experiments. However for exon 5 neither of the
gels tested without glycerol at 4°C demonstrated an abnormal SSCP
pattern for H69 cell line DNA and therefore 1 was chosen randomly; the
same applied to exon 6 for T47D cell line DNA and gels with glycerol run
at 4°C.
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The following gels were used in analysis of clinical samples:
Exon 5 A: 10G,RT C: 8NG,C
C: 8NG,C
E: 8G,C
Exon 6 A: 10G,RT E: 8G,C
Exon 7 A: 10G,RT D: 10NG,C E: 8G,C
Exon 8 A: 10G,RT D: 10NG,C E: 8G,C
It is fully appreciated that the sensitivities of SSCP elicited in the mixing
experiments will not apply to all mutations in that particular exon, as the
nature of the mutation will influence SSCP migration patterns and thus
possibly sensitivity. Elowever the sensitivities were used as a pragmatic
guide, in the absence of more reliable guides to making a rational choice.
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CHAPTER 4
STUDIES ON p53 MUTATIONS IN BLADDERWASHING SPECIMENS
FROM PATIENTS WITH BLADDER CANCER
Aims: The objective of this part of the study was to investigate whether it
was possible to detect the presence of malignancy in bladder washing
samples from patients with known bladder cancer, using p53 mutations
as a biochemical marker. Previously published work based on a small
series of patients had indicated that the presence of p53 mutations was
detectable in the urine of such patients by using time consuming
methodologies involving cloning and the use of mutation specific
oligonucleotide probes designed for the particular mutation earlier
identified in that subject's tumour ( Sidransky et al 1991).
For the purposes of this study mutations in p53 were screened for using
SSCP, which as has been discussed earlier is a comparatively simple
mutation detection method, not requiring prior characterisation of the
particular mutation present.
The DNA yield from bladder washing specimens was found to be such
that it was feasible to perform multiple PCR reactions on DNA extracted
from each specimen (data not shown). Therefore the strategy of
investigation was first to screen the bladdder washing samples for the
presence of mutations and subsequently to confirm their presence in the
corresponding bladder tumour sample whilst also screening the tumour
samples for the presence of any mutations not detected in the bladder
washings. Any samples found on SSCP to have an abnormal pattern




4.1 SSCP Analysis of Bladder Washing Specimens
31 bladder washing specimens were collected from a total of 27 patients
with known bladder cancer, samples being collected from 4 patients on 2
separate occasions. In all cases there was a macroscopically visible bladder
abnormality present at the time the bladder washing was collected. Details
of the age of subject, histological type and grade of tumour, pathological
stage when known and details of any previous treatment for bladder
cancer are shown in Appendix 2. Pathological evaluation of the surgical
biopsy from 2 patients with a prior history of bladder cancer revealed no
tumour but the presence of CIS in one case and dysplastic urothelium in
the other.
DNA was extracted from the bladder washing samples. PCR-SSCP was
performed for each of exons 5-8 of the p53 gene using 3 sets of SSCP
conditions for each exon as discussed in Chapter 3. For each exon studied
the PCR reaction included a negative, no template control to demonstrate
absence of contamination of the PCR reaction and a sample both of wild
type and mutation carrying cell line DNA for that exon; the wild type
sample acting as a normal reference control, to which the migration
pattern of the tumour DNA samples could be compared and the
mutation carrying sample allowing comparison of migration pattern to
that of previous gels run under the same conditions ensuring interassay
consistency. Where the migration pattern of a sample indicated the
possibility of a p53 mutation a further PCR reaction was performed and
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SSCP repeated. If there was a disparity between the 2 results the PCR-SSCP
was repeated again and the sample only considered to potentially contain
a mutation if the same abnormal migration pattern was seen on at least 2
occasions, the abnormal pattern otherwise being attributed to artifact.
A total of 5 samples from 5 separate patients demonstrated an abnormal
SSCP pattern. Two abnormalities were seen in exon 6, 2 in exon 7 and 1 in
exon 8, whilst for all subjects the SSCP pattern for exon 5 was
indistinguishable from wild type. These abnormalities are demonstrated
in Figure 4.1 and the results are summarised in Table 4.1 (exons 5 and 6)
and Table 4.2 (exons 7 and 8).
It is noteworthy that of the 5 subjects in whom an abnormal SSCP pattern
was demonstrated 1 had 2 bladder washing samples collected at the time
of different cystoscopies, with 1 sample demonstrating an abnormality
and the other not (samples 18 and 26 respectively; Figure 4.1a,b, Table 4.1).
It can also be seen that of the 5 abnormalities found, only 2 were seen
under all 3 sets of gel conditions used (samples 18 and 27; Table 4.1), with
1 being seen under 1 (sample 30; Table 4.2) and 2 under 2 sets of
conditions (samples 3 and 19; Table 4.2).
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Figure 4.1
Autoradiographs of SSCP gels demonstrating abnormal migration
patterns consistent with the of the presence of mutations in 5 out of 31
bladder washing samples from patients with bladder cancer,
a) Exon 6. An abnormal extra band is seen in sample 18 (indicated by
arrow); lane A is A2780 cell line normal control; all other lanes contain
bladder washing samples with normal SSCP pattern.
i.lllii::
A 18
b) Exon 6. An abnormal extra band is seen in sample 27 (indicated by
arrow); lane A is A2780 cell line normal control; all other lanes contain
bladder washing samples with normal SSCP pattern, in particular sample
26 which is from the same patient as sample 18 (Figure 4.1a) but taken on
a separate occasion doesn't show an abnormality despite the presence of
tumour at cystoscopy at the time of sample collection.
27 26
Ml
Figure 4.1 c) Exon 7. An abnormal extra band is seen in sample 3 and two
extra bands in sample 30 (indicated by arrows); lane A is A2780 cell line
normal control.
A 30
d) Exon 8. An abnormal extra band is seen in sample 19 (indicated by
arrow); lane A is A2780 cell line normal control; all other lanes contain



















A 3 N N N N N N
B 6 N N N N N N
C 7 N N N N N N
























G1 12 N N N N N N
G2 33 N N N N N N
H 13 N N N N N N
I 14 N N N N N N
J1 15 N N N N N N
J2 31 N N N N N N
K 16 N N N N N N
L 17 N N N N N N
Ml 18 N N N ABN ABN ABN
M2 26 N N N N N N
N 19 N N N N N N
O 20 N N N N N N
P 21 N N N N N N
Q 22 N N N N N N
R 23 N N n n n n
S 25 n n N n N n
T 27 n n N ABN ABN ABN
U 28 N N N N N N
V 29 N N N N n N
w 30 N N N N n N
X 32 N n : N N 1n N
Y 40 N N | N N N N
Z 41 N N N N N N
AA 50 N N N N N N
Patient suffix 1 and 2 indicates samples taken on separate occasions
N : Normal SSCP Pattern ABN: Abnormal SSCP Pattern
Gel A: 10% acrylamide, 1.3% bisacrylamide, no glycerol, 4°C
Gel C: 8% acrylamide, 2% bisacrylamide, 10% glycerol, 4°C




Results of SSCP analysis of Exons 7 and 8 of the p53 gene in 31 Bladder
Washing Samples.
Exon 7 Exon 7
Gel C
Exon 7 Exon 8 Exon 8 Exon 8
Patient Sample Gel B Gel D Gel B Gel C Gel D
A 3 ABN N ABN N N N
B 6 N N N N N N
C 7 N N N N N N
D 8 N N N N N N
El 9 N N N N N N
E2 24 N N N N N N
F 10 N N N N N N
G1 12 N N N N N IN
33 N N N N N N
H 13 N N N N N N
I 14 N N N N N N
n 15 N N N N N N
J2 31 N N N N N N
K 16 N N N N N N
ir^H 17 N N N N N N
Ml 18 N N N N N N
M2 26 N N N N N N
N 19 N N N ABN N ABN
O 20 N N N N N N
P
Q
21 N fN N N N N
22 N N N N N N
R 23 N N N N N N
S 25 N N N N N N
I 27 n N N N N N
u 28 N N N N N N
v | 29 N N N nT N N
W ! 30 ABN ! N N N N N
X ! 32 N ; N N N N N
Y —| 40 N | N N N N j N
Z 41 N N N N N N
AA 50 N I N N N N N
Patient suffix 1 and 2 indicates samples taken on separate occasions
N : Normal SSCP Pattern ABN: Abnormal SSCP Pattern
Gel B: 8% acrylamide, 2% bisacrylamide, no glycerol, 4°C
Gel C: 8% acrylamide, 2% bisacrylamide, 10% glycerol, 4°C
Gel D: 10% acrylamide, 1.3% bisacrylamide, 10% glycerol,
room temperature
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4.2 SSCP Analysis of Bladder Tumour Specimens
Freshly-stored bladder tumour specimens collected at the time of bladder
washing sample collection were available for 23 of the 31 washing
samples. These included samples from 16 of the 23 subjects from whom 1
bladder washing was collected. Of the 4 subjects from whom 2 washings
were collected, fresh tumour was available from 1 of the cystoscopies in 1
case and both in 3 cases. All tumour samples available were screened for
the presence of mutations in exons 5,6,7, and 8 of the p53 gene as
described for the bladder washing specimens.
Six tumour specimens from 4 subjects demonstrated an abnormal SSCP
pattern . Of the mutations, 1 was in exon 7, 2 in exon 6 and 3 in exon 8.
These abnormalities are demonstrated in Figure 4.2 and the results
summarised in Table 4.3 (exons 5 and 6) and Table 4.4 (exons 7 and 8). The
abnormal samples included 3 tumour specimens from 2 of the 5 patients
who had bladder washing samples demonstrating an SSCP abnormality.
In these cases the abnormal patterns of the washing and corresponding
tumour were of similar appearance, this being highly indicative of the
samples carrying the same mutation (an example is demonstrated in
Figure 4.2c). There were in addition 3 tumour samples (from 2 patients)
with abnormal SSCP patterns in whom the corresponding washing
samples were of normal appearance (demonstrated in Figures 4.2b and
4.2c); of these the abnormality from one patient was seen on only 1 gel
type and from the other on 2 gel types.
Therefore there were 3 cases (samples 3, 27 and 30) in which the tumour
showed no evidence of a mutation but in whom the bladder washing
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Figure 4.2
SSCP gels demonstrating abnormal migration patterns consistent with
the presence of mutations in the p53 gene in 6 out of 23 bladder tumour
specimens.
a) Exon 6. An abnormal extra band (indicated by arrow) is seen in the
same position in both samples 18 and 26; these samples being bladder
tumour specimens collected from the same patient on 2 separate
occasions.
18 26
b) Exon 7. An abnormal extra band (indicated by arrow) is seen in sample
41T (bladder tumour). Lane A is an A2780 cell line normal control.
Sample 41W is the bladder washing sample corresponding to sample 41T;




c) Exon 8. An abnormal extra band (indicated by arrow) is seen in the
same position in both samples 9T and 24T; these samples being bladder
tumour specimens collected from patient E on 2 separate occasions.
However this abnormal extra band is not visualised in either of the
corresponding bladder washing samples 9W and 24W. An abnormal extra
band (indicated by ) is seen in the same position in samples 19T and
19W representing bladder tumour and bladder washing samples
respectively taken on the same occasion from patient N, demonstrating
the same abnormality in matched samples. Lane A is an A2780 cell line
normal control.
9 19T 24 19W 9W24W A
Table 4.3
Results of SSCP analysis of Exons 5 and 6 of the p53 gene in the 23 Bladder
Tumour Specimens available that were collected at the same time as
corresponding Bladder Washing Samples (no tumour being available on
8 out of 31 occasions).
Patient suffix 1 and 2 indicates samples taken on separate occasions
N : Normal SSCP Pattern ABN: Abnormal SSCP Pattern
Gel A: 10% acrylamide, 1.3% bisacrylamide, no glycerol, 4°C
Gel C: 8% acrylamide, 2% bisacrylamide, 10% glycerol, 4°C
GelD: 10% acrylamide, 1.3% bisacrylamide, 10% glycerol,
room temperature
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Table 4.4 Results of SSCP analysis of Exons 7 and 8 of the p53 gene in
the 23 Bladder Tumour Specimens available that were collected at the
same time as corresponding Bladder Washing Samples (no tumour being
available on 8 out of 31 occasions).
Patient suffix 1 and 2 indicates samples taken on separate occasions
N : Normal SSCP Pattern ABN: Abnormal SSCP Pattern
Gel B: 8% acrylamide, 2% bisacrylamide, no glycerol, 4°C
Gel C: 8% acrylamide, 2% bisacrylamide, 10% glycerol, 4°C
Gel D: 10% acrylamide, 1.3% bisacrylamide, 10% glycerol,
room temperature
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showed an abnormality in p53. The 4 main potential reasons for this are:
i) that the abnormalities demonstrated in the washing were artifacts; ii)
the tumour specimen taken was not representative of the tumour as a
whole; iii) the supposed tumour specimen actually consisted largely of
normal tissue despite its macroscopic appearance; and finally iv) the p53
abnormality seen in the washing sample had a source other than the
visible bladder tumour.
To attempt to address this issue paraffin embedded bladder tumour
specimens were obtained from the pathology department for all 3 subjects
in this category, the tumour sample having been obtained at the
operation at which the washing specimen was taken. DNA was extracted
from these specimens and PCR-SSCP performed for the relevant exon.
The results are illustrated in Figure 4.3. It can be seen that in each case an
abnormal SSCP pattern is demonstrated for the paraffin embedded
tumour sample including abnormal bands comigrating with the
abnormal bands seen in the corresponding bladder washing samples.
However for tumour samples corresponding to bladder wash 30
(Patient W) only 1 extra band is seen rather than the expected 2; the
paraffin blocks from which samples were taken for this patient contained
an estimated 20-40% tumour and this level may be the explanation for
only 1 of the 2 abnormal bands being seen.
The results indicate that low representation by tumour in the fresh




SSCP gels demonstrating the presence of abnormal migration patterns in
bladder washing samples and paraffin embedded tissue samples from
subjects from whom the fresh sample did not demonstrate a p53
abnormality.
a) Exon 6. Bladder washing samples (W) and paraffin embedded tumour
samples (T) in triplicate from patient T. An abnormal extra band
(indicated by arrow) is seen in all samples except the A2780 cell line
normal controls (A).
AWWWTTTA
b) Exon 7. An abnormal extra band is clearly seen in bladder washing
sample 3W (-► ) and 2 extra abnormal bands in bladder washing sample
30W (-<- and^* ), when compared to A2780 cell line normal control (A).
The corresponding abnormal band is seen in samples of paraffin
embedded tumour for sample 3 (labelled 3T). For sample 30 only 1 of the 2
extra bands is seen in paraffin embedded tumour (30T).
A 3W 30W 30T 30T 3T 3T
ibl
4.3 Correlation Between Mutation Detection In Surgical
Biopsy /Resection Samples and Bladder Washing Samples.
The concordance between the SSCP results obtained in tumour tissue and
bladder washing samples was evaluated. For the purposes of this
correlation a bladder tumour specimen was regarded as containing a
mutation if an abnormal SSCP pattern was seen in either fresh tissue or
in paraffin embedded tissue. There were 20 patients for whom pairs of
tumour and bladder washings were available for study:
16 with 1 bladder washing sample and corresponding tumour
3 with 2 bladder washings and tumour samples from both occasions
1 with 2 bladder washings but tumour from only 1 occasion.
In total therefore there were 23 pairs of samples obtained synchronously.
As demonstrated in Table 4.5, concordant results were obtained for the
p53 status of tumour and bladder washing specimens on 19 out of 23
occasions (83%). A total of 9 tumour samples from 7 patients
demonstrated a p53 abnormality with the abnormality seen in the
corresponding bladder washing sample in 5 cases ( 56%). In 1 patient 2
pairs of samples showed an abnormality in the tumour samples but
neither of the bladder washings. In 1 case 2 pairs of samples were again
available with only 1 of the 2 bladder washings demonstrating the
abnormality seen in both tumour samples. In the final case an




Correlation between SSCP abnormalities in the p53 gene detected in
paired Bladder Washing and Tumour Samples. Suffix 1 and 2 indicate
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4.4 Sequencing of Mutations Detected
Samples demonstrating an abnormal SSCP pattern were subjected to
direct sequencing to characterise the exact nature of the mutation present.
There were specimens from 7 patients that had shown an abnormal SSCP
pattern in either bladder washing samples, bladder tumour samples or
both (Table 4.5).
Mutations successfully characterised are demonstrated in Figure 4.4. They
include the following 3 mutations from patients who had an abnormal
SSCP pattern in their bladder washing samples:
Sample Patient Exon Wild Type Mutation Codon
18 M 6 GAG(Glu) GCG(Ala) 224
27 T 6 TAG TAA Upstream Splice Site
19 N 8 AGA(Arg) ACA(Thr) 280
In addition the following 2 samples (from the same patient E) were
sequenced in which the bladder washing had a normal SSCP pattern but
in which the tumour sample was abnormal :
Sample Exon Wild Type Mutation Codon
9 8 GAC(Asp) AAC(Asn) 281
24 8 GAC(Asp) AAC(Asn) 281
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Figure 4.4
Autoradiographs of sequencing gels confirming the presence of
mutations in samples from 4 patients with bladder cancer,
a) Bladder Washing Sample 18 from patient M demonstrating a
GAG - GCG mutation in codon 224 (exon 6).
b) Bladder Washing Sample 27 from patient T demonstrating a
TAG - TAA mutation at the 5' splice site of exon 6.
G A T C
\U.^>
c) Bladder Tumour Sample 19 from patient N demonstrating a
AGA - ACA mutation in codon 280 (exon 8). The bladder washing sample
from this patient demonstrated the same SSCP abnormality as the
Bladder Tumour Sample.
G A T C
d) Bladder Tumour Sample 9 from patient E demonstrating a
GAC - AAC mutation at codon 281 (exon 8). Bladder Tumour Sample 24
from the same patient demonstrated the same mutation on sequencing,





The putative mutation in 3 specimens showing SSCP abnormalities in
exon 7 could not be characterised. In all 3 cases when sequencing was
attempted using amplified DNA from the washing sample and/or
tumour the resulting sequence was indistinguishable from wild type.
This was most likely due to to the presence of a predominance of DNA of
normal tissue origin in the sample. Subsequently the abnormally
migrating bands seen on SSCP were excised from dried SSCP gels, the
single stranded product eluted and used as the template for
reamplification as a source of mutation carrying DNA for sequencing.
However despite several attempts using bands cut from different gels it
proved impossible to obtain a reamplification product for any of the
samples tested for this exon; (this method had been successfully used for
samples with mutations in other exons). It was felt likely that this was a
methodological problem reflecting the nature of that particular pair of
primers. Having failed to characterise the putative mutation in these 3
samples, the issue of whether or not the SSCP abnormalities seen actually
reflected the presence of mutation in these samples merited
consideration. In all 3 cases the same abnormal pattern was seen
reproducibly on at least 4 occasions using the products of different PCR
reactions. In addition for the 2 bladder washing samples concerned
(samples 3 and 30) duplicate stored pellets were available. DNA was
extracted from these and PCR - SSCP demonstrated the same abnormal
migration pattern that had previously been seen. Furthermore although
the originally studied fresh bladder tumour specimen from 2 of these
cases failed to show the SSCP abnormality the paraffin embedded tissue
did, the difference in pattern between samples most likely reflecting a
genuine difference between them i.e. the presence of mutation carrying
cells in variable amount rather than artifact. The observation that for
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tumour sample 41 the corresponding washing appeared normal could be
interpreted similarly.
4.5 SSCP Analysis of Tumour samples Without Corresponding
Washing Samples.
There were 2 tumour samples available for study for which there was no
corresponding washing available. For completeness these were also
screened for the presence of mutations in exon 5-8 of the p53 gene. Both
were from patients with high grade transitional cell carcinomas of the
bladder and 1 demonstrated an abnormality in exon 7 on SSCP with the
abnormality seen under all 3 sets of gel conditions used. The mutation
was sequenced as follows:
Exon Wild Type Mutation Codon
7 CGG (Arg) GAG (Gin) 248
This mutation is demonstrated in Figure 4.5. As discussed earlier
sequencing exon 7 mutations by reamplifying abnormal single stranded
DNA excised from dried gels did not prove technically possible. The high
ratio of abnormal to normal sequence seen on the SSCP gel allowed this
particular sample to be successfully sequenced direct from the PCR
product without the need for band excision and reamplification.
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Figure 4.5
Autoradiograph of a sequencing gel confirming the presence of a
CGG - CAG mutation in codon 248 (exon 7) in a bladder tumour sample
from a patient with a high grade transitional cell carcinoma of bladder
from whom no bladder washing sample was collected.
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4.6 Clinico-Pathological Characteristics of mutation Carrying Samples.
All mutation-carrying samples were from patients with high grade,
poorly differentiated cancers. In each case the histology was of transitional
cell carcinoma, although 2 samples from one patient also contained
elements of squamous carcinoma, that is mixed histology (samples 9 and
24 from patient E). All but 1 of the mutation carrying samples were from
patients with pTl or pT2 tumours, invading either the lamina propria or
deeper into detrusor muscle. The exception was a high grade pTa
recurrence in a patient treated with intravesical chemotherapy for a pTl
tumour that had demonstrated the same SSCP abnormality (sample 26
from patient M).
Samples were available from a total of 8 patients with well or moderately
differentiated bladder cancers (grade 1 or 2). No mutations were found in
either the bladder washing or tumour samples from any of these patients.
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Discussion
31 bladder washing samples from 27 patients with urothelial malignancy
were screened for mutations in exons 5-8 of the p53 gene. Bladder
washing samples from 5 patients with bladder cancer were found to
contain evidence of the presence of p53 mutations. In each case it was
possible to demonstrate SSCP abnormalities in the corresponding bladder
tumour sample. It proved possible to characterise the mutation by direct
sequencing in 3 of the 5 cases. In the other 2, both with abnormalities in
the same exon, technical difficulties did not permit the successful
reamplification of single stranded DNA bands excised from SSCP gels.
However the reproducible finding of the same SSCP abnormalities in the
bladder washings on repeat testing and the presence of the same
abnormal pattern in tumour samples is highly indicative of the presence
of mutation. Bladder tumour samples were also analysed in the same
way. When the results of studying fresh tumour and paraffin embedded
tissue are considered together a total of 9 out of 23 samples were shown to
carry a mutation in the p53 gene, representing samples from 7 out of 20
patients studied. There were 4 instances therefore in which a mutation
could be demonstrated in the tumour specimen but not in the
corresponding bladder washing sample.
Several observations concerning the above results are worthy of note.
Firstly, the detection of p53 mutations in tumour samples from 7 out of
the 20 patients from whom paired tumour and washing samples were
collected is consistent with previously published data, given that the
cohort included 4 patients with moderately or well differentiated
papillary superfical cancers that have a low incidence of mutations
(Fujimoto et al 1992, Esrig et al 1993). Despite this there remains concern
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that mutations were missed because of inadequate sampling of tumour.
The fresh tumour samples taken at operation represent shavings of
tumour resected endoscopically and were chosen macroscopically from
the debris evacuated from the bladder at the completion of the operation.
In retrospect it is quite likely that only a small proportion of tumour may
have been present in some samples. This is borne out by the fact that in
those instances in which the bladder washing showed a mutation but the
fresh frozen tissue did not, the mutation could be demonstrated in DNA
extracted from paraffin embedded tissue. As paraffin embedded tissue was
only obtained for those samples in which the washing showed a
mutation but fresh tumour did not, it remains possible other mutations
went undetected. The proportion of tumour in the paraffin embedded
samples was assessed by a pathologist (Dr. J. Webb, Western General
Hospital) and was found to be variable and on some occasions very low
(range <10% - 80%). It seems appropriate therefore to suggest that in any
further studies of this nature on bladder cancer that DNA is extracted
from microdissected tissue for analysis, or at least that the proportion of
tumour in the sample is assessed prior to DNA extraction. Whether this
tissue is frozen or paraffin embedded would depend on the proposed use
of the DNA. Fresh tissue provides higher yields of longer fragments of
well preserved DNA amenable to study with a larger range of techniques
but paraffin embedded tissue is often more readily available, easier to
store and yields DNA of adequate quality for a number of PCR based
techniques.
Five bladder washing samples from different patients were found to
contain mutations. For 1 patient 2 samples taken on different occasions
were studied and of these only 1 was positive for the presence of a
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mutation and the other negative. In addition primary tumour from 2
patients showed a mutation when the bladder washing appeared normal
(in 1 case on 2 separate occasions). In total there were 9 washing samples
available from patients whose primary tumour harboured a mutation,
with the mutation detected in the washing in 5 out of 9 cases (56%). It can
therefore be seen that by analysing the bladder washing samples alone
there were a number of false negative results, and that the proportion of
false negatives may well be an underestimate in view of the potential
sampling problem with tumour tissue discussed above. As bladder
washing samples were only taken when there was obvious tumour
visualised at cystoscopy, it seems likely that the washing sample would
have contained at least a small proportion of tumour cells and therefore
that the most likely explanation for the false negative results was the
limited sensitivity of SSCP in detecting minority cells in a mixed cell
population. In this study no attempt was made to quantify the proportion
of malignant cells in the bladder washings by conventional cytological
techniques, mainly because of the inherent unreliablity of such
techniques (Vet et al 1996). However the proportion would be expected to
vary depending on the size of the tumour, its biological properties in
particular the degree of cellular adhesion and other factors such as the
amount of ulceration and necrosis on the tumour's surface (the part of
the tumour sampled by bladder washing).
The original study on p53 mutations in bladder cancer reported by
Sidransky et al (1991) as well as characterising mutations in a cohort of 16
bladder cancers used mutation specific oligonucleotide probes to study the
corresponding urine samples from 3 patients with mutation carrying
tumours. Each of these 3 samples contained the same mutation as the
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tumour but such mutation-carrying cells were estimated to represent only
1 -7 % of the cellular component of the urinary sediment. It is thus
apparent that the proportion of tumour derived cells in that one small
study overlaps with the limits of sensitivity of SSCP that was
demonstrated in the cell mixing experiments of the current study
described in Chapter 3. It however is important to note that in at least
some patients in the current study the proportion of tumour cells in the
bladder washing samples would appear to be very much greater . This is
demonstrated by the prominent relative intensity of the abnormally
migrating SSCP band compared to the normal bands, as visualised on
autoradiographs, and is consistent with findings of other investigators
(Mao et al 1996, Xu et al 1996). This may in part be due the increased
cellularity of bladder washings compared to voided urine samples. In
addition it has been suggested that details of sample storage may have a
bearing on proportion of malignant cells in a sample, with the possibility
that malignant cells may have a survival advantage in certain conditions
(Mao et al 1996).
In the above studies a total of 8 different mutations were identified in one
or more of the sample types studied. It is noted that only 2 of the
mutations were unambiguously identifiable under all 3 sets of gel
conditions employed for that particular exon, and 2 mutations were only
identified under 1 set of conditions. The importance of using at least 2 sets
of SSCP gel conditions to maximise mutation detection is thus apparent.
It is relevant to discuss the above results in the light of previous related
work. It has been demonstrated previously that cancer related genetic
abnormalities can be detected in urine and bladder washing samples de
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novo, using H-ras as a marker (Levesque et al 1993, Fitzgerald et al 1995).
However H-ras mutations may be primarily important in the more
indolent, less aggressive types of bladder cancer (Fitzgerald et al 1995) and
at other sites can occur in benign proliferative disorders (Hollywood et al
1995). The findings of the current study, along with 2 reports published
whilst this study was in progress confirm that p53 mutations (an event
relevant to more clinically aggressive bladder cancers) can be detected in
such samples using techniques that do not require prior characterisation
of the mutation being sought (Vet et al 1996, Xu et al 1996). These are
therefore novel findings as the only prior reports on p53 and urine
samples had utilised mutation specific oligonucleotides (Sidransky et al
1991, Hruban et al 1994). The current work is the first that correlates the
p53 mutational status of bladder washings with corresponding tumour
specimens, although Xu et al (1996) addressed this important issue using
direct sequencing of DNA extracted from urinary sediments. Differences
in results obtained bear further discussion. It is apparent from the current
study that analysing bladder washing samples for p53 status has an
appreciable false negative rate, that is sensitivity is a limiting factor and
reasons for this are discussed earlier. There are few data comparing the
sensitivity of SSCP and direct sequencing in a mixed cell population,
though it has been reported that SSCP is possibly more sensitive in this
regard (Smith et al 1992, Wu et al 1993). It is of interest therefore that 24 of
30 urine samples from 8 patients with bladder cancers harbouring a p53
mutation demonstrated the relevant mutation by direct sequencing (Xu et
al 1996). Furthermore the 6 remaining cases coincided with negative
cystocopies. These data suggest enhanced sensitivity compared to the
current study. Of additional interest is the observation that abnormal p53
can be detected in bladder washings or urine samples by SSCP and direct
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sequencing respectively despite normal cystoscopic appearances in
patients with a prior history of bladder cancer (Vet et al 1996, Xu et al
1996). That these findings were achieved using mutation detection
techniques of limited sensitivity in a mixed cell population emphasises
that the detection of molecular abnormalities may offer earlier detection
of relapsed or recurrent disease than is possible cystoscopically.
The results therefore demonstrate that it is possible to detect tumour
suppressor gene abnormalities in bladder washings from patients with
bladder cancer, using the p53 gene as a marker. Such abnormalties can be
confirmed and characterised by direct sequencing and the presence of the
same mutation in corresponding tumour samples has been confirmed.
Thus the primary aims of the pilot study were fulfilled. Being a pilot
study a major objective is to enable the rational design of further studies.
Such further studies would fall naturally into 3 groups with different
objectives:
1) From the results of this study and the results of others it is apparent
that the detection de novo of oncogene abnormalities in urine and
bladder washing samples is achievable albeit with potentially limited
sensitivities. Such samples are an ideal way to study the entire
urothelium of the bladder and as such hold great promise for study of the
early genetic events in groups of subjects at high risk of developing
bladder cancer and of progressing from superficial to invasive disease.
Such studies would ideally involve the collection of serial samples
prospectively and subsequent analysis in the light of clinical progression.
Continuing advances in the technologies of molecular biology may
overcome some of the problems of sensitivity, as may the use of cell
sorting techniques utilising cytokeratin labelling to enrich the epithelial
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component of samples (Griffiths et al 1995). There is potential therefore
for such approaches to add significantly to the understanding the
molecular biology of the natural hisory of bladder cancer.
2) The second potential area for further study is the utilitisation of
molecular abnormality detection in the screening of asymptomatic
subjects for the detection of clinically important bladder pathologies early
in their natural history of the disease when medical intervention is likely
to have a beneficial effect on outcome. In this regard work on
microsatellite analysis is potentially interesting (Mao et al 1996). However
to be introduced into clinical practise such a test or series of tests would
have to meet stringent standards in terms of sensitivity (to avoid
inappropriate reassurance in the presence of significant disease) and
specificity (to avoid unnessecary investigation to pursue the diagnosis in
the presence of a false positive test). Other issues such as subject
convenience, aspects of psychological and physical distress to subjects,
cost effectiveness and resource priorities would need to be addressed.
Thus whilst intellectually and clinically appealing major developments
are awaited before a clinically robust screening assay for the early
detection of bladder cancer is realised.
3) The final avenue of potential further research that merits discussion is
the use of molecular markers to aid follow up of patients with bladder
cancer who have undergone bladder preserving treatments, and whom
traditionally have been followed up primarily with regular cytoscopic
examination. With the advent of automated microchip sequencing
techniques allowing rapid characterisation of genes of interest (Kozal et al
1996) it may soon be practicable to screen tumour specimens routinely for
abnormalities in a variety of genes. With further elucidation of the
molecular biology of bladder cancer, genes to study could be chosen that
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maximised the chances of finding an abnormality for an individual
patient taking into account for instance factors such as histology, stage and
grade. Having identified a mutation in an individual patient's tumour a
sensitive mutation specific assay could be used to determine the presence
or absence of that mutation in urine or bladder washing samples
following the completion of treatment, and thus inferring the presence or
absence of disease. Such an approach would obviously require rigorous
standards of quality control given the potential for contamination in PCR
based techniques. Prospective evaluation of its clinical sensitivity in
particular with regards to correlation to cystoscopic findings would be
imperative including evaluation of the significance of a positive
molecular test in the absence of cystoscopic abnormality as such findings
have already been described (Mao et al 1996, Xu et al 1996). It is possible
that sensitive molecular techniques may reduce the need for cystoscopy,
permitting cystoscopy only when a positive test suggests the likely
presence of tumour. At first glance the level of scientific effort required
per patient in terms of both cost and time may appear prohibitive,
however with increasing automation and speed of molecular biological
techniques unit costs may fall, and such assays may eventually become
readily achievable in hospital clinical laboratories. When compared to
the expense and patient inconvenience of regular cystoscopies, including
the inherent risks of general anaesthesia in a predominantly elderly
patient population with their associated smoking related comorbidities,
pursuing the development of assays utilising molecular abnormalities as




STUDIES ON p53 MUTATIONS IN NIPPLE ASPIRATE FLUIDS FROM
PATIENTS WITH BREAST CANCER
Aims
The objective of this part of the study was to determine whether it was
possible to detect the presence of malignancy in the breast fluid (obtained
by nipple aspiration) of patients with breast cancer by using mutations in
the p53 gene as a biochemical marker. This was a pilot study, building on
previous observations that it was possible to amplify DNA for genes such
as c-erbB-2, p53 and aromatase from nipple aspirate fluid. It was clear
from the published literature that the quantity of fluid obtained for study
may be small. Therefore the plan of investigation was different to that
employed for the bladder cancer arm of the study described in Chapter 4. It
was decided first to screen the breast tumour samples for the presence of
mutations in exons 5-8 of the p53 gene and then investigate whether
those mutations found could be demonstrated in the corresponding
nipple aspirate sample. This approach minimises the amount of fluid
sample required to test the hypothesis, as potentially only 1 PCR reaction
is required per aspirate sample rather than 4 if the nipple aspirate fluid
was to be screened for mutations in all 4 exons of interest, assuming that a
mutation was demonstrated in only 1 exon per tumour.
Results
5.1 Nipple Aspirate Collection
Breast fluid collection by nipple aspiration was attempted in 30 subjects
and fluid obtained from 21 (70%). The clinical details of the subjects from
whom a nipple aspirate sample was obtained are tabulated in Appendix 3,
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and include: the patienf s age, the size, histological type, grade and
oestrogen receptor status of the tumour, the nature of the operation
performed and finally whether or not a sample of macroscopically
normal breast tissue was obtained.
5.2 Screening of Breast Tumour Specimens for Mutations in Exons 5-8 of
the p53 Gene.
Paired samples of breast tumour and nipple aspirate fluid from the same
breast were obtained from 21 patients with histologically confirmed breast
cancer. One patient who underwent a mastectomy was demonstrated
preoperatively to have 3 discrete masses, both clinically and
mammographically; tumour samples were collected from each of the 3
lesions, giving a total of 23 tumours from 21 subjects. DNA was extracted
from either fresh frozen or paraffin embedded tumour tissue. PCR-SSCP
was performed for each of the 4 exons of interest in turn, using 3 sets of
SSCP conditions for each exon as discussed in Chapter 3. For each exon
studied the PCR reaction included a negative, no template control to
demonstrate absence of contamination of the PCR reaction and a sample
both of wild type and mutation carrying cell line DNA for that exon; the
wild type sample acting as a normal reference control, to which the
migration pattern of the tumour DNA samples could be compared and
the mutation carrying sample allowing comparison of migration pattern
to that of previous gels run under the same conditions ensuring
interassay consistency. When the migration pattern of a sample indicated
the possibility of a p53 mutation a further PCR reaction was performed
and SSCP repeated. If there was a disparity between the 2 results the
PCR-SSCP was repeated again and the sample only considered to
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potentially contain a mutation if the same abnormal migration pattern
was seen on at least 2 occasions, the abnormal pattern otherwise being
attributed to artifact.
A total of 4 samples demonstrated an abnormal SSCP pattern, 2 in exon 5,
1 in exon 6 and 1 in exon 8. These abnormalities are demonstrated in
Figure 5.1, and the results are summarised in Table 5.1 (exons 5 and 6) and
Table 5.2 (exons 7 and 8). It can be seen that whilst 3 out of 4 of the
putative mutations were seen on all 3 sets of gel conditions, the
remaining 1 (sample 6) was seen on only one set of conditions.
5.3 Screening of Normal Breast Tissue Specimens from Tumour Bearing
Breasts for mutations in exons 5-8 of the p53 gene.
Macroscopically normal breast tissue was available from the
tumour-bearing breast in 5 out of the 21 patients studied. Exons 5-8 of the
p53 gene were screened for mutations using PCR-SSCP as described for
the breast tumour samples. No mutations were demonstrated in any of
the 5 samples. These 5 samples included 2 from patients whose tumours
displayed an abnormal SSCP pattern for 1 of the exons studied (samples 6
and 18).
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Figure 5.1 Autoradiographs of SSCP gels demonstrating the presence of
abnormal SSCP migration patterns suggesting the likely presence of
mutation in breast cancer tumour samples 1,6,9 and 18.
a) Exon 5. An abnormal extra band is seen in sample 6 and 2 abnormal
extra bands are seen in sample 9 (indicated by arrows); lane A is an A2780
cell line normal control.
A
b) Exon 6. An abnormal extra band is seen in sample 1 (indicated by
arrow); lane M is a T47D cell line known mutant control and lane A is an




c) Exon 8. Abnormal extra bands are seen in sample 18. SS and DS indicate
the normal migrating single and double strands respectively. In addition
2 extra single strand bands are seen (indicated by arrows) as well as an
extra double stranded band (indicated by *). These appearances indicate
the presence of a mutation carrying a sizeable deletion giving rise to PCR
products that migrate faster and therefore further than their wild type
counterparts. Lanes labelled A carry A2780 cell line normal controls.
lt>4
Table 5.1
Results of SSCP analysis of Exons 5 and 6 of the p53 gene in 23 Breast
Tumour Samples
N : Normal SSCP Pattern ABN: Abnormal SSCP Pattern
Gel A: 10% acrylamide, 1.3% bisacrylamide, no glycerol, 4°C
Gel C: 8% acrylamide, 2% bisacrylamide, 10% glycerol, 4°C




Results of SSCP analysis of Exons 7 and 8 of the p53 gene in 23 Breast
Tumour Samples
N : Normal SSCP Pattern ABN: Abnormal SSCP Pattern
Gel B: 8% acrylamide, 2% bisacrylamide, no glycerol, 4°C
Gel C: 8% acrylamide, 2% bisacrylamide, 10% glycerol, 4°C
Gel D: 10% acrylamide, 1.3% bisacrylamide, 10% glycerol,
room temperature
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5.4 Characterisation of p53 Mutations by Direct DNA Sequencing.
The 4 samples with abnormal SSCP pattern were subjected to direct
sequencing of the putative mutation carrying exon. For samples 1, 6 and 9
template DNA for sequencing purposes was obtained either by
reamplification of single stranded DNA eluted from SSCP gels or direct
from a non-radiolabelled double stranded PCR product. Sample 18 (Figure
5.1c) demonstrated not only abnormally-migrating single strands on SSCP
but also an abnormal double stranded product which migrated further
than the wild type product on the SSCP gel implying the presence of a
sizeable deletion. To sequence this sample the PCR reaction (non
radiolabeled) was repeated and the products run on a 1.5% agarose gel.
The presence of 2 double stranded products was confirmed and the
abnormally migrating band was excised. DNA was extracted from the gel,
reamplified and then sequenced.
In each of the 4 cases the presence of a mutation was confirmed (Figure
5.2) and the details are tabulated in Table 5.3.
Table 5.3
Sample Exon Wild Type Mutation Codon
1 6 CAG (Gin) TAG(stop) 192
6 5 CAT (Pro) CGT (Arg) 179
9 5 GGT GTT (3') downstream splice site
18 8 48 base pair in frame deletion of codons
275-290 inclusive.
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Figure 5.2. Autoradiographs confirming by direct sequencing the presence
of p53 mutations in breast cancer tumour samples 1,6/9 and 18.
a) Sample 1; CAG - TAG mutation at codon 192 in exon 6.
G A T C
b) Sample 6; CAT - CGT mutation at codon 179 in exon 5.
G A T C
Figure 5.2 contd.
c) Sample 9; GGT - GTT mutation at 3' splice site of exon 5.
G A T C
d) Sample 18; 48 base pair in-frame deletion of codons 275-290 of exon 8.
G A T C
5.5 PCR Studies on Nipple Aspirate Samples
Following the above experiments characterising the mutations present in
breast tumours, the nipple aspirate samples from those subjects whose
tumour carried a mutation were put aside for later analysis. The
remaining fluid samples (that is those from subjects whose tumour was
not found to carry a p53 mutation) were used in studies attempting to
define an effective method to prepare the DNA in the samples for PCR.
Two methods were used:
1)The first method involved the addition of a sample of nipple aspirate
fluid to a tube prior to the addition of the other reagents for a PGR
reaction as described by Motomura et al (1994). Duplicate samples (5-10gl)
of nipple aspirate fluid from 1 subject were used as PCR template in lOOjil
PCR reactions. No PCR product was obtained in either case. Aliquots
(10ql) of the first round amplification were used as substrate for a second
reaction yielding a product in 1 case. A second experiment using duplicate
aliquots of nipple fluid from a further subject yielded no product for
either sample on either first or second rounds of amplification.
2) The second method involved the addition of a lysis buffer to the nipple
aspirate fluid and subsequent incubation prior to the addition of the
remaining PCR reagents and thermal cycling. On the first occasion this
was attempted 2 NAF samples were split between 4 PCR tubes, but no
product was seen from any or the positive control indicating the whole
reaction had failed and had to be disregarded. In a further experiment a
large sample was split between 3 tubes, lysed then amplified. No product
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was seen from any of the 3 samples but the positive control on this
occasion yielded a product. A further round of amplification using
product from the first reaction as template for the second again yielded no
product.
It can be seen that using the above 2 methods PCR product was seen from
only 1 of 7 reactions and in that 1 case this was only following
reamplification in a second PCR. There were 3 main possibilities that
could account for this: firstly there was little or no DNA in the samples
tested; secondly, that despite using 2 methods previously reported as
having been used successfully to amplify the DNA from small samples,
the DNA present was not being released into solution; and thirdly that
the nipple fluid sample contained a factor inhibiting what had been, in
the investigator's hands, robust PCR conditions. It was felt most
appropriate to investigate the latter possibility, as if that suspicion was
confirmed a DNA extraction method involving separation of the
resultant DNA from the sample fluid would be mandatory.
5.6 Testing The Hypothesis That Nipple Aspirate Fluid Contains A Factor
Inhibiting PCR Reactions
Nipple aspirate fluid was added to a known quantity of A2780 cell line
DNA prior to PCR. The intensity of the product was compared to that of
the same quantity of A2780 DNA amplified on the same reaction run. All
reactions amplified exon 5 of the p53 gene.
1) In the first experiment lpl (lOOng) of A2780 DNA was amplified in the
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presence and absence of 5^1 of nipple aspirate fluid. The PCR run
included a no template negative control and a tube containg 5pi of nipple
aspirate fluid but no cell line DNA. The nipple aspirate fluid alone and
the negative control yielded no product on agarose gel electrophoresis
and the intensity of product from amplification of the the mixed A2780
DNA and aspirate was less than that of the A2780 alone (Figure 5.3a). The
apparent partial inhibition observed may have simply been accounted for
by inter tube variations in amplification.
2) To address this issue a second experiment was performed in an
identical manner to experiment 1, save that 2 tubes rather than 1
containing A2780 template alone were set up. On this occasion, whilst
both the A2780 samples revealed products of similar intensity the A2780/
aspirate mix showed no visible product. The aspirate alone sample and
negative controls again yielded no product (data not shown).
3) The final experiment utilised 3 nipple aspirate samples. Approximately
5gl of each sample was added to separate tubes each containing lyl (lOOng)
of A2780 DNA. A negative no template control and 2 x A2780 only tubes
were also set up. There was insufficient aspirate fluid for aspirate alone
tubes to be set up. Two of the 3 A2780/ aspirate mix samples yielded no
product as did the no template control and the remaining A2780/
aspirate mix sample had a product intensity less than either of the 2
A2780-only specimens (Figure 5.3b).
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Figure 5.3
Agarose gel electrophoresis demonstrating the effect of mixing nipple
aspirate fluid and cell line DNA on PCR product yield.
a) Lane 1: DNA ladder. Lane 2: no-template negative control. Lane 3: 5ul
NAF as PCR substrate. Lane 4: lOOng A2780 cell line DNA as PCR
substrate. Lane 5: mix of 5pl NAF and lOOng A2780 as PCR substrate. No
PCR product is visualised when NAF alone is the substrate and the yield
of product appears less for the mix of cell line DNA and NAF, than for
the cell line DNA alone.
1 2 3 4 5
b) Lanes 1 and 8: DNA ladder. Lane 2: no-template negative control. Lanes
3 and 4: lOOng A2780 cell line DNA as PCR substrate. Lane 5-7: mix of 5pi
NAF from 3 different subjects and lOOng A2780 as PCR substrate. The
additon of NAF to cell line DNA results in absence of product in lanes 5
and 7 and decrease in product intensity in lane 6, implying an inhibitory
effect (noting however that the product intensity differs between the 2
A2780 samples).
1 2 3 4 5 6 7 8
lTl>
Taken together the 3 experiments support the presence in nipple aspirate
fluid of agents which either partially or completely inhibit the PCR
reaction. Inhibition was complete on 3 out of 5 occasions. It was therefore
decided to attempt DNA extraction using the Qiagen Tissue kit employing
a modification of a method described by the manufacturers for extracting
DNA from small quantities of body fluids dried on microscope slides
(Chapter 2.4.le). Five extractions were performed using fluid samples
from 4 patients and a PCR product obtained after 1 round of amplification
in 2 case and after a 2nd round in another. A decision was taken to
proceed with this method for the index cases.
5.7 SSCP analysis of nipple aspirate samples from subjects whose breast
cancer revealed a p53 mutation.
DNA was extracted from the nipple aspirate samples of the 4 subjects
whose breast tumours were shown to contain a p53 mutation. PCR-SSCP
was performed for each sample only for the exon previously shown in
the corresponding tumour sample to carry a mutation. Some previous
reports on PCR using small samples have utilised either an initial PCR
reaction of a conventional number of cycles and then used an aliquot of
the first round product as the DNA template for a second round of
amplification (Kovach et al 1991) or used upwards of 50 cycles of
amplification replenishing the DNA polymerase mid procedure (to
ensure continued activity) (Frye et al 1989); the aim of both procedures
being to maximise amplification. In the current study the following
approach was adopted. A first round of amplification was performed in a
100j.il PCR reaction (non radiolabeled) using 2 different quantities of
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sample as template (2j.il or lOjil). Agarose gel electrophoresis failed to
demonstrate a clear DNA product for any of the 4 samples. Then a 20j.il
32p labelled PCR was performed using the following as template:
1) 2pl DNA extracted from aspirate sample
2) 10j.il DNA extracted from aspirate sample
3) 2pl aliquot of first round product from the initial
lOOpl PCR in which lOpl of DNA template was used
4) lOpl aliquot of first round product from the initial
lOOpl PCR in which 10pl of DNA template was used
Appropriate positive and negative controls were included in the reaction
as were samples of DNA from the corresponding mutation carrying
tumours. SSCP analysis was performed, as previously, on 3 sets of gel
conditions for each exon studied. Nipple aspirate samples corresponding
to tumour samples 6 and 9 yielded no product despite prolonged
autoradiography for any of the 4 aspirate templates used. Three and 4 of
the templates from the aspirates corresponding to tumour samples 1 and
18 respectively yielded product visualised on SSCP gels. No abnormally
migrating bands were demonstrated (Figure 5.4), that is using SSCP, no
evidence of tumour derived genetic material could be demonstrated in
the 4 aspirate samples studied.
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Figure 5.4
SSCP analysis of nipple aspirate fluid sample corresponding to tumour
sample 18. Lane 1 is an A2780 cell line normal control. Lane 2 is tumour
sample 18 demonstrating abnormal single strands (indicated by arrows)
and an abnormal double stranded product (labelled *; DS representing the
normal double stranded product). Lanes 3-6 represent nipple aspirate
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5.8 Mutation Specific Amplification of Sample 18
As described earlier breast tumour sample 18 was demonstrated to carry a
sizeable deletion. A pair of mutation specific primers were designed to
amplify this mutation.
The primers were as follows:
sense 5' GC TTT GAG GTG CGT GTT AAG 3'
corresponding codon 269 270 271 272 273 274 291
antisense 5' CAGTGCTAGGAAAGAGGCAA 3'
The antisense primer was entirely intronic with its 5' end being 98 bases
downstream from the 3' end of exon 8. The sense primer spanned the
deletion and was therefore mutation specific.
Following optimisation experiments it was found that this pair of
primers would specifically and reproducibly amplify the mutation, if an
annealing temperature of 55°C was used with a MgCl2 concentration of
ImM , all other reaction conditions being as described in Chapter 2.
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5.9 Mutation Specific Amplification of Nipple Aspirate Corrresponding
To Tumour Sample 18.
Having failed by SSCP to detect the presence of tumour derived DNA in
the aspirate corresponding to tumour sample 18, the possibility was
investigated that the use of mutation specific primers may demonstrate
its presence. The rational was that mutation specific amplification allows
amplification of as little as 1 copy in 105-6 (mutant: wild type ratio) (Cha et
al 1992, Jacobson and Mills 1994, Rhodes et al 1997) a sensitivity several
fold better than established in this study for SSCP. Using the PCR reaction
conditions described in the previous section a lOOpl PCR reaction was
performed, using as template 2pl and 10 pi aliquots of aspirate DNA
extract, as well as wild type DNA (A2780 cell line) and tumour sample 18
DNA along with a negative, no template control. Sample 18 tumour
DNA was the only reaction to yield a product that could be visualised on
agarose gel electrophoresis (Figure 5.5). A further lOpl aspirate DNA
sample was subjected to PCR and again yielded no product. Aliquots of
the first round of PCR reactions were used as template for second round
amplification and no definite bands were observed on agarose gel
electrophoresis. It can be concluded that despite the use of mutation
specific primers it was still not possible to demonstrate the presence of




Agarose gel electrophoresis of a PCR using primers specific for the
mutation in tumour sample 18. Lane 1 contains a 100 base pair DNA
ladder, lane 2 a no-template control, lanes 3 and 4 A2780 cell line DNA
(as a non-mutation carrying negative control), lanes 5 and 6 sample 18
aspirate DNA and lanes 7 and 8 sample 18 tumour DNA. A PCR product
is visualised only in lanes 7 and 8 (sample 18 tumour DNA) and not in
the corresponding nipple aspirate samples.
\F9
Discussion
Employing standard methodologies it was possible to demonstrate the
presence of p53 gene mutations in breast tumours from 4 out of 21
patients (19%), and characterise those mutations found by direct
sequencing. This proportion of mutation carrying tumours whilst
consistent with previous data is at the lower end of the range of reported
frequencies (Andersen et al 1993, Dunn et al 1993, Merlo et al 1993, Sasa et
al 1993, Tsuda et al 1993, Saitoh et al 1994 ). There are several possible
explanations for this: i) the presence of normal tissue may mask tumour
mutation by dilution of abnormal DNA, ii) a lack of sensitivity of SSCP in
detecting the presence of mutations, iii) a statistical phenomenon of a
small series, iv) the fact that only exons 5-8 were studied or v) bias in
terms of recruitment. Each of these factors will be considered in turn. The
tumour samples were macroscopically dissected from visible tumour
masses by experienced pathologists and it is unlikely that the samples
contained a lesser proportion of tumour than could be detected by SSCP
(1-30% as demonstrated in Chapter 3). SSCP has been demonstrated to
detect upwards of 70-90% of mutations present (Grompe 1993, Ravnik-
Glavac et al 1994) and given the conditions employed in this study
including the use of 3 gel conditions for each sample it seems unlikely
that a large proportion of mutation carrying tumours were missed. The
sample size was small and a statistical quirk may account for the low
proportion of mutation carrying tumours found. As described in the
introduction many of the series reporting on p53 mutations screened only
the highly conserved regions of the gene (as in this study). Whilst
mutations are described in other regions they are less common;
nevertheless the restriction of mutation screening to exons 5-8 may
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account in part for the low incidence of mutations found. The subjects
recruited into the study presented in the main with early breast cancer
and were all treated with primary surgery. Patients with large or locally
advanced tumours who received neoadjuvant systemic therapy with
either chemotherapy or endocrine therapy prior to surgery were excluded
from the study. Given the high relative frequency of p53 mutations in
locally advanced breast cancers (Faille et al 1994) this is a potential bias
that may have affected the incidence of mutations found in the current
study. The study population was restricted to women aged 55 or younger
and this is another potential bias.
It proved impossible to demonstrate p53 abnormalities in the nipple
aspirate fluid samples of the subjects whose breast tumour specimens
were shown to carry mutatons. Indeed it was only possible to obtain a
PCR product from 2 out of the 4 samples, neither of which demonstrated
an abnormal band on SSCP analysis. It is known that a proportion of
nipple aspirate samples will be either acellular or sparsely cellular, and
this may account for the failure to obtain a PCR product from the 2 fluid
samples concerned. It appears that breast fluid samples contain an
inhibitor to PCR reactions when using the conditions employed in this
study. The addition of a small quantiity of NAF (5j.rl or less) to a 100}d
PCR reaction containing lOOng of extracted cell line DNA resulted in
either the complete inhibition of the reaction or a significant reduction in
the quantity of product obtained. It was not possible to undertake studies
to define the nature of the factor or factors responsible. However it was
concluded that for the PCR conditions used it was necessary to extract
DNA from the sample fluid rather than simply release DNA into the PCR
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reaction solution by cell lysis. Out of necessity this will result in a dilution
of DNA concentration and possibly loss of some material in the various
steps involved both of which may be of critical importance when samples
contain very small amounts of genetic material. DNA in sufficient
quantities to subject to PCR could be obtained from approximately half
the fluids tested using a modification of a commercially available DNA
extraction kit. It would obviously be advantageous to improve upon this
ratio, and the development of a method analogous to that used for single
cell sample such as sperm (Li et al 1988) would be a significant advance in
allowing the study the molecular biology of nipple aspirate fluids.
The reasons for the 2 successfully amplified nipple aspirate samples not
demonstrating any evidence of the p53 mutation detected in the
corresponding tumour sample bear exploration. An obvious explanation
could be that there was no shed tumour material in the fluid. It is
noteworthy that Sartorius et al (1977) have reported an inverse
correlation between tumour size and the likelihood of nipple aspirate
fluid demonstrating cytologically abnormal cells. They argue that the
larger the tumour the more likely it is that the ductal architecture of the
diseased part of the breast is disrupted and consequently the fluid
aspirated coming from a healthy part of the breast, citing evidence from
radiological studies confirming such distortion. However evidence from
a detailed pathological study of mastectomy specimens (Andersen and
Pallesen 1979) demonstrated the presence of tumour within 10mm of the
nipple in 50% of specimens studied, and whilst this could be accounted
for as much by tumour multifocality as by intra-luminal spread it does
suggest that using optimal techniques a proportion of nipple aspirate
fluids may reasonably be expected to contain shed tumour DNA either in
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the form of intact cells or cellular debris. Another potential explanation is
that the nipple aspirate samples did contain tumour derived DNA, but in
low proportion relative to that of shed non-tumour cells. As was
demonstrated in this thesis SSCP was able to detect between 1 and 30
mutation bearing cells per 100 in cell line mixing experiments, and thus if
tumour cells comprised a lesser amount of the sample their presence
would not be detected by SSCP. Mutant specific primers were developed
for one of the mutations found but using these it was not possible to
detect presence of the mutation in the corresponding NAF sample.
Unfortunately it was not possible to assess formally the sensitivity of this
system to pick up small numbers of mutant carrying cells amongst larger
numbers of wild type due to lack of a pure source of mutant DNA to
allow quantification. However when mutant specific primers have been
used in other situations they have been reported to detect 1 mutant cell in
105"6 (Cha et al 1992, Jacobson and Mills 1994, Rhodes et al 1997). It is
therefore likely that the nipple aspirate sample from the subject in
question carried little or no tumour derived DNA.
A further limiting factor was the small quantity of fluid obtained from
some subjects and the difficulty in efficiently collecting it. The fluid
appeared subjectively to vary in viscosity between subjects and collection
of fluid by capillary action into glass tubes worked well only for a
proportion of subjects, in others whilst fluid could be collected there was
significant wastage of scant material. In the latter part of the study fluid
was aspirated from the nipple surface using a 200f.il micropipette. This
was technically easier and less wasteful of precious sample and would be
recommended as the method of choice for future studies.
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The quantity of fluid obtained was variable and small. It was not posible
to determine whether the collection of aspirate samples with the patient
anaesthetised had any adverse bearing on yield though in theory this is
possible. Previous authors have emphasised the importance of the
patient gently massaging the breast during sample collection
(Papanicolaou et al 1958, Sartorius et al 1977) and psychological factors
such as the patient being in a relaxed and comfortable state during the
procedure appear to be important predictors of success (I. McFadyen
personal communication of unpublished observations). Reasons for the
procedure being carried out under anaesthetic were discussed in Chapter
2.3.2.. The question arises as to whether or not the yield of fluid could in
any way be enhanced. Galactorrhea is a potential side effect of a variety of
drugs, mainly with dopamine antagonist activity (Thorner MO 1996), and
administration of such an agent could theoretically enhance yield of
nipple aspirate fluid samples. There are no published data investigating
this possibility and whilst such an approach would not find routine use it
may, if successful, have a role in well defined circumstances.
It is clear from the published data discussed in the introduction that
useful information about the biochemistry and pathophysiology of breast
cancer has been derived from the study of nipple aspirate fluids. This
study aimed to take this branch of breast cancer research forward by
investigating whether tumour specific genetic mutations could be
detected in such fluid samples. That it failed to do so should not close the
door on future attempts but rather attention should be turned to
addressing the following issues:
1) The optimal collection and preparation of nipple aspirate fluid for
genetic analysis, including assessment, if possible, of sample cellularity is
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of great importance.
2) Consideration should be given to which subjects can most profitably be
studied. Sartorius et al (1977) demonstrated a lower likelihood of
abnormal cytology in nipple aspirates from subjects with large breast
cancers. It may be appropriate therefore to concentrate further efforts on
those with small lesions or with carcinoma in situ, groups less likely to
have disruption of ductal architecture, but it has to be remembered that to
evaluate studies on mutation detection it is desirable to have tissue from
an operative specimen to confirm the presence in the lesion of any
mutations found in the corresponding fluid. Were such methods found
to be valuable extending their use to the study of high risk groups such as
found in breast cancer family clinics, may be appropriate, not only from a
scientific point of view but also from a clinical one.
3) Attention is required to which marker or markers should be examined.
As described in the introduction p53 mutations are probably the most
common genetic aberrations reported to date in breast cancer. The
abnormalities have the additional advantage of being qualitative rather
than quantitive, which would tend potentially to increase sensitivity.
However considerably over half of all breast cancers do not have a p53
mutation, and therefore even if a reliable method for detecting such
mutations in nipple aspirate samples were developed its scope for use as
an adjunct to screening programmes would be limited to a subset of
patients. Recent data in preliminary form may however be relevant
(Crook et al 1997). All 8 tumours (7 breast and 1 ovarian cancers) from 4
different families carrying BRCA-1 germline mutations were found to
have p53 mutations. The authors conclude that acquired p53 mutations
may have a pivotal role in the development of BRCA-1 associated
cancers. The sequential study of nipple aspirate samples from both breasts
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in women from such families may be potentially a useful adjunct to the
mammographic and clinical surveillance already offered to them,
particularly when the difficulties of interpreting premenopausal womens
mammograms are considered (screening, in this context, often starting
many years before the menopause). The physiology of the BRCA-1
protein is by no means established but the description of it as a secreted
molecule present in breast milk is potentially of interest in future studies
(Jensen et al 1996, Diamandis 1996).
As a greater understanding of the molecular biology of sporadic breast
cancer unfolds other potential markers for such studies may become
apparent.
4) What is the most appropriate method for mutation detection? This
would very much depend on the gene of interest. For instance a gene like
p53 in which mutations are described throughout a large part of the gene
requires a screening method such as SSCP to potentially detect the
majority of mutations. In colonic and pancreatic cancers mutations in the
RAS family of genes are common, and because most mutations are
confined to a few codons it is feasible to use mutation specific approaches
to enhance sensitivity in detecting mutations in the background of a large
proportion of normal cells. However RAS mutations are uncommon in
breast cancer (Capella et al 1991)
5) Is there scope for investigating methods other than mutation
detection? In good quality cellular aspirates immunohistochemical
analysis may have a role, with the relative expression of various
oncogene products being inferred. The limiting factor here being the
cellularity of the sample. However with the recent description of a
method by which a single paraffin embedded tissue slice was used for
both immunohistochemical and subsequent DNA analysis (Chen et al
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1996), it is feasible that such an approach could be extended to a nipple
aspirate smear on a microscope slide.
In conclusion it remains to be hoped that, with the rapidly ongoing
developments in molecular biological techniques, studies on genetic
abnormalities in nipple aspirate fluid samples may further the




Mutations of the p53 gene are a common feature of a variety of malignant
diseases. The studies set out in this thesis investigated the potential for
using the detection of p53 mutations as a means of demonstrating the
presence of malignancy in 2 biological fluids, namely in nipple aspirate
fluid samples from patients with breast cancer and in bladder washing
samples from patients with bladder cancer.
SSCP was the method used to screen samples for the presence of
mutations. Before its use on clinical samples, the methodology was
optimised and its sensitivity evaluated using cell lines with known p53
status. Using polyacrylamide gel electrophoresis it was demonstrated that
an abnormal SSCP pattern was discernible under optimal conditions for
samples in which mutation-carrying cells represented as little as 5% of the
total. Optimal conditions varied between particular mutations studied
and were not predictable; thus to maximise the sensitivity of the
technique to detect mutation carrying cells in the background of an excess
of wild type cells it was necessary to use 2 or more sets of electrophoresis
conditions in a largely empirical manner. The use of MDE as a gel matrix
for SSCP was shown to offer no advantage over polyacrylamide.
The ductal epithelium of the breast is the site of origin of the majority of
breast cancers. Breast ductal fluid is secreted by this epithelium and
samples of the fluid obtained by nipple aspiration from patients with
breast cancer can exhibit cellular and biochemical features reflecting the
presence of the underlying disease. The detection of cancer-related gene
mutations in nipple aspirate fluids has not to date been reported and the
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current studies were unable to demonstrate p53 mutations in nipple
aspirate fluids from patients whose primary tumours carried mutations.
Problems encountered included the limits of sensitivity of the mutation
detection assay used and the preparation of DNA from small samples for
PCR. Concern remains that distortion of breast ductal architecture by
invasive cancers may prevent, at least on occasions, the aspiration of fluid
from the diseased ductal system. Further studies are however warranted
and these issues would need to be addressed. The study of molecular
abnormalities in nipple aspirate fluid samples could potentially further
the understanding of the molecular events involved in breast
carcinogenesis, and could eventually become clinically relevant to the
disease screening of individuals at high-risk.
Patients with bladder cancer shed tumour cells into the bladder. Despite
this, urine cytology and other non-invasive tests have well documented
limitations with the result that the diagnosis and follow-up of patients
with, or suspected of having bladder cancer rely heavily on invasive
techniques. A variety of approaches have been adopted to enhance the
diagnostic potential of urine and bladder washing samples. Of these the
study of cancer-related molecular abnormalities is of particular interest
and potential. The current study demonstrated that it was possible to
detect p53 mutations in bladder washing specimens from a proportion of
patients with bladder cancer. Furthermore it was possible to define the
exact nature of the mutation in some cases and confirm the presence of
the same abnormality in bladder tumour samples. There were occasions
however when a mutation was present in tumour samples but not
detectable in corresponding bladder washing samples. The most likely
explanation being the limited sensitivity of the mutation detection assay
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(SSCP) employed. This work and that of others enforce the potential for
the use of molecular markers in bladder cancer. Further studies are clearly
warranted both on bladder washing samples and on urine samples with
issues of sensitivity and correlation with clinical and pathological
findings being of paramount importance.
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Patient information sheet and consent form for nipple aspirate subjects
PATIENT INFORMATION SHEET
We would like to explain some research being done by Dr Hamish
Phillips, a Research Fellow at the University, and then ask you if you
would like to take part.
We are studying the differences between normal cells and cancer cells in
the laboratory. This usually involves taking a specimen during an
operation but we are interested in assessing very small samples which
could avoid the need for biopsies for this type of research.
You are about to have an operation to remove the tumour or cancer from
your breast. We would like to take a small piece of the tumour to be
studied in the laboratory and in addition will ask you to let us take a
small sample of the fluid normally found in the breast to be studied in
the same way. The fluid will be obtained by applying gentle suction to the
nipple by means of a plastic cup placed over the nipple. This will be done
whilst you are under a general anaesthetic for your operation.
Your treatment will be entirely unaffected by this study should you
choose to take part.
No side-effects are expected from the collection of the fluid from your
breast but the procedure may cause mild discomfort. The method has
been widely used in the past.
You are under no obligation to take part in the study. If you do decide to
take part you are free to withdraw or change your mind at any stage
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I agree to paticipate in this study
I have read this consent form and the attached Patient Information Sheet
and had the opportunity to ask questions about them
I agree for notice to be sent to my General Practitioner about my
participation in this study
I agree to the provision of any clinically significant information to my
General Practioner
I understand that I am under no obligation to take part in this study and
that a decision not to participate will not alter the treatment that I would
normally receive
I understand that I have the right to withdraw from the study at any stage
and that to do so will not affect my treatment
I understand that this is non-therapeutic research from which I can't







Sequence of Exons 5, 6, 7 and 8 of the human p53 gene and surrounding
intronic areas (sequence x54156 obtained from the European Molecular
Biology Laboratory Genbank database: submitted by Chumakov PM). Exon
sequences are in upper case and intron sequences in lower case, with
underlined sequences representing sites of primers.
Exon 5: 5' tgtgccctgactttcaactc tgtctccttcctcttcctacagTAC TCC CCT
GCC CTC AAC AAG ATG TTT TGC CAA CTG GCC AAG ACC TGC
CCT GTG CAG CTG TGG GTT GAT TCC ACA CCC CCG CCC GGC
ACC CGC GTC CGC GCC ATG GCCATC TAC AAG CAG TCA CAG
CAC ATG ACG GAG GTT GTG AGG CGC TGC CCC CAC CAT GAG
CGC TGC TCA GAT AGC GAT G gtgagcagctggggctgg
agagacgacagggctggtt 3'
Exon 6: 5' tgattcctcactgattgctc ttag GT CTG GCC CCT CCT CAG
CAT CTT ATC CGAGTG GAA GGA AAT TTG CGT GTG GAG
TAT TTG GAT GAG AGA AAC ACT TTT CGA CAT AGT GTG
GTG GTG CCC TAT GAG CCG CCT GAG gtctggtttgcaactggggt 3'
Exon 7: 5' aaggcgcactggcctcatct tgggcctgtgttatctcctag GTT GGC TCT
GAC TGT ACC ACC ATC CAC TAC AAC TAC ATG TGT AAC
AGT TCC TGC ATG GGC GGC ATG AAC CGG AGG CCC ATC CTC
ACC ATC ATC ACA CTG GAA GAC TCC AG gtcaggagcc
acttgccaccctgcacactgg 3'
Exon 8: 5' ggacctgatttcctttactgc etcttgcttctcttttcctatcctgagtag GGT
AAT CTA CTG GGA CGG AAC AGC TTT GAG GTG CGT GTT TGT
GCC TGT CCT GGG AGA GAC CGG CGC ACA GAG GAA GAG
AAT CTC CGC AAG AAA GGG GAG CCT CAC CAC GAG CTG




Appendix 3 tabulates on the following 2 pages the clinical details of
subjects from whom bladder washing samples were obtained. Details
include pateients' age, whether or not fresh tumour was obtained at the
same time as the bladder washing, the histological type, pathological stage
and grade of the bladder cancer, as well as details of previous treatment
recieved.
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Appendix 4
Appendix 4 tabulates the clinical details of the subjects from whom nipple
aspirate fluid samples were obtained. Details include patients' age, the size
of their tumour, the nature of their operation, the pathological type, grade
and oestrogen receptor status of the tumours and finally whether or not a
sample of macroscopically normal breast tissue was obtained.
Key:
Size Clinically measured tumour size
Operation MX: Mastectomy
WLE: Wide Local Excision
R : Right L: Left
Pathology ID NST : Invasive Ductal Carcinoma of No Special Type
ILOB : Invasive Lobular Carcinoma
1 CRIB: Invasive Cribriform
DC.IS : Ductal Carcinoma in Situ
Grade Histological Grade for Invasive Cancers
1: Well differentiated
2 : Moderately differentiated
3 : Poorly differentiated
ER Status Oestrogen Receptor Status
-VE Oestrogen receptor poor or negative. Level >20 fmol
per mg protein being regarded as ER rich.
+ VE Oestrogen receptor rich
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IX) IX) co
PatientCode
TumourNu be
Age
Size
Operation
Pathology
Grade
ERStatus
NormalBreastSample
A
1
45
1.9cm
RWLE
IDNST
2
+VE
NO
B
2
41
1.0cm
LMX
IDNST
3
+VE
NO
3
1.5cm
IDNST
3
+VE
NO
4
3.0cm
IDNST
3
+VE
NO
C
5
49
2.7cm
LMX
DCIS
HIGH
-VE
NO
D
6
34
4.6cm
RWLE
IDNST
3
-VE
YES
E
8
51
2.0cm
LWLE
IDNST
2
+VE
NO
F
9
55
1.5cm
LWLE
IDNST
3
+VE
NO
G
10
49
2.6cm
RMX
ILOB
2
+VE
YES
H
12
40
4.0cm
RWLE
IDNST
1
+VE
NO
I
13
47
3.1cm
LWLE
ILOB
2
+VE
NO
J
14
48
1.9cm
LWLE
IDNST
2
+VE
NO
K
15
45
1.5cm
LWLE
IDNST/ILOB
2
+VE
NO
L
16
34
4.2cm
RWLE
IDNST
2
+VE
NO
M
17
54
2.0cm
RWLE
ILOB
2
+VE
NO
N
18
47
2.0cm
RWLE
IDNST
3
-VE
YES
O
20
50
3.0cm
RMX
DCIS
HIGH
-VE
NO
P
21
50
4.0cm
RMX
IDNST
2
+VE
YES
Q
23
52
5.0cm
LMX
IDNST
3
-VE
YES
R
25
47
2.5cm
RWLE
IDNST
3
-VE
NO
S
26
51
1.5cm
LWLE
ICRIB
1
+VE
NO
T
27
45
1.0cm
RWLE
IDNST
2
+VE
NO
U
28
39
2.8cm
RWLE
IDNST
2
+VE
NO
